,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,855613,4485,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11111548,4485,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,357,2,1,,11111549,4485,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
3,361,1,2,,855613,4485,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
4,364,1,3,,855613,4485,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
5,368,2,3,,855613,4485,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
6,371,1,1,,855613,4485,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
7,373,1,4,,855613,4485,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
8,374,2,3,,855613,4485,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
9,375,2,3,,855613,4485,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
10,410,1,5,,11111548,4485,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
11,410,1,5,,11111549,4485,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
12,410,1,5,,11113899,4485,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
13,411,2,1,,855613,4485,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
14,411,2,1,,11111548,4485,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
15,411,2,1,,11111549,4485,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
16,411,2,1,,11113899,4485,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
17,421,1,3,,17388858,4485,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
18,422,1,5,,855613,4485,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
19,422,1,5,,17405380,4485,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
20,425,3,2,,855613,4485,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
21,426,1,2,,17388858,4485,Inconclusive,,,,,Cell Viability - Jurkat,Confirmatory,,
22,427,1,1,,17388858,4485,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
23,429,1,5,,855613,4485,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
24,429,1,5,,855613,4485,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
25,429,1,5,,17405380,4485,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
26,429,1,5,,17405380,4485,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
27,430,2,4,,855613,4485,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
28,431,2,4,,855613,4485,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
29,432,2,4,,855613,4485,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
30,433,1,1,,17388858,4485,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
31,434,1,2,,17388858,4485,Inconclusive,,,,,Cell Viability - MRC5,Confirmatory,,
32,435,1,2,,17388858,4485,Inconclusive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
33,436,2,1,,855613,4485,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
34,436,2,1,,17405380,4485,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
35,438,1,4,,855613,4485,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
36,440,3,3,,855613,4485,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
37,441,3,3,,855613,4485,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
38,444,1,1,,855613,4485,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
39,444,1,1,,11111548,4485,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
40,444,1,1,,11111549,4485,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
41,445,3,1,,11111548,4485,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
42,445,3,1,,11111549,4485,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
43,445,3,1,,11113899,4485,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
44,445,3,1,,17388858,4485,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
45,446,1,1,,855613,4485,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
46,446,1,1,,11111548,4485,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
47,446,1,1,,11111549,4485,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
48,447,1,1,,11111548,4485,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
49,447,1,1,,11111549,4485,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
50,447,1,1,,11113899,4485,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
51,448,1,2,,11111548,4485,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
52,448,1,2,,11111549,4485,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
53,448,1,2,,11113899,4485,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
54,449,1,5,,855613,4485,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
55,450,1,2,,855613,4485,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
56,450,1,2,,11111548,4485,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
57,450,1,2,,11111549,4485,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
58,450,1,2,,11113899,4485,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
59,451,1,2,,11111548,4485,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
60,451,1,2,,11111549,4485,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
61,451,1,2,,11113899,4485,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
62,453,2,2,,855613,4485,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
63,454,1,7,,855613,4485,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
64,455,1,7,,855613,4485,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
65,456,1,7,,855613,4485,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
66,457,1,7,,855613,4485,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
67,460,2,2,,855613,4485,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
68,483,1,6,,855613,4485,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
69,485,1,8,,855613,4485,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
70,487,1,2,,855613,4485,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
71,488,2,1,,855613,4485,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
72,501,2,2,,855613,4485,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
73,518,2,6,,855613,4485,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
74,521,2,5,,855613,4485,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
75,522,1,2,,855613,4485,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
76,524,1,3,,855613,4485,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
77,525,1,3,,855613,4485,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
78,526,1,1,,11111548,4485,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
79,526,1,1,,11111549,4485,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
80,526,1,1,,11113899,4485,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
81,527,3,1,,855613,4485,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
82,528,1,4,,855613,4485,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
83,529,1,4,,855613,4485,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
84,530,1,1,,11111548,4485,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
85,530,1,1,,11111549,4485,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
86,530,1,1,,11113899,4485,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
87,530,1,1,,17388858,4485,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
88,538,2,2,,855613,4485,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
89,539,1,2,,855613,4485,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
90,540,1,1,,17388858,4485,Inconclusive,,,,,Cell Viability - N2a,Confirmatory,,
91,541,1,1,,17388858,4485,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
92,542,1,1,,17388858,4485,Inconclusive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
93,543,1,1,,17388858,4485,Inconclusive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
94,544,2,1,,17388858,4485,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
95,545,1,1,,17388858,4485,Active,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
96,546,1,1,,17388858,4485,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
97,547,1,4,,17405380,4485,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
98,552,1,3,,855613,4485,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
99,555,1,2,,855613,4485,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
100,556,1,3,,855613,4485,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
101,559,2,2,,855613,4485,Inactive,147728.0,,,,RNA polymerase,Screening,,
102,560,1,2,,855613,4485,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
103,561,1,3,,855613,4485,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
104,565,1,4,,855613,4485,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
105,567,1,4,,855613,4485,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
106,568,1,7,,855613,4485,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
107,568,1,7,,855613,4485,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
108,570,1,4,,855613,4485,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
109,571,1,4,,855613,4485,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
110,572,1,5,,855613,4485,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
111,573,1,4,,855613,4485,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
112,574,1,3,,855613,4485,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
113,575,1,4,,855613,4485,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
114,576,1,2,,855613,4485,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
115,577,1,1,,855613,4485,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
116,580,1,5,,855613,4485,Inconclusive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
117,581,2,2,,855613,4485,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
118,583,2,6,,855613,4485,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
119,584,1,3,,11111548,4485,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
120,584,1,3,,11111549,4485,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
121,584,1,3,,11113899,4485,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
122,584,1,3,,17388858,4485,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
123,585,1,4,,11111548,4485,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
124,585,1,4,,11111549,4485,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
125,585,1,4,,11113899,4485,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
126,585,1,4,,17388858,4485,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
127,587,1,5,,855613,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
128,587,1,5,,11111548,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
129,587,1,5,,11111549,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
130,588,1,4,,855613,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
131,588,1,4,,11111548,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
132,588,1,4,,11111549,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
133,589,1,3,,855613,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
134,589,1,3,,11111548,4485,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
135,589,1,3,,11111549,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
136,590,1,3,,855613,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
137,590,1,3,,11111548,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
138,590,1,3,,11111549,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
139,591,1,4,,855613,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
140,591,1,4,,11111548,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
141,591,1,4,,11111549,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
142,592,1,6,,855613,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
143,592,1,6,,11111548,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
144,592,1,6,,11111549,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
145,593,1,4,,855613,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
146,593,1,4,,11111548,4485,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
147,593,1,4,,11111549,4485,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
148,594,1,4,,855613,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
149,594,1,4,,11111548,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
150,594,1,4,,11111549,4485,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
151,595,1,3,,11111548,4485,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
152,595,1,3,,11111549,4485,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
153,595,1,3,,11113899,4485,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
154,595,1,3,,17388858,4485,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
155,596,1,2,,11111548,4485,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
156,596,1,2,,11111549,4485,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
157,596,1,2,,11113899,4485,Inconclusive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
158,596,1,2,,17388858,4485,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
159,597,1,3,,855613,4485,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
160,597,1,3,,11111548,4485,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
161,597,1,3,,11111549,4485,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
162,597,1,3,,11113899,4485,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
163,598,1,4,,855613,4485,Active,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
164,601,1,4,,855613,4485,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
165,602,1,4,,855613,4485,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
166,603,1,2,,11111548,4485,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
167,603,1,2,,11111549,4485,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
168,603,1,2,,11113899,4485,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
169,603,1,2,,17388858,4485,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
170,604,1,3,,855613,4485,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
171,605,1,2,,11111548,4485,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
172,605,1,2,,11111549,4485,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
173,605,1,2,,11113899,4485,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
174,605,1,2,,17388858,4485,Inconclusive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
175,606,1,3,,855613,4485,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
176,606,1,3,,855613,4485,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
177,607,1,3,,11111548,4485,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
178,607,1,3,,11111549,4485,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
179,607,1,3,,11113899,4485,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
180,609,1,2,,855613,4485,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
181,614,1,6,,855613,4485,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
182,615,1,6,,855613,4485,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
183,618,2,6,,855613,4485,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
184,620,2,5,,855613,4485,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
185,622,1,2,,855613,4485,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
186,623,1,3,,855613,4485,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
187,624,1,2,,855613,4485,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
188,625,1,2,,855613,4485,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
189,626,1,3,,855613,4485,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
190,628,2,4,,855613,4485,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
191,629,1,3,,855613,4485,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
192,630,1,1,,855613,4485,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
193,631,1,4,,855613,4485,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
194,631,1,4,,855613,4485,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
195,633,1,3,,855613,4485,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
196,636,1,4,,855613,4485,Inactive,,,,,Modulators of Post-Golgi Transport - 384-well pilot screen,Screening,,
197,637,1,4,,855613,4485,Inactive,,,,,Modulators of Post-Golgi Transport - 1536-well pilot screen,Screening,,
198,639,1,2,,855613,4485,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
199,641,1,4,,855613,4485,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
200,645,1,4,,855613,4485,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
201,648,1,3,,855613,4485,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
202,654,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
203,655,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
204,656,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
205,657,1,1,,17388858,4485,Inconclusive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
206,658,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
207,659,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
208,660,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
209,661,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
210,662,1,1,,11111548,4485,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
211,662,1,1,,11111549,4485,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
212,662,1,1,,11113899,4485,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
213,662,1,1,,17388858,4485,Active,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
214,663,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
215,664,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
216,665,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
217,666,1,1,,17388858,4485,Inconclusive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
218,667,1,1,,17388858,4485,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
219,680,1,10,,855613,4485,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
220,684,1,12,,855613,4485,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
221,686,1,1,,855613,4485,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
222,687,1,17,,855613,4485,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
223,694,1,1,,17405380,4485,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
224,701,1,17,,855613,4485,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
225,708,1,4,,855613,4485,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
226,709,1,2,,855613,4485,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
227,719,1,3,,855613,4485,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
228,731,1,5,,855613,4485,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
229,731,1,5,,855613,4485,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
230,732,1,2,,17405380,4485,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
231,746,1,1,,855613,4485,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
232,750,1,3,,855613,4485,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
233,751,1,3,,855613,4485,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
234,757,1,4,,855613,4485,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
235,758,1,4,,855613,4485,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
236,759,1,4,,855613,4485,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
237,760,1,4,,855613,4485,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
238,761,1,4,,855613,4485,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
239,764,1,4,,855613,4485,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
240,770,1,1,,855613,4485,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
241,771,1,2,,855613,4485,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
242,772,1,2,,855613,4485,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
243,774,1,2,,855613,4485,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
244,775,1,3,,855613,4485,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
245,781,1,1,,855613,4485,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
246,782,1,2,,855613,4485,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
247,782,1,2,,855613,4485,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
248,784,1,4,,855613,4485,Inactive,55584151.0,2629.0,,,Primary Cell Based High Throughput Screening Assay for Enhancers of Beta-Glucosidase Activity,Screening,,
249,793,1,2,,855613,4485,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
250,795,1,1,,855613,4485,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
251,797,1,1,,855613,4485,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
252,798,2,12,,855613,4485,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
253,799,1,5,,855613,4485,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
254,800,2,11,,855613,4485,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
255,803,1,4,,855613,4485,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
256,804,1,3,,855613,4485,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
257,813,1,4,,855613,4485,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
258,817,1,1,,855613,4485,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
259,818,1,2,,855613,4485,Active,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
260,827,1,2,,855613,4485,Active,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
261,828,1,5,,855613,4485,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
262,834,1,3,,855613,4485,Inactive,,,,,C. albicans biofilm killing,Screening,,
263,841,1,1,,855613,4485,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
264,847,1,2,,855613,4485,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
265,861,1,1,,855613,4485,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
266,862,1,2,,855613,4485,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
267,868,1,3,,855613,4485,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
268,871,1,2,,855613,4485,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
269,873,1,13,,855613,4485,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
270,875,1,2,,11111549,4485,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
271,875,1,2,,11113899,4485,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
272,875,1,2,,17388858,4485,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
273,878,1,2,,855613,4485,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
274,879,1,2,,11113899,4485,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
275,879,1,2,,11113899,4485,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
276,880,2,1,,855613,4485,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
277,880,2,1,,855613,4485,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
278,880,2,1,,11111549,4485,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
279,880,2,1,,11111549,4485,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
280,880,2,1,,11113899,4485,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
281,880,2,1,,11113899,4485,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
282,880,2,1,,17388858,4485,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
283,880,2,1,,17388858,4485,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
284,880,2,1,,26747150,4485,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
285,880,2,1,,26747150,4485,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
286,880,2,1,,26752059,4485,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
287,880,2,1,,26752059,4485,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
288,880,2,1,,26752060,4485,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
289,880,2,1,,26752060,4485,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
290,880,2,1,,50104712,4485,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
291,880,2,1,,50104712,4485,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
292,881,2,2,,11111549,4485,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
293,881,2,2,,11113899,4485,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
294,881,2,2,,17388858,4485,Inconclusive,317373425.0,247.0,10.0,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
295,883,1,3,,11111548,4485,Inconclusive,13699818.0,1559.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
296,883,1,3,,11111549,4485,Inconclusive,13699818.0,1559.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
297,883,1,3,,11113899,4485,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
298,884,1,2,,11111549,4485,Active,13435386.0,1576.0,10.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
299,884,1,2,,11113899,4485,Active,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
300,884,1,2,,17388858,4485,Inconclusive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
301,885,1,2,,11111549,4485,Inactive,13435386.0,1576.0,10.0,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
302,885,1,2,,11113899,4485,Inactive,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
303,885,1,2,,17388858,4485,Inactive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
304,886,1,2,,11111548,4485,Inactive,122921310.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
305,886,1,2,,11111548,4485,Inactive,122921311.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
306,886,1,2,,11111549,4485,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
307,886,1,2,,11111549,4485,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
308,886,1,2,,11113899,4485,Inactive,122921310.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
309,886,1,2,,11113899,4485,Inactive,122921311.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
310,886,1,2,,17388858,4485,Inactive,122921310.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
311,886,1,2,,17388858,4485,Inactive,122921311.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
312,887,1,2,,11111549,4485,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
313,887,1,2,,11113899,4485,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
314,887,1,2,,17388858,4485,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
315,889,1,3,,11111549,4485,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
316,889,1,3,,11113899,4485,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
317,889,1,3,,17388858,4485,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
318,891,1,2,,11111548,4485,Inconclusive,40805836.0,1565.0,39.8107,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
319,891,1,2,,11111549,4485,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
320,891,1,2,,11113899,4485,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
321,892,1,2,,11111549,4485,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
322,892,1,2,,11113899,4485,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
323,892,1,2,,17388858,4485,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
324,893,1,2,,11111549,4485,Inconclusive,122921310.0,,12.5893,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
325,893,1,2,,11111549,4485,Inconclusive,122921311.0,,12.5893,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
326,893,1,2,,11113899,4485,Active,122921310.0,,10.0,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
327,893,1,2,,11113899,4485,Active,122921311.0,,10.0,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
328,893,1,2,,17388858,4485,Active,122921310.0,,7.9433,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
329,893,1,2,,17388858,4485,Active,122921311.0,,7.9433,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
330,894,2,1,,855613,4485,Active,31542939.0,3248.0,11.2202,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
331,894,2,1,,11111549,4485,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
332,894,2,1,,11113899,4485,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
333,894,2,1,,17388858,4485,Inconclusive,31542939.0,3248.0,15.8489,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
334,894,2,1,,26747150,4485,Inconclusive,31542939.0,3248.0,28.1838,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
335,894,2,1,,50104712,4485,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
336,895,1,2,,11113899,4485,Active,21620132.0,4790.0,11.2202,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
337,898,1,1,,855613,4485,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
338,899,1,2,,11111548,4485,Active,4503219.0,1557.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
339,899,1,2,,11111549,4485,Inconclusive,4503219.0,1557.0,7.9433,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
340,899,1,2,,11113899,4485,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
341,900,1,3,,11111549,4485,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
342,900,1,3,,11113899,4485,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
343,900,1,3,,17388858,4485,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
344,901,1,2,,11111549,4485,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
345,901,1,2,,11113899,4485,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
346,902,1,2,,11111549,4485,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
347,902,1,2,,11113899,4485,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
348,902,1,2,,17388858,4485,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
349,910,1,2,,11113899,4485,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
350,912,1,2,,11111548,4485,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
351,912,1,2,,11111549,4485,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
352,912,1,2,,11113899,4485,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
353,912,1,2,,17388858,4485,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
354,914,1,3,,855613,4485,Inconclusive,32879895.0,3091.0,0.5012,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
355,914,1,3,,11111548,4485,Inconclusive,32879895.0,3091.0,1.0,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
356,914,1,3,,11111549,4485,Inconclusive,32879895.0,3091.0,0.5012,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
357,915,1,3,,855613,4485,Active,32879895.0,3091.0,0.5012,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
358,915,1,3,,11111548,4485,Active,32879895.0,3091.0,1.0,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
359,915,1,3,,11111549,4485,Inconclusive,32879895.0,3091.0,0.5012,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
360,917,1,3,,11113899,4485,Inconclusive,120660324.0,7066.0,1.5849,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
361,918,1,3,,11113899,4485,Inconclusive,120660324.0,7066.0,1.5849,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
362,920,1,2,,855613,4485,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
363,921,1,2,,17388858,4485,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-001,Confirmatory,,
364,923,1,2,,11111549,4485,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
365,923,1,2,,11113899,4485,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
366,923,1,2,,17388858,4485,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
367,924,1,2,,11111549,4485,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
368,924,1,2,,11113899,4485,Inactive,120407068.0,7157.0,31.6228,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
369,924,1,2,,17388858,4485,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
370,925,1,2,,11111548,4485,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
371,925,1,2,,11111549,4485,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
372,925,1,2,,17388858,4485,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
373,926,1,2,,11111548,4485,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
374,926,1,2,,11111549,4485,Unspecified,38016895.0,7253.0,0.1585,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
375,926,1,2,,11113899,4485,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
376,926,1,2,,17388858,4485,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
377,927,1,3,,11111549,4485,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
378,927,1,3,,11113899,4485,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
379,928,1,2,,11113899,4485,Inconclusive,21620132.0,4790.0,11.2202,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
380,930,1,2,,11113899,4485,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
381,932,1,4,,855613,4485,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
382,938,1,2,,11111548,4485,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
383,938,1,2,,11111549,4485,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
384,938,1,2,,11113899,4485,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
385,938,1,2,,17388858,4485,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
386,940,1,2,,855613,4485,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
387,940,1,2,,17405380,4485,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
388,940,1,2,,26611837,4485,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
389,943,1,2,,11113899,4485,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
390,944,1,2,,11113899,4485,Inconclusive,18249941.0,25229.0,15.8489,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
391,945,1,4,,11113899,4485,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
392,946,1,2,,17388858,4485,Active,,,50.1187,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
393,947,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
394,948,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
395,950,1,1,,855613,4485,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
396,951,1,1,,855613,4485,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
397,952,1,1,,855613,4485,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
398,954,1,2,,11113899,4485,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
399,955,1,2,,17388858,4485,Active,,,31.6228,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
400,957,1,2,,11113899,4485,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
401,958,1,2,,11113899,4485,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
402,959,1,4,,11113899,4485,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
403,960,1,2,,17388858,4485,Inconclusive,,,31.6228,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
404,961,1,2,,17388858,4485,Active,,,50.1187,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
405,962,1,2,,17388858,4485,Inconclusive,,,100.0,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
406,963,1,2,,17388858,4485,Active,,,50.1187,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
407,964,1,2,,17388858,4485,Active,,,39.8107,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
408,965,1,2,,17388858,4485,Active,,,50.1187,Potency,Cell Viability - LYMP2-003,Confirmatory,,
409,966,1,2,,17388858,4485,Active,,,31.6228,Potency,Cell Viability - LYMP2-004,Confirmatory,,
410,967,1,2,,17388858,4485,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-005,Confirmatory,,
411,968,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-009,Confirmatory,,
412,969,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-011,Confirmatory,,
413,970,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-013,Confirmatory,,
414,971,1,2,,17388858,4485,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-015,Confirmatory,,
415,972,1,2,,17388858,4485,Active,,,50.1187,Potency,Cell Viability - LYMP2-017,Confirmatory,,
416,973,1,2,,17388858,4485,Active,,,79.4328,Potency,Cell Viability - LYMP2-019,Confirmatory,,
417,974,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-021,Confirmatory,,
418,975,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-023,Confirmatory,,
419,976,1,2,,17388858,4485,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
420,977,1,2,,17388858,4485,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-002,Confirmatory,,
421,978,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-006,Confirmatory,,
422,979,1,2,,17388858,4485,Active,,,39.8107,Potency,Cell Viability - LYMP2-007,Confirmatory,,
423,980,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-008,Confirmatory,,
424,981,1,2,,17388858,4485,Active,,,39.8107,Potency,Cell Viability - LYMP2-010,Confirmatory,,
425,982,1,2,,17388858,4485,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-012,Confirmatory,,
426,983,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-014,Confirmatory,,
427,984,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-016,Confirmatory,,
428,985,1,2,,17388858,4485,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-018,Confirmatory,,
429,986,1,2,,17388858,4485,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-020,Confirmatory,,
430,987,1,2,,17388858,4485,Active,,,50.1187,Potency,Cell Viability - LYMP2-022,Confirmatory,,
431,988,1,2,,17388858,4485,Active,,,39.8107,Potency,Cell Viability - LYMP2-024,Confirmatory,,
432,989,1,2,,17388858,4485,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
433,992,1,3,,11113899,4485,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
434,993,1,2,,17388858,4485,Active,,,50.1187,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
435,994,1,2,,17388858,4485,Active,,,39.8107,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
436,995,1,2,,11111549,4485,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
437,995,1,2,,11113899,4485,Active,66932916.0,5594.0,25.1189,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
438,995,1,2,,17388858,4485,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
439,997,1,2,,11113899,4485,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
440,998,1,2,,11113899,4485,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
441,1001,2,2,,855613,4485,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
442,1006,1,6,,855613,4485,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
443,1007,1,1,,855613,4485,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
444,1008,1,2,,855613,4485,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
445,1009,1,2,,855613,4485,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
446,1012,1,4,,855613,4485,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
447,1016,1,4,,855613,4485,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
448,1018,2,5,,855613,4485,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
449,1019,1,4,,855613,4485,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
450,1020,1,5,,855613,4485,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
451,1021,1,1,,855613,4485,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
452,1022,1,1,,855613,4485,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
453,1027,1,3,,855613,4485,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
454,1030,2,1,,855613,4485,Active,30582681.0,216.0,15.8489,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
455,1030,2,1,,11111549,4485,Inconclusive,30582681.0,216.0,12.5893,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
456,1030,2,1,,11113899,4485,Inconclusive,30582681.0,216.0,31.6228,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
457,1030,2,1,,17388858,4485,Active,30582681.0,216.0,8.9125,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
458,1030,2,1,,26747150,4485,Inconclusive,30582681.0,216.0,7.9433,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
459,1030,2,1,,26752059,4485,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
460,1030,2,1,,26752060,4485,Inconclusive,30582681.0,216.0,25.1189,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
461,1030,2,1,,50104712,4485,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
462,1032,1,2,,855613,4485,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
463,1032,1,2,,855613,4485,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
464,1040,1,2,,855613,4485,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
465,1046,1,6,,855613,4485,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
466,1048,1,1,,855613,4485,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
467,1048,1,1,,855613,4485,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
468,1049,1,1,,855613,4485,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
469,1049,1,1,,855613,4485,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
470,1051,1,1,,855613,4485,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
471,1051,1,1,,855613,4485,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
472,1063,1,1,,855613,4485,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
473,1066,1,2,,855613,4485,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
474,1085,1,1,,855613,4485,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
475,1135,1,3,,855613,4485,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
476,1136,1,3,,855613,4485,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
477,1203,1,3,,855613,4485,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
478,1209,2,2,,855613,4485,Active,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
479,1214,1,4,,855613,4485,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
480,1216,1,5,,855613,4485,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
481,1217,1,4,,855613,4485,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
482,1220,2,2,,855613,4485,Active,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
483,1222,1,6,,855613,4485,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
484,1229,1,3,,855613,4485,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
485,1235,1,2,,855613,4485,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
486,1236,1,1,,855613,4485,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
487,1239,1,3,,855613,4485,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
488,1239,1,3,,855613,4485,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
489,1242,1,1,,855613,4485,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
490,1246,1,2,,855613,4485,Inactive,56417702.0,,,,Primary HTS assay for chemical inhibitors of TNF alpha stimulated E-Selectin expression,Screening,,
491,1251,1,1,,855613,4485,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
492,1273,1,1,,855613,4485,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
493,1274,1,2,,855613,4485,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
494,1276,1,1,,855613,4485,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
495,1285,1,1,,855613,4485,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
496,1296,1,1,,855613,4485,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
497,1304,1,2,,855613,4485,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
498,1321,1,2,,855613,4485,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
499,1325,1,2,,855613,4485,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
500,1326,1,4,,855613,4485,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
501,1332,1,1,,49698329,4485,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
502,1359,1,4,,855613,4485,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
503,1362,1,2,,855613,4485,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
504,1376,1,2,,855613,4485,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
505,1377,1,1,,855613,4485,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
506,1379,1,2,,855613,4485,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
507,1379,1,2,,11111549,4485,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
508,1379,1,2,,11113899,4485,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
509,1379,1,2,,26747150,4485,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
510,1379,1,2,,50104712,4485,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
511,1381,1,1,,855613,4485,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
512,1385,2,2,,855613,4485,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
513,1416,1,2,,855613,4485,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
514,1422,1,1,,855613,4485,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
515,1422,1,1,,17405380,4485,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
516,1422,1,1,,26611837,4485,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
517,1424,1,1,,855613,4485,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
518,1430,1,1,,855613,4485,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
519,1434,2,3,,855613,4485,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
520,1434,2,3,,855613,4485,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
521,1443,1,3,,855613,4485,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
522,1445,1,1,,855613,4485,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
523,1446,1,3,,855613,4485,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
524,1448,1,3,,855613,4485,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
525,1452,1,1,,855613,4485,Inconclusive,154426292.0,239.0,31.6228,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
526,1452,1,1,,11111549,4485,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
527,1452,1,1,,11113899,4485,Inconclusive,154426292.0,239.0,22.3872,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
528,1452,1,1,,17388858,4485,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
529,1454,1,1,,855613,4485,Inconclusive,66932916.0,5594.0,39.8107,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
530,1454,1,1,,11111549,4485,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
531,1454,1,1,,11113899,4485,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
532,1454,1,1,,26747150,4485,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
533,1454,1,1,,50104712,4485,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
534,1456,1,1,,855613,4485,Active,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
535,1457,1,1,,855613,4485,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
536,1457,1,1,,11111549,4485,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
537,1457,1,1,,11113899,4485,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
538,1457,1,1,,17388858,4485,Inactive,44888968.0,83523.0,11.2202,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
539,1457,1,1,,26747150,4485,Inactive,44888968.0,83523.0,8.9125,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
540,1457,1,1,,26752059,4485,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
541,1457,1,1,,26752060,4485,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
542,1457,1,1,,50104712,4485,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
543,1458,1,1,,855613,4485,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
544,1458,1,1,,11111549,4485,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
545,1458,1,1,,17388858,4485,Inactive,10937869.0,6607.0,28.1838,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
546,1458,1,1,,26747150,4485,Inconclusive,10937869.0,6607.0,5.6234,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
547,1458,1,1,,26752059,4485,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
548,1458,1,1,,26752060,4485,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
549,1458,1,1,,50104712,4485,Inactive,10937869.0,6607.0,19.9526,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
550,1459,1,1,,50104712,4485,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
551,1460,1,3,,855613,4485,Active,92096784.0,4137.0,3.5481,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
552,1460,1,3,,11113899,4485,Active,92096784.0,4137.0,12.5893,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
553,1460,1,3,,26747150,4485,Active,92096784.0,4137.0,3.9811,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
554,1460,1,3,,26752059,4485,Active,92096784.0,4137.0,14.1254,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
555,1460,1,3,,26752060,4485,Active,92096784.0,4137.0,4.4668,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
556,1460,1,3,,50104712,4485,Active,92096784.0,4137.0,19.9526,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
557,1461,1,2,,855613,4485,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
558,1461,1,2,,50104712,4485,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
559,1463,1,1,,855613,4485,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
560,1463,1,1,,11113899,4485,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
561,1463,1,1,,26747150,4485,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
562,1463,1,1,,26752059,4485,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
563,1463,1,1,,26752060,4485,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
564,1463,1,1,,50104712,4485,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
565,1465,1,1,,855613,4485,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
566,1466,1,2,,855613,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
567,1467,1,3,,855613,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
568,1467,1,3,,11111549,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
569,1467,1,3,,11113899,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
570,1467,1,3,,26747150,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
571,1467,1,3,,50104712,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
572,1468,1,1,,855613,4485,Active,92096784.0,4137.0,3.5481,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
573,1468,1,1,,11113899,4485,Active,92096784.0,4137.0,19.9526,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
574,1468,1,1,,26747150,4485,Active,92096784.0,4137.0,8.9125,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
575,1468,1,1,,26752059,4485,Active,92096784.0,4137.0,15.8489,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
576,1468,1,1,,26752060,4485,Active,92096784.0,4137.0,7.9433,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
577,1468,1,1,,50104712,4485,Active,92096784.0,4137.0,22.3872,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
578,1469,1,1,,855613,4485,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
579,1469,1,1,,11111549,4485,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
580,1469,1,1,,11113899,4485,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
581,1469,1,1,,17388858,4485,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
582,1469,1,1,,26747150,4485,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
583,1469,1,1,,26752059,4485,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
584,1469,1,1,,26752060,4485,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
585,1469,1,1,,50104712,4485,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
586,1471,2,1,,11111548,4485,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
587,1471,2,1,,11111549,4485,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
588,1471,2,1,,11113899,4485,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
589,1471,2,1,,17388858,4485,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
590,1471,2,1,,26747150,4485,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
591,1471,2,1,,26752059,4485,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
592,1471,2,1,,26752060,4485,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
593,1476,2,1,,855613,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
594,1476,2,1,,11111549,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
595,1476,2,1,,11113899,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
596,1476,2,1,,17388858,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
597,1476,2,1,,26747150,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
598,1476,2,1,,50104712,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
599,1477,1,1,,855613,4485,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
600,1477,1,1,,11111549,4485,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
601,1477,1,1,,11113899,4485,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
602,1477,1,1,,17388858,4485,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
603,1477,1,1,,26747150,4485,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
604,1477,1,1,,26752059,4485,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
605,1477,1,1,,26752060,4485,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
606,1477,1,1,,50104712,4485,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
607,1478,2,1,,855613,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
608,1478,2,1,,11111549,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
609,1478,2,1,,11113899,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
610,1478,2,1,,17388858,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
611,1478,2,1,,26747150,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
612,1478,2,1,,50104712,4485,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
613,1479,1,2,,855613,4485,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
614,1479,1,2,,11111549,4485,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
615,1479,1,2,,11113899,4485,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
616,1479,1,2,,17388858,4485,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
617,1479,1,2,,26747150,4485,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
618,1479,1,2,,26752059,4485,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
619,1479,1,2,,26752060,4485,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
620,1479,1,2,,50104712,4485,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
621,1481,1,2,,855613,4485,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
622,1486,1,3,,855613,4485,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
623,1487,1,1,,855613,4485,Inconclusive,27436948.0,4000.0,1.122,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
624,1487,1,1,,11111549,4485,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
625,1487,1,1,,50104712,4485,Inconclusive,27436948.0,4000.0,22.3872,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
626,1490,2,1,,855613,4485,Active,10954339.0,,17.7828,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
627,1490,2,1,,11111549,4485,Inconclusive,10954339.0,,12.5893,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
628,1490,2,1,,11113899,4485,Active,10954339.0,,56.2341,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
629,1490,2,1,,26747150,4485,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
630,1490,2,1,,26752059,4485,Active,10954339.0,,39.8107,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
631,1490,2,1,,26752060,4485,Active,10954339.0,,17.7828,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
632,1496,1,4,,855613,4485,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
633,1496,1,4,,855613,4485,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
634,1509,1,2,,855613,4485,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
635,1510,1,3,,855613,4485,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
636,1511,1,3,,49732003,4485,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
637,1515,1,2,,855613,4485,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
638,1519,1,3,,11111549,4485,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
639,1519,1,3,,11113899,4485,Inconclusive,,,3.1623,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
640,1519,1,3,,26747150,4485,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
641,1519,1,3,,50104712,4485,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
642,1527,1,3,,855613,4485,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
643,1529,1,1,,855613,4485,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
644,1529,1,1,,49732003,4485,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
645,1530,1,1,,855613,4485,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
646,1530,1,1,,49732003,4485,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
647,1531,1,1,,855613,4485,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
648,1531,1,1,,49732003,4485,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
649,1532,1,1,,855613,4485,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
650,1554,1,1,,49732003,4485,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
651,1556,1,4,,855613,4485,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
652,1565,2,2,,855613,4485,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
653,1566,2,3,,855613,4485,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
654,1578,3,2,,855613,4485,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
655,1580,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
656,1581,1,1,,8149443,4485,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
657,1582,1,1,,8149443,4485,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
658,1583,1,1,,8149443,4485,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
659,1584,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
660,1585,1,1,,8149443,4485,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
661,1586,1,1,,8149443,4485,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
662,1587,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
663,1588,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
664,1589,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
665,1590,1,1,,8149443,4485,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
666,1593,1,1,,8149443,4485,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
667,1594,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
668,1595,1,1,,8149443,4485,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
669,1596,1,1,,8149443,4485,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
670,1597,1,1,,8149443,4485,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
671,1598,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
672,1599,1,1,,8149443,4485,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
673,1600,1,1,,8149443,4485,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
674,1601,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
675,1602,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
676,1603,1,1,,8149443,4485,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
677,1604,1,1,,8149443,4485,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
678,1605,1,1,,8149443,4485,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
679,1606,1,1,,8149443,4485,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
680,1607,1,1,,8149443,4485,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
681,1608,1,1,,8149443,4485,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
682,1609,1,1,,8149443,4485,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
683,1610,1,1,,8149443,4485,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
684,1611,1,1,,8149443,4485,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
685,1612,1,1,,8149443,4485,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
686,1613,1,1,,8149443,4485,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
687,1614,1,1,,8149443,4485,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
688,1616,1,1,,8149443,4485,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
689,1619,1,2,,855613,4485,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
690,1621,1,2,,855613,4485,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
691,1626,1,2,,855613,4485,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
692,1631,3,1,,855613,4485,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
693,1634,3,1,,855613,4485,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
694,1654,2,2,,855613,4485,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
695,1656,2,2,,855613,4485,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
696,1662,1,2,,49732003,4485,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
697,1663,1,2,,49732003,4485,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
698,1672,1,3,,49732003,4485,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
699,1688,1,1,,855613,4485,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
700,1688,1,1,,26752060,4485,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
701,1700,1,2,,855613,4485,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
702,1705,1,2,,50104712,4485,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
703,1706,1,2,,855613,4485,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
704,1707,1,3,,50104712,4485,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
705,1708,1,3,,50104712,4485,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
706,1721,1,2,,855613,4485,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
707,1722,1,2,,855613,4485,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
708,1766,1,1,,855613,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
709,1766,1,1,,855613,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
710,1766,1,1,,11111549,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
711,1766,1,1,,11111549,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
712,1766,1,1,,11113899,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
713,1766,1,1,,11113899,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
714,1766,1,1,,26747150,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
715,1766,1,1,,26747150,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
716,1766,1,1,,26752060,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
717,1766,1,1,,26752060,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
718,1766,1,1,,50104712,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
719,1766,1,1,,50104712,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
720,1768,1,1,,855613,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
721,1768,1,1,,855613,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
722,1768,1,1,,11111549,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
723,1768,1,1,,11111549,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
724,1768,1,1,,11113899,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
725,1768,1,1,,11113899,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
726,1768,1,1,,26747150,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
727,1768,1,1,,26747150,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
728,1768,1,1,,26752060,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
729,1768,1,1,,26752060,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
730,1768,1,1,,50104712,4485,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
731,1768,1,1,,50104712,4485,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
732,1776,1,2,,855613,4485,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
733,1777,3,2,,855613,4485,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
734,1778,3,3,,855613,4485,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
735,1779,2,2,,855613,4485,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
736,1789,1,2,,855613,4485,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
737,1800,1,2,,855613,4485,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
738,1813,1,2,,49732003,4485,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
739,1814,1,2,,49732003,4485,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
740,1815,1,1,,50104712,4485,Inconclusive,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
741,1816,1,1,,50104712,4485,Inconclusive,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
742,1817,2,2,,855613,4485,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
743,1822,1,3,,855613,4485,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
744,1825,1,1,,855613,4485,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
745,1828,2,1,,50104712,4485,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
746,1832,2,1,,49732003,4485,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
747,1845,1,2,,855613,4485,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
748,1850,2,1,,855613,4485,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
749,1850,2,1,,49732003,4485,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
750,1851,1,2,,11111549,4485,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
751,1851,1,2,,11113899,4485,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
752,1851,1,2,1.0,11111549,4485,Inconclusive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
753,1851,1,2,1.0,11113899,4485,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
754,1851,1,2,2.0,11111549,4485,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
755,1851,1,2,2.0,11113899,4485,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
756,1851,1,2,3.0,11111549,4485,Active,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
757,1851,1,2,3.0,11113899,4485,Active,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
758,1851,1,2,4.0,11111549,4485,Active,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
759,1851,1,2,4.0,11113899,4485,Active,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
760,1851,1,2,5.0,11111549,4485,Inconclusive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
761,1851,1,2,5.0,11113899,4485,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
762,1861,2,1,,855613,4485,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
763,1862,1,4,,49732003,4485,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
764,1863,2,1,,855613,4485,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
765,1863,2,1,,49732003,4485,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
766,1865,1,1,,855613,4485,Inconclusive,,,5.6234,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
767,1865,1,1,,11111549,4485,Inconclusive,,,12.5893,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
768,1865,1,1,,11113899,4485,Inconclusive,,,35.4813,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
769,1865,1,1,,26747150,4485,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
770,1865,1,1,,26752059,4485,Inconclusive,,,25.1189,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
771,1865,1,1,,26752060,4485,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
772,1865,1,1,,50104712,4485,Inconclusive,,,22.3872,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
773,1867,1,4,,49732003,4485,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
774,1868,1,4,,855613,4485,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
775,1870,1,4,,49732003,4485,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
776,1873,1,4,,49732003,4485,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
777,1875,2,1,,49732003,4485,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
778,1876,1,1,,50104712,4485,Inconclusive,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
779,1877,1,1,,50104712,4485,Inconclusive,,,15.8489,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
780,1882,1,1,,50104712,4485,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
781,1883,1,1,,50104712,4485,Active,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
782,1885,2,1,,49732003,4485,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
783,1886,1,1,,50104712,4485,Inconclusive,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
784,1887,1,4,,49732003,4485,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
785,1899,1,3,,49732003,4485,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
786,1903,2,3,,855613,4485,Inconclusive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
787,1903,2,3,,49732003,4485,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
788,1906,1,3,,49732003,4485,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
789,1910,1,2,,49732003,4485,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
790,1918,1,2,,855613,4485,Active,223460826.0,3758.0,,,High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen,Screening,,
791,1947,1,2,,49732003,4485,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
792,1948,1,1,,11111549,4485,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
793,1948,1,1,,11113899,4485,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
794,1948,1,1,,17388858,4485,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
795,1948,1,1,,26747150,4485,Inactive,,,31.6228,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
796,1948,1,1,,50104712,4485,Inactive,,,15.8489,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
797,1950,1,3,,49732003,4485,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
798,1956,1,1,,855613,4485,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
799,1961,2,2,,855613,4485,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
800,1962,1,2,,49732003,4485,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
801,1967,1,1,,85231157,4485,Inconclusive,4505907.0,5376.0,75.6863,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
802,1974,1,2,,49732003,4485,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
803,1979,1,1,,49732003,4485,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
804,1984,1,3,,855613,4485,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
805,1986,1,2,,855613,4485,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
806,1987,1,2,,49732003,4485,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
807,2006,3,2,,855613,4485,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
808,2006,3,2,,855613,4485,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
809,2006,3,2,,855613,4485,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
810,2012,3,2,,855613,4485,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
811,2013,2,2,,855613,4485,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
812,2014,3,2,,855613,4485,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
813,2016,1,3,,49732003,4485,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
814,2023,1,3,,49732003,4485,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
815,2025,1,3,,49732003,4485,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
816,2029,1,3,,49732003,4485,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
817,2052,2,1,,49732003,4485,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
818,2057,1,2,,49732003,4485,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
819,2058,3,2,,855613,4485,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
820,2062,1,2,,85209750,4485,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
821,2066,1,4,,49732003,4485,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
822,2071,2,2,,855613,4485,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
823,2073,2,3,,855613,4485,Active,2625023.0,83589.0,1.12,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
824,2073,2,3,,855613,4485,Active,4502523.0,774.0,1.12,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
825,2091,1,3,,855613,4485,Active,2625023.0,83589.0,10.1,IC50,uHTS Homogeneous Terbium Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
826,2091,1,3,,855613,4485,Active,4502523.0,774.0,10.1,IC50,uHTS Homogeneous Terbium Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
827,2094,1,2,,855613,4485,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
828,2094,1,2,,855613,4485,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
829,2094,1,2,,855613,4485,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
830,2094,1,2,,49732003,4485,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
831,2094,1,2,,49732003,4485,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
832,2094,1,2,,49732003,4485,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
833,2097,1,2,,49732003,4485,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
834,2098,1,1,,49732003,4485,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
835,2099,1,1,,855613,4485,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
836,2099,1,1,,49732003,4485,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
837,2100,1,1,,855613,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
838,2101,1,1,,855613,4485,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
839,2101,1,1,,11111549,4485,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
840,2101,1,1,,11113899,4485,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
841,2101,1,1,,17388858,4485,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
842,2101,1,1,,26747150,4485,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
843,2101,1,1,,26752059,4485,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
844,2101,1,1,,26752060,4485,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
845,2101,1,1,,50104712,4485,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
846,2107,1,1,,855613,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
847,2107,1,1,,11111549,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
848,2107,1,1,,11113899,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
849,2107,1,1,,17388858,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
850,2107,1,1,,26747150,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
851,2107,1,1,,26752059,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
852,2107,1,1,,26752060,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
853,2107,1,1,,50104712,4485,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
854,2112,1,1,,855613,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
855,2112,1,1,,11111549,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
856,2112,1,1,,11113899,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
857,2112,1,1,,17388858,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
858,2112,1,1,,26747150,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
859,2112,1,1,,26752059,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
860,2112,1,1,,26752060,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
861,2112,1,1,,50104712,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
862,2120,1,1,,17388858,4485,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
863,2129,1,2,,49732003,4485,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
864,2130,1,3,,49732003,4485,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
865,2147,1,1,,855613,4485,Active,221046486.0,,25.1189,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
866,2147,1,1,,11111549,4485,Inconclusive,221046486.0,,15.8489,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
867,2147,1,1,,11113899,4485,Active,221046486.0,,28.1838,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
868,2147,1,1,,26747150,4485,Active,221046486.0,,14.1254,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
869,2147,1,1,,50104712,4485,Active,221046486.0,,22.3872,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
870,2156,2,2,,49732003,4485,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
871,2174,1,3,,49732003,4485,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
872,2177,1,3,,49732003,4485,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
873,2205,1,1,,855613,4485,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
874,2216,1,3,,49732003,4485,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
875,2221,1,2,,855613,4485,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
876,2221,1,2,,49732003,4485,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
877,2227,1,2,,49732003,4485,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
878,2234,1,2,,49732003,4485,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
879,2235,1,2,,49732003,4485,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
880,2237,1,2,,49732003,4485,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
881,2239,1,2,,49732003,4485,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
882,2242,1,1,,855613,4485,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
883,2247,1,2,,49732003,4485,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
884,2280,2,3,,49732003,4485,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
885,2288,1,1,,855613,4485,Inconclusive,,,26.1216,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
886,2289,1,1,,855613,4485,Inconclusive,,,26.1216,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
887,2300,1,3,,49732003,4485,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
888,2314,1,2,,855613,4485,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
889,2314,1,2,,855613,4485,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
890,2315,1,2,,855613,4485,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
891,2315,1,2,,855613,4485,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
892,2323,1,1,,50104712,4485,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
893,2326,1,1,,855613,4485,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
894,2326,1,1,,50104712,4485,Inactive,194352380.0,,63.0957,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
895,2353,1,3,,50104712,4485,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
896,2364,1,2,,50104712,4485,Inconclusive,4557365.0,641.0,3.9811,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
897,2380,1,2,,49732003,4485,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
898,2391,1,1,,49732003,4485,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
899,2417,1,1,,855613,4485,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
900,2435,1,2,,49732003,4485,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
901,2445,1,2,,49732003,4485,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
902,2451,1,2,,855613,4485,Active,122920737.0,,7.9245,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
903,2451,1,2,,11111549,4485,Inconclusive,122920737.0,,12.5594,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
904,2451,1,2,,11113899,4485,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
905,2451,1,2,,26747150,4485,Active,122920737.0,,17.7407,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
906,2451,1,2,,50104712,4485,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
907,2462,1,1,,49732003,4485,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
908,2462,1,1,,49732003,4485,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
909,2472,1,2,,855613,4485,Active,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
910,2472,1,2,,11111549,4485,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
911,2472,1,2,,11113899,4485,Active,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
912,2472,1,2,,26747150,4485,Active,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
913,2517,2,1,,855613,4485,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
914,2517,2,1,,11111549,4485,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
915,2517,2,1,,11113899,4485,Inactive,6980812.0,,1.122,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
916,2517,2,1,,17388858,4485,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
917,2517,2,1,,26747150,4485,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
918,2517,2,1,,26752059,4485,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
919,2517,2,1,,26752060,4485,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
920,2517,2,1,,50104712,4485,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
921,2520,1,4,,49732003,4485,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
922,2521,1,3,,49732003,4485,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
923,2523,1,1,,49732003,4485,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
924,2524,1,2,,49732003,4485,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
925,2528,1,2,,855613,4485,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
926,2528,1,2,,11111549,4485,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
927,2528,1,2,,11113899,4485,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
928,2528,1,2,,26747150,4485,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
929,2528,1,2,,26752060,4485,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
930,2528,1,2,,50104712,4485,Inconclusive,4557365.0,641.0,3.9811,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
931,2540,1,2,,49732003,4485,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
932,2544,1,2,,49732003,4485,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
933,2546,1,1,,855613,4485,Active,188536040.0,19885.0,3.1623,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
934,2546,1,1,,11111549,4485,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
935,2546,1,1,,11113899,4485,Active,188536040.0,19885.0,28.1838,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
936,2546,1,1,,17388858,4485,Active,188536040.0,19885.0,12.5893,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
937,2546,1,1,,26747150,4485,Active,188536040.0,19885.0,10.0,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
938,2546,1,1,,26752060,4485,Inconclusive,188536040.0,19885.0,35.4813,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
939,2549,1,1,,855613,4485,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
940,2549,1,1,,11111549,4485,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
941,2549,1,1,,11113899,4485,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
942,2549,1,1,,17388858,4485,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
943,2549,1,1,,26747150,4485,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
944,2549,1,1,,26752059,4485,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
945,2549,1,1,,26752060,4485,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
946,2549,1,1,,50104712,4485,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
947,2550,1,3,,49732003,4485,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
948,2551,1,1,,855613,4485,Active,188536040.0,19885.0,7.0795,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
949,2551,1,1,,11111549,4485,Active,188536040.0,19885.0,12.5893,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
950,2551,1,1,,11113899,4485,Active,188536040.0,19885.0,11.2202,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
951,2551,1,1,,17388858,4485,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
952,2551,1,1,,26747150,4485,Active,188536040.0,19885.0,7.9433,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
953,2551,1,1,,26752060,4485,Inconclusive,188536040.0,19885.0,35.4813,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
954,2553,1,2,,49732003,4485,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
955,2557,1,3,,49732003,4485,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
956,2563,1,1,,855613,4485,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
957,2563,1,1,,49732003,4485,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
958,2599,1,2,,49732003,4485,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
959,2606,1,2,,49732003,4485,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
960,2629,1,1,,49732003,4485,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
961,2642,1,2,,49732003,4485,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
962,2648,1,2,,49732003,4485,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
963,2650,2,1,,49732003,4485,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
964,2660,1,1,,90341123,4485,Inconclusive,4826730.0,2475.0,16.4816,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
965,2661,1,1,,49732003,4485,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
966,2662,2,1,,855613,4485,Inconclusive,56550039.0,4297.0,39.8107,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
967,2662,2,1,,85231157,4485,Inconclusive,56550039.0,4297.0,50.1187,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
968,2666,1,1,,90341123,4485,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
969,2667,1,1,,90341123,4485,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
970,2668,1,1,,90341123,4485,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
971,2674,1,1,,49732003,4485,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
972,2675,1,1,,855613,4485,Inconclusive,41281591.0,4154.0,79.4328,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
973,2675,1,1,,50104712,4485,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
974,2676,1,2,,855613,4485,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
975,2685,1,1,,855613,4485,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
976,2690,1,2,,49732003,4485,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
977,2701,1,1,,855613,4485,Active,10954339.0,,37.2898,Potency,Confirmation qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
978,2706,1,1,,49732003,4485,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
979,2716,1,1,,49732003,4485,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
980,2717,1,2,,49732003,4485,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
981,2718,1,1,,49732003,4485,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
982,2732,1,1,,855613,4485,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
983,2732,1,1,,17405380,4485,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
984,2751,2,2,,49732003,4485,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
985,2774,1,3,,92304176,4485,Inactive,,,,,LOPAC Circadian Assay,Screening,,
986,2796,1,4,,49732003,4485,Active,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
987,2797,1,2,,49732003,4485,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
988,2805,2,2,,49732003,4485,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
989,2806,2,2,,49732003,4485,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
990,2825,1,2,,49732003,4485,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
991,2845,1,3,,49732003,4485,Inactive,4502003.0,196.0,,,Luminescence-based cell-based high throughput confirmation assay for activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
992,7783,3,4,,103557046,4485,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
993,8002,5,2,,103557046,4485,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
994,9718,5,2,,103557046,4485,Unspecified,,,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Other,2552119.0,
995,9879,3,3,,103557046,4485,Unspecified,,,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Other,2552119.0,
996,10375,4,3,,103557046,4485,Unspecified,,,,,Hill coefficient of the compound,Other,3023614.0,
997,17659,6,3,,103557046,4485,Active,,,12.0,Kd,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,Confirmatory,2002467.0,
998,17662,3,4,,103557046,4485,Unspecified,,,,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,Other,2002467.0,
999,18875,5,2,,103557046,4485,Unspecified,,,,,Half life of the compound,Other,2342074.0,
1000,19006,4,3,,103557046,4485,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
1001,19262,5,1,,103557046,4485,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
1002,19424,3,4,,103557046,4485,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
1003,19427,3,3,,103557046,4485,Unspecified,,,,,HPLC capacity factor (k),Other,10956200.0,
1004,19429,3,3,,103557046,4485,Unspecified,,,,,Partition coefficient (logP),Other,9154974.0,
1005,21233,3,3,,103557046,4485,Unspecified,,,,,Partition coefficient of compound in to biological membranes,Other,2002467.0,
1006,21661,3,3,,103557046,4485,Unspecified,,,,,Calculated partition coefficient (clogP) (PALLAS),Other,9154974.0,
1007,22293,4,4,,103557046,4485,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
1008,22770,5,2,,103557046,4485,Unspecified,,,,,"Time taken for 50% recovery of coronary vascular resistance in dogs, after administration of a dose of 150 micorg/kg intravenously",Other,2795609.0,
1009,22772,3,3,,103557046,4485,Unspecified,,,,,"Time taken for 50% recovery of coronary vascular resistance, expressed in hours was determined in dogs",Other,2918502.0,
1010,26304,4,4,,103557046,4485,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
1011,26380,3,3,,103557046,4485,Inconclusive,,,,,Dissociation constant (pKa),Other,14971904.0,
1012,27580,3,3,,103557046,4485,Unspecified,,,,,Partition coefficient (logP),Other,10956200.0,
1013,27900,6,2,,103557046,4485,Unspecified,,,,,Plasma clearance of the compound,Other,11311053.0,
1014,28233,3,3,,103557046,4485,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
1015,28235,3,3,,103557046,4485,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
1016,28236,3,3,,103557046,4485,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
1017,28677,3,4,,103557046,4485,Unspecified,,,,,Partition coefficient (logD),Other,11311053.0,
1018,29360,4,3,,103557046,4485,Inconclusive,,,,,Ionization constant (pKa),Other,10891117.0,
1019,29421,3,3,,103557046,4485,Unspecified,,,,,Partition coefficient (logP) (HPLC),Other,10956200.0,
1020,29423,3,4,,103557046,4485,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
1021,29811,4,3,,103557046,4485,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
1022,29851,3,3,,103557046,4485,Unspecified,,,,,Half life was measured as time taken to decrease half of its initial concentration,Other,11311053.0,
1023,29925,5,2,,103557046,4485,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
1024,30135,5,2,,103557046,4485,Unspecified,,,,,Volume of distribution of the compound,Other,11311053.0,
1025,31706,9,2,,103557046,4485,Active,,,10.0,Ki,Displacement of [3H](R)-PIA binding to Adenosine A1 receptor in rat brain membranes,Confirmatory,8709132.0,
1026,32018,9,1,,103557046,4485,Active,,,2.89,Ki,Binding affinity against adenosine A1 receptor in rat cerebral cortex membrane by radioligand binding assay using [3H](R)-PIA.,Confirmatory,8917655.0,
1027,33788,9,2,,103557046,4485,Active,,,10.0,Ki,Displacement of [3H]-CGS- 21680 binding to Adenosine A2A receptor in rat striatal membranes,Confirmatory,8709132.0,
1028,34125,9,5,,103557046,4485,Active,803374855.0,140.0,8.29,Ki,Inhibition of [125I]- AB-MECA binding to human Adenosine A3 receptors expressed in HEK cells,Confirmatory,8917655.0,
1029,34237,8,5,,103557046,4485,Active,543740.0,135.0,22.2,Ki,"Binding affinity for HA-tagged mutant human Adenosine A2A receptor (H250N) using [3H]-CGS-21,680 as radioligand expressed in COS-7 cells",Confirmatory,9258366.0,
1030,34238,8,5,,103557046,4485,Active,543740.0,135.0,22.2,Ki,"Binding affinity for HA-tagged mutant human Adenosine A2A receptor (V84L), using [3H]CGS-21680 as radioligand expressed in COS-7 cells",Confirmatory,9258366.0,
1031,34239,8,5,,103557046,4485,Unspecified,543740.0,135.0,244.0,Ki,Binding affinity for HA-tagged wild type human Adenosine A2A receptor (WT) using [3H]CGS-21680 as radioligand expressed in COS-7 cells,Confirmatory,9258366.0,
1032,34564,9,2,,103557046,4485,Active,,,10.0,Ki,Displacement of [125]AB-MECA binding to human Adenosine A3 receptor expressed in HEK cells,Confirmatory,8709132.0,
1033,36439,7,3,,103557046,4485,Unspecified,,,1.0,Ki,Alpha-1 adrenergic receptor binding affinity was evaluated by its ability to displace [3H]prazosin in rat brain synaptosomes,Confirmatory,,
1034,39458,3,3,,103557046,4485,Unspecified,,,,,Coronary vasodilator activity in anesthetized dogs at the dose of 150 ug/kg (iv),Other,2342074.0,
1035,44639,4,4,,103557046,4485,Active,,,1.0,IC50,IKCa channel inhibition was determined measuring ionomycin-induced Rb+ efflux of pre loaded rat C6BU1 glioma cell in comparison with Nifedipine,Confirmatory,12873483.0,
1036,44919,4,5,,103557046,4485,Active,,,0.00053,Ki,[Ca2+] channel binding affinity was evaluated by its ability to displace [3H]-PN-200-110 in rat brain synaptosomes,Confirmatory,,
1037,45600,6,4,,103557046,4485,Active,,,0.00053,Ki,The compound was tested in vitro for its ability to displace [3H]PN-200-110 from Calcium Channel in rat brain membranes.,Confirmatory,,
1038,45604,3,7,,103557046,4485,Unspecified,,,,,Negative log antagonist concentration causing 50% displacement of [3H]nifedipine from guinea pig ileal smooth muscle membrane.,Other,3560157.0,
1039,45614,6,3,,103557046,4485,Active,,,0.0025,IC50,Displacement of [3H]nitrendipine binding to L-type calcium channel of Guinea pig cerebral cortex membranes,Confirmatory,1552511.0,
1040,45618,3,7,,103557046,4485,Active,,,,,Dissociation constant for inhibition of [3H]nitrendipine binding to guinea pig myocardial membranes,Other,2834556.0,
1041,45634,10,5,,103557046,4485,Active,116411.0,100144322.0,0.001,IC50,Inhibition of [3H]nitrendipine binding to calcium channels in Rabbit cardiac muscle.,Confirmatory,3184128.0,
1042,45635,6,2,,103557046,4485,Active,,,0.001,IC50,Calcium channel blocking activity in rabbit,Confirmatory,2435903.0,
1043,45781,10,5,,103557046,4485,Active,116412.0,24239.0,0.00465,Ki,Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenate,Confirmatory,3023614.0,
1044,45781,10,5,,103557046,4485,Active,6165987.0,29716.0,0.00465,Ki,Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenate,Confirmatory,3023614.0,
1045,45781,10,5,,103557046,4485,Active,6165996.0,682930.0,0.00465,Ki,Inhibition of [3H]nitrendipine binding to L-type calcium channel from rat brain cortex homogenate,Confirmatory,3023614.0,
1046,47565,7,2,,103557046,4485,Active,,,0.0027,IC50,Inhibitory concentration for L-type [Ca2+] channels was measured through displacement of [3H]nitrendipine on rat cortex homogenates.,Confirmatory,9876109.0,
1047,47566,7,2,,103557046,4485,Active,,,0.0012,Ki,Binding affinity for L-type [Ca2+] channels was measured through displacement of [3H]nitrendipine on rat cortex homogenates.,Confirmatory,9876109.0,
1048,48347,8,1,,103557046,4485,Active,,,0.6,ID50,[Ca2+] antagonistic activity on [Ca2+] current in cat papillary.,Confirmatory,6304312.0,
1049,48348,8,1,,103557046,4485,Active,,,0.6,ID50,[Ca2+] antagonistic activity on [Ca2+] current in cat ventricular trabeculae,Confirmatory,6304312.0,
1050,54753,6,7,,103557046,4485,Active,116241312.0,1576.0,10.0,IC50,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,Confirmatory,14552748.0,
1051,55898,3,7,,103557046,4485,Unspecified,,,,,Bmax1 from dihydropyridine receptor binding assay in guinea pig myocardial membranes,Other,2834556.0,
1052,55902,3,3,,103557046,4485,Unspecified,,,,,Cardiovascular effect upon coronary artery blood flow(CBF) in anesthetized open-chest dogs at a dose of 10 ug/ kg administered intravenously,Other,12825942.0,
1053,56025,9,2,,103557046,4485,Active,,,0.0004,Kd,Displacement of [3H]nitrendipine from dihydropyridine receptor of guinea pig myocardial membranes,Confirmatory,7837222.0,
1054,56027,9,2,,103557046,4485,Active,,,0.001,Ki,Inhibition of [3H]nitrendipine binding to L-type calcium channel dihydropyridine site of porcine cardiac sarcolemma membrane vesicles,Confirmatory,2435904.0,
1055,56033,7,1,,103557046,4485,Active,,,0.00165,IC50,Inhibition of [3H]nitrendipine binding to calcium channels in the rat brain.,Confirmatory,2840504.0,
1056,57847,3,4,,103557046,4485,Unspecified,,,,,Cardiovascular effect upon blood pressure(BP) in anesthetized open-chest dogs at a dose of 10 ug/ kg administered intravenously,Other,12825942.0,
1057,58963,3,3,,103557046,4485,Unspecified,,,,,Duration of time taken for the compound for % decrease in coronary vasodilator activity,Other,2153819.0,
1058,59297,3,3,,103557046,4485,Unspecified,,,,,"Effective dose that lowers vascular resistance by, 30% in dogs when administered intravenously",Other,2552119.0,
1059,60650,3,3,,103557046,4485,Unspecified,,,,,The compound was tested for % decrease in coronary vasodilator activity in anesthetized dogs following intravenous administration,Other,2153819.0,
1060,60702,3,3,,103557046,4485,Unspecified,,,,,Cardiovascular effect upon femoral artery blood flow(FBF) in anesthetized open-chest dogs at a dose of 10 ug/ kg administered intravenously,Other,12825942.0,
1061,60874,4,3,,103557046,4485,Unspecified,,,,,Percent inhibition of calcium-dependent potassium-polarized smooth muscle contraction in canine trachea,Other,3184128.0,
1062,61748,3,3,,103557046,4485,Unspecified,,,,,"Coronary vasodilator activity in dogs, after administration of a dose of 150 micorg/kg intravenously",Other,2795609.0,
1063,61754,3,4,,103557046,4485,Unspecified,,,,,Percent decrease in coronary vascular resistance in dogs at 150 u/kg intravenous dose,Other,2918502.0,
1064,73721,6,3,,103557046,4485,Unspecified,,,2000000.0,EC50,Effect on BaCl2-stimulated contraction of ileum of guinea pig,Confirmatory,1319494.0,
1065,73722,6,3,,103557046,4485,Unspecified,,,8900000.0,EC50,Effect on KCl-stimulated contraction of aortic strips of guinea pig,Confirmatory,1319494.0,
1066,73832,3,3,,103557046,4485,Unspecified,,,,,Negative inotropy measured as the concentration required to depress contraction in the isolated Langendorff-perfused guinea pig heart by 25%,Other,2943898.0,
1067,75198,7,1,,103557046,4485,Active,,,,,"Concentration needed to elicit a 75% increase beyond control in coronary flow in ''Langendorff'', guinea pig heart (in vitro)",Other,3346879.0,
1068,75504,3,4,,103557046,4485,Unspecified,,,,,"Concentration needed to achieve a 75% increase in coronary blood flow in 'Langendorff', guinea pig heart (in vitro negative inotropic activity)",Other,3346879.0,
1069,76313,5,1,,103557046,4485,Unspecified,,,,,"Concentration needed to achieve a 75% increase in coronary blood flow in 'Langendorff', guinea pig heart (in vitro Negative inotropic potency)",Other,3346879.0,
1070,76357,5,3,,103557046,4485,Active,,,0.00513,EC50,Effective concentration required to produce mechanical response determined in muscle strips of guinea pig,Confirmatory,2846838.0,
1071,76358,5,2,,103557046,4485,Active,,,0.0008320000000000001,IC50,Compound was tested for its antagonist activity against calcium channel,Confirmatory,2846838.0,
1072,76370,4,3,,103557046,4485,Active,,,0.0315,IC50,Tested for [Ca2+] antagonism in guinea pig atria,Confirmatory,8411014.0,
1073,76371,4,3,,103557046,4485,Active,,,0.0047,IC50,Tested for [Ca2+] antagonism in guinea pig ileum,Confirmatory,8411014.0,
1074,76372,6,2,,103557046,4485,Active,,,0.004,IC50,Inhibition of K+ induced contractions of the isolated guinea pig ileum.,Confirmatory,8411014.0,
1075,76373,4,3,,103557046,4485,Active,,,0.0578,IC50,Tested for [Ca2+] antagonism in guinea pig right ventricle,Confirmatory,8411014.0,
1076,76393,6,3,,103557046,4485,Unspecified,,,20.0,IC50,Inhibition of spontaneous tone in Guinea pig tracheal spiral strips.,Confirmatory,2231602.0,
1077,76580,3,4,,103557046,4485,Unspecified,,,,,Maximum inhibition of BaCl2-stimulated contraction of ileum of guinea pig,Other,1319494.0,
1078,76581,3,4,,103557046,4485,Unspecified,,,,,Maximum inhibition of KCl-stimulated contraction of aortic strips of guinea pig,Other,1319494.0,
1079,76659,8,1,,103557046,4485,Active,,,0.01,ID50,Antagonistic activity against ACh in guinea pig ileum.,Confirmatory,6304312.0,
1080,76660,8,1,,103557046,4485,Unspecified,,,,ID50,Antagonistic activity against K+ induced responses in guinea pig ileum.,Confirmatory,6304312.0,
1081,76669,8,1,,103557046,4485,Active,,,1.0,ID50,[Ca2+] antagonistic activity on contraction in guinea pig atria.,Confirmatory,6304312.0,
1082,76978,8,1,,103557046,4485,Active,,,0.01,ID50,Inhibition of muscarinic receptor mediated [Ca2+] dependent contraction of guinea pig ileal longitudinal smooth muscle,Confirmatory,7057416.0,
1083,76980,7,1,,103557046,4485,Unspecified,,,1400000.0,ID50,Inhibition of muscarinic receptor mediated [Ca2+] dependent contraction of guinea pig ileal longitudinal smooth muscle.,Confirmatory,3560157.0,
1084,76985,8,1,,103557046,4485,Active,,,0.01,ID50,Inhibition of the muscarinic receptor mediated [Ca(2+)]-dependent contraction of guinea pig ileal longitudinal smooth muscle.,Confirmatory,3783612.0,
1085,77008,8,1,,103557046,4485,Active,,,0.01,ID50,The compound was tested for inhibition of muscarinic responses in guinea pig ileal longitudinal smooth muscle,Confirmatory,6256552.0,
1086,77341,4,7,,103557046,4485,Unspecified,,,,,"Calcium channel antagonistic activity relative to 2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester(=100)",Other,7057416.0,
1087,77612,4,4,,103557046,4485,Unspecified,,,,,Intrinsic activity measured on Guinea pig tracheal spiral strips.,Other,2231602.0,
1088,77874,4,3,,103557046,4485,Unspecified,,,,,Intrinsic activity value in comparison with nifedipine.,Other,1319494.0,
1089,78157,6,3,,103557046,4485,Active,,,0.013999999999999999,IC50,Calcium channel antagonist activity causing 50% inhibition of carbachol (1.6 x 10-7 M) induced Ca++ dependent contraction (tonic response) in guinea pig ileum longitudinal smooth muscle,Confirmatory,14695839.0,
1090,78278,6,3,,103557046,4485,Active,,,6.0,IC50,Effect on force of atrial contractions induced by PTX-B in guinea pig,Confirmatory,3981541.0,
1091,78279,6,3,,103557046,4485,Active,,,0.4,IC50,Effect on force of atrial contractions induced by PTX-B in guinea pig (control value),Confirmatory,3981541.0,
1092,78280,6,3,,103557046,4485,Active,,,12.0,IC50,Effect on rate of atrial contractions induced by PTX-B in guinea pig,Confirmatory,3981541.0,
1093,78281,6,3,,103557046,4485,Active,,,0.6,IC50,Effect on rate of atrial contractions induced by PTX-B in guinea pig (control value),Confirmatory,3981541.0,
1094,78491,4,7,,103557046,4485,Active,,,0.0025,IC50,Inhibitory concentration of [3H]- nitrendipine binding against guinea pig cerebral cortex membrane,Confirmatory,8496910.0,
1095,78672,3,3,,103557046,4485,Unspecified,,,,,Concentration required to depress contraction in the Langendorff-perfused guinea pig heart,Other,2342074.0,
1096,79033,6,2,,103557046,4485,Active,,,0.013999999999999999,IC50,Inhibition of carbachol-induced tonic contractile response in guinea pig ileal longitudinal smooth muscle,Confirmatory,9484501.0,
1097,79826,3,3,,103557046,4485,Unspecified,,,,,Evaluated for the negative ionotropy logarithm of the molar concentration required to depress contraction in the Langendorff-perfused guinea pig heart by 25%,Other,1992115.0,
1098,79827,3,3,,103557046,4485,Unspecified,,,,,In vitro assessment of negative inotropy in the isolated Langendorff perfused guinea pig heart,Other,2918502.0,
1099,79829,3,3,,103557046,4485,Unspecified,,,,,Negative logarithm of the concentration required to depress contraction in the Langendorff perfused guinea pig heart by 25%,Other,2153819.0,
1100,79830,3,3,,103557046,4485,Unspecified,,,,,Negative logarithm of the molar concentration required to depress contraction in the Langendorff-perfused guinea pig heart by 25%.,Other,2795609.0,
1101,80745,5,1,,103557046,4485,Unspecified,,,,,Evaluated in vitro for its effect on spontaneous atrial contractility in isolated guinea pig atria,Other,2261014.0,
1102,80746,5,1,,103557046,4485,Unspecified,,,,,Evaluated in vitro for the effect on spontaneous atrial rate in isolated guinea pig atria,Other,2261014.0,
1103,86389,3,4,,103557046,4485,Unspecified,,,,,Inhibitory effect on L-triiodothyronine (L-T3) uptake by human HepG2 hepatoma cells at an application dose 10E-5 M,Other,9154974.0,
1104,89416,6,2,,103557046,4485,Unspecified,,,100000000.0,IC50,Inhibition of collagen induced platelet aggregation in platelet-rich human plasma (PRP),Confirmatory,3172124.0,
1105,91705,6,3,,103557046,4485,Active,,,0.013999999999999999,IC50,Percent decrease in tonic contractile response in guinea pig ileal longitudinal smooth muscle.,Confirmatory,9599233.0,
1106,95580,10,5,,103557046,4485,Active,116412.0,24239.0,0.0035,Ki,"Inhibition of [3H](+)-PN200-110 binding to L-type calcium channel 1,4-DHP binding site of rat ventricular myocytes",Confirmatory,8246246.0,
1107,95589,3,11,,103557046,4485,Unspecified,116412.0,24239.0,,,"Effect on L-type [Ca2+] channels of rat RIN-m5F insulinoma cells in 10 mM Ba2+, -60 mV holding potential at 3uM, -20 mV",Other,15115410.0,
1108,95589,3,11,,103557046,4485,Unspecified,6165987.0,29716.0,,,"Effect on L-type [Ca2+] channels of rat RIN-m5F insulinoma cells in 10 mM Ba2+, -60 mV holding potential at 3uM, -20 mV",Other,15115410.0,
1109,95589,3,11,,103557046,4485,Unspecified,6165996.0,682930.0,,,"Effect on L-type [Ca2+] channels of rat RIN-m5F insulinoma cells in 10 mM Ba2+, -60 mV holding potential at 3uM, -20 mV",Other,15115410.0,
1110,95740,4,7,,103557046,4485,Unspecified,,,,,Evaluated for the free energies of binding (delta G) (in the resting state (rs) of voltage-gated L-type [Ca2+] channel (VGCCs)),Other,10377225.0,
1111,95741,4,7,,103557046,4485,Unspecified,,,,,Free energy of binding (delta G) for inactivated state (is) of voltage-gated L-type [Ca2+] channel(VGCCs),Other,10377225.0,
1112,95743,3,7,,103557046,4485,Unspecified,,,,,Free energies of binding (delta G) in the Resting state (rs) of voltage-gated L-type [Ca2+] channel(VGCCs),Other,10377225.0,
1113,101854,3,9,,103557046,4485,Unspecified,,,,,Compound was tested for percent of fraction inhibition by anti-P-450 NF.,Other,3746811.0,
1114,101858,3,9,,103557046,4485,Unspecified,116241312.0,1576.0,,,Rate of Oxidation in human liver microsomes is measured as mean (nmol product) formed / min per nmol cytochrome P-450,Other,3746811.0,
1115,112426,8,1,,103557046,4485,Unspecified,,,,,Effect on acute thrombic death induced by collagen in mice,Other,3361580.0,
1116,127918,3,3,,103557046,4485,Unspecified,,,,,Concentration causing local anesthetic activity in mice,Other,3184128.0,
1117,132053,9,1,,103557046,4485,Unspecified,,,,,Dose required to protect 50% of tested mice against experimental antithrombosis.,Other,3172124.0,
1118,160680,6,2,,103557046,4485,Active,,,0.0036,IC50,Vasorelaxant effect on KCl-Induced contraction of porcine coronary artery,Confirmatory,8809167.0,
1119,161281,10,5,,103557046,4485,Unspecified,7531135.0,3757.0,50.1187,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
1120,165364,4,3,,103557046,4485,Active,,,0.0069,IC50,Tested for [Ca2+] antagonism in rabbit renal artery,Confirmatory,8411014.0,
1121,165382,6,3,,103557046,4485,Active,,,0.2,IC50,The compound was tested for inhibition of potassium depolarized Rabbit aorta,Confirmatory,2840504.0,
1122,165447,4,3,,103557046,4485,Active,,,0.1131,IC50,Inhibition of electrically stimulated rabbit left atria contraction.,Confirmatory,1377748.0,
1123,165587,3,4,,103557046,4485,Unspecified,,,,,The vascular smooth muscle relaxant activity was expressed as percent relaxation of the developed isometric tension in potassium depolarized rabbit aortic smooth muscle,Other,6502606.0,
1124,165719,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-10 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine.,Other,2066997.0,
1125,165720,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-10 M on rabbit aortic rings previously contracted with 50 mM KCl.,Other,2066997.0,
1126,165723,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-5 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine.,Other,2066997.0,
1127,165724,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-5 M on rabbit aortic rings previously contracted with 50 mM KCl.,Other,2066997.0,
1128,165725,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-6 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine.,Other,2066997.0,
1129,165726,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-6 M on rabbit aortic rings previously contracted with 50 mM KCl.,Other,2066997.0,
1130,165727,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-7 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine.,Other,2066997.0,
1131,165728,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-7 M on rabbit aortic rings previously contracted with 50 mM KCl.,Other,2066997.0,
1132,165729,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-8 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine.,Other,2066997.0,
1133,165730,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-8 M on rabbit aortic rings previously contracted with 50 mM KCl.,Other,2066997.0,
1134,165731,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-9 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine.,Other,2066997.0,
1135,165732,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect at a concentration of 10e-9 M on rabbit aortic rings previously contracted with 50 mM KCl.,Other,2066997.0,
1136,165758,4,5,,103557046,4485,Active,,,0.0025,IC50,Compound was evaluated for vasorelaxant activity determined using potassium-depolarized rabbit thoracic aorta,Confirmatory,,
1137,166473,6,3,,103557046,4485,Inconclusive,,,,,Effect on 35 mM K+-induced contraction on rabbit aorta at a dose of 10E-6 mol/L; NT=Not tested,Other,3172124.0,
1138,166478,6,3,,103557046,4485,Inconclusive,,,,,Effect on 35 mM K+-induced contraction on rabbit aorta at a dose of 3*10e-6 mol/L; NT=Not tested,Other,3172124.0,
1139,166480,6,3,,103557046,4485,Inconclusive,,,,,Effect on 35 mM K+-induced contraction on rabbit aorta at a dose of 3*10e-7 mol/L; NT=Not tested,Other,3172124.0,
1140,167265,3,3,,103557046,4485,Unspecified,,,,,Electrophysiological effect in isolated rabbit hearts in atrio-His bundle (A-H) interval,Other,3361580.0,
1141,167351,5,1,,103557046,4485,Active,116411.0,100144322.0,0.0029,IC50,Blockade of calcium-evoked contractions in depolarized aortic strips,Confirmatory,1377748.0,
1142,167363,3,4,,103557046,4485,Unspecified,,,,,Effect on 35 mM K+-induced contraction on rabbit aorta at a dose of 10e-7 mol/L,Other,3172124.0,
1143,167364,3,4,,103557046,4485,Unspecified,,,,,Effect on 35 mM K+-induced contraction on rabbit aorta at a dose of 10e-8 mol\\L,Other,3172124.0,
1144,167365,3,4,,103557046,4485,Unspecified,,,,,Effect on 35 mM K+-induced contraction on rabbit aorta at a dose of 10e-9 mol\\L,Other,3172124.0,
1145,167366,3,4,,103557046,4485,Unspecified,,,,,Effect on 35 mM K+-induced contraction on rabbit aorta at a dose of 3*10e-8 mol/L,Other,3172124.0,
1146,167367,3,4,,103557046,4485,Unspecified,,,,,Effect on 35 mM K+-induced contraction on rabbit aorta at a dose of 3*10e-9 mol\\L,Other,3172124.0,
1147,167373,5,4,,103557046,4485,Unspecified,116411.0,100144322.0,,,Rate of reversal by Bay K 8644 of the blockade of K+ - stimulated rabbit aortic strips produced by the compound,Other,1377748.0,
1148,167546,3,4,,103557046,4485,Unspecified,,,,,"Recovery of the initial contraction of rabbit aortic strips, blocked at 10e-4 M concentration.",Other,1377748.0,
1149,167549,3,3,,103557046,4485,Unspecified,,,,,Relative potency was evaluated. (relative potency = IC50 of compound / IC50 of nifedipine),Other,1377748.0,
1150,167552,6,3,,103557046,4485,Unspecified,,,30.0,EC50,In vitro contraction of rabbit aorta strips.,Confirmatory,7837222.0,
1151,167553,6,3,,103557046,4485,Active,,,0.019,IC50,In vitro inhibition of potassium-induced contractions in rabbit aorta strips.,Confirmatory,7837222.0,
1152,167568,5,3,,103557046,4485,Active,,,0.00015800000000000002,Kd,Calcium channel-blocking activity by determined by ability to antagonize calcium-induced contractions of isolated rabbit aortic strips,Confirmatory,1920352.0,
1153,167659,4,4,,103557046,4485,Active,,,0.0005,IC50,Compound was tested for ability to relax potassium-contracted rabbit aorta smooth muscle,Confirmatory,2834556.0,
1154,167820,4,4,,103557046,4485,Active,,,0.002,IC50,In vitro evaluation for the inhibition of potassium-contracted rabbit aorta strips by vasorelaxant assay.,Confirmatory,1387168.0,
1155,168532,3,3,,103557046,4485,Active,,,,,Tested for reflex tachycardia at the dose of 50 mg/kg when administered intraperitoneally in spontaneously hypertensive rats; active,Other,10714490.0,
1156,168563,2,4,,103557046,4485,Unspecified,,,,,The compound was evaluated for the antihypertensive activity at a dose of 45 umol/kg given orally.,Other,,
1157,169102,5,3,,103557046,4485,Active,,,0.00398,IC50,In vitro calcium antagonist activity was assessed against sodium induced constriction of potassium -depolarized rat aorta by 50%,Confirmatory,2943898.0,
1158,171865,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity expressed as change in mean arterial blood pressure (MABP) in spontaneously hypertensive rats (SHR),at 0.5-2h after 30 mg/kg oral administration",Other,1920352.0,
1159,171866,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity expressed as change in mean arterial blood pressure (MABP) in spontaneously hypertensive rats (SHR), at 3-6h after 30 mg/kg oral administration",Other,1920352.0,
1160,172998,3,11,,103557046,4485,Unspecified,116412.0,24239.0,,,Percent block of total Ba2+ current on L-type [Ca2+] channels in rat RIN-m5F at 3 insulinoma cells (n = 14),Other,10212128.0,
1161,172998,3,11,,103557046,4485,Unspecified,6165987.0,29716.0,,,Percent block of total Ba2+ current on L-type [Ca2+] channels in rat RIN-m5F at 3 insulinoma cells (n = 14),Other,10212128.0,
1162,172998,3,11,,103557046,4485,Unspecified,6165996.0,682930.0,,,Percent block of total Ba2+ current on L-type [Ca2+] channels in rat RIN-m5F at 3 insulinoma cells (n = 14),Other,10212128.0,
1163,173542,3,4,,103557046,4485,Unspecified,,,,,Percent decrease in blood pressure in hypertensive rat at 16 mg/kg po,Other,2435903.0,
1164,173970,3,4,,103557046,4485,Unspecified,,,,,Compound evaluated for reducing diastolic blood pressure spontaneously hypertensive rats.,Other,1377748.0,
1165,173971,3,4,,103557046,4485,Unspecified,,,,,Reducing systolic blood pressure in spontaneously hypertensive rats.,Other,1377748.0,
1166,174616,3,3,,103557046,4485,Unspecified,,,,,Duration of action in spontaneously hypertensive rats.,Other,1377748.0,
1167,175301,3,3,,103557046,4485,Active,,,,,Concentration required to produce 25% increase in coronary flow,Other,2840504.0,
1168,175303,3,3,,103557046,4485,Active,,,,,Concentration required to produce 25% increase in intraventricular pressure(LV dp/dt),Other,2840504.0,
1169,179416,6,3,,103557046,4485,Active,,,0.0088,IC50,Dose-dependent inhibition of calcium contraction in depolarized rat aortic strips,Confirmatory,2435904.0,
1170,180311,4,11,,103557046,4485,Active,116412.0,24239.0,0.00253,IC50,Inhibition of [3H]nitrendipine binding to L-type calcium channels of rat cerebral cortex,Confirmatory,2552119.0,
1171,180311,4,11,,103557046,4485,Active,6165987.0,29716.0,0.00253,IC50,Inhibition of [3H]nitrendipine binding to L-type calcium channels of rat cerebral cortex,Confirmatory,2552119.0,
1172,180311,4,11,,103557046,4485,Active,6165996.0,682930.0,0.00253,IC50,Inhibition of [3H]nitrendipine binding to L-type calcium channels of rat cerebral cortex,Confirmatory,2552119.0,
1173,180478,4,4,,103557046,4485,Active,,,0.00116,IC50,Molar concentration required to block [Ca2+] induced contraction of K+ depolarized rat aorta by 50%,Confirmatory,1552511.0,
1174,180683,6,4,,103557046,4485,Active,,,0.004,IC50,Vasorelaxant potency by relaxation of the methoxamine contracted rat aorta,Confirmatory,,
1175,181533,4,3,,103557046,4485,Active,,,0.0025,IC50,Antihypertensive activity when administered orally to spontaneously hypertensive rats,Confirmatory,1995904.0,
1176,185729,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive effects in conscious, unrestrained, spontaneously hypertensive rats after 30 mg/kg i.p. administration.",Other,2296021.0,
1177,185730,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive effects in conscious, unrestrained, spontaneously hypertensive rats after 100 mg/kg p.o. administration.",Other,2296021.0,
1178,185878,3,5,,103557046,4485,Unspecified,,,,,Ability to lower blood pressure in the spontaneously hypertensive rat (SHR) at 10 mg/kg (p.o.),Other,3346879.0,
1179,185885,3,4,,103557046,4485,Unspecified,,,,,Maximum fall in systolic blood pressure at interval from 1 to 6 hours at a dose of 0.3 mg/kg when administered perorally in rats,Other,6631915.0,
1180,185886,3,4,,103557046,4485,Unspecified,,,,,Maximum fall in systolic blood pressure at interval from 1 to 6 hours at a dose of 1 mg/kg when administered perorally in rats,Other,6631915.0,
1181,185889,3,4,,103557046,4485,Unspecified,,,,,Maximum fall in systolic blood pressure at interval from 1 to 6 hours at a dose of 3 mg/kg when administered perorally in rats,Other,6631915.0,
1182,185906,4,4,,103557046,4485,Unspecified,,,,,Maximum fall in blood pressure was evaluated at an oral dose of 1.0 mg/kg in (SHR) spontaneous hypertensive rats,Other,3783581.0,
1183,185907,3,4,,103557046,4485,Unspecified,,,,,Maximum fall in blood pressure was evaluated at an oral dose of 10.0 mg/kg in (SHR) spontaneous hypertensive rats,Other,3783581.0,
1184,185909,3,4,,103557046,4485,Unspecified,,,,,Maximum fall in blood pressure was evaluated at an oral dose of 3.0 mg/kg in (SHR) spontaneous hypertensive rats,Other,3783581.0,
1185,187134,3,5,,103557046,4485,Active,,,,,Inhibition of contractions induced by K+ depolarization in rat dorsal aorta,Other,,
1186,188533,3,5,,103557046,4485,Unspecified,,,,,In vivo antihypertensive activity of compound was determined at 45 umol/kg administered orally in spontaneously hypertensive rats; % reduction in blood pressure,Other,,
1187,192055,3,4,,103557046,4485,Unspecified,,,,,Systolic blood pressure after administration of a single oral dose (20 mg/kg),Other,1377748.0,
1188,194466,3,5,,103557046,4485,Unspecified,,,,,Antihypertensive activity expressed as maximal change in systolic blood pressure (SBP) from pretreatment levels at either 1.5 or 4 hr after dosing,Other,6502606.0,
1189,194503,3,4,,103557046,4485,Unspecified,,,,,Compound was evaluated for antihypertensive activity in deoxy-corticosterone acetate (DOCA) treated hypertensive rats at 0.3 mg/kg peroral administration,Other,6471067.0,
1190,194644,3,4,,103557046,4485,Unspecified,,,,,Compound was evaluated for antihypertensive activity in deoxy-corticosterone acetate (DOCA) treated hypertensive rats at 1 mg/kg peroral administration,Other,6471067.0,
1191,194645,3,4,,103557046,4485,Unspecified,,,,,Compound was evaluated for antihypertensive activity in deoxy-corticosterone acetate (DOCA) treated hypertensive rats at 3 mg/kg peroral administration,Other,6471067.0,
1192,194650,3,4,,103557046,4485,Unspecified,,,,,Compound was evaluated for oral antihypertensive activity in spontaneously hypertensive rats at 0.3 mg/kg peroral administration,Other,6471067.0,
1193,194653,3,4,,103557046,4485,Unspecified,,,,,Compound was evaluated for oral antihypertensive activity in spontaneously hypertensive rats at 1 mg/kg peroral administration,Other,6471067.0,
1194,194654,3,4,,103557046,4485,Unspecified,,,,,Compound was evaluated for oral antihypertensive activity in spontaneously hypertensive rats at 3 mg/kg peroral administration,Other,6471067.0,
1195,195176,3,5,,103557046,4485,Unspecified,,,,,Inhibition constant by its ability to inhibit contractions induced by phenylephrine in rabbit dorsal aorta,Other,,
1196,195182,4,4,,103557046,4485,Active,,,0.0032,EC50,Vasodilator activity was measured on rat aorta in the presence of guanylate cyclase methylene blue(MB).,Confirmatory,9876109.0,
1197,195183,4,4,,103557046,4485,Active,,,,,Vasodilator activity was measured on rat aorta in the presence of ODQ.,Other,9876109.0,
1198,195195,4,4,,103557046,4485,Active,,,0.004,IC50,Inhibitory effect of compound on calcium influx by high potassium in isolated rat aorta,Confirmatory,2002473.0,
1199,195196,4,4,,103557046,4485,Active,,,0.002,IC50,Inhibitory effect of compound on contraction induced by high potassium in isolated rat aorta,Confirmatory,2002473.0,
1200,195197,4,4,,103557046,4485,Active,,,0.0012,IC50,Inhibition of [Ca2+] induced contraction of K+ depolarized rat aorta by 50%,Confirmatory,8496910.0,
1201,195214,4,5,,103557046,4485,Active,,,,,Inhibition constant by its ability to inhibit (act through Ca++ ion channel) contractions induced by K+ depolarization in rat dorsal aorta,Other,,
1202,195351,5,3,,103557046,4485,Active,,,0.000148,Kd,Inhibition of calcium activation was assessed against calcium-induced constriction of potassium-depolarized rat aorta (Negative logarithm of the molar concentration),Confirmatory,2002473.0,
1203,195355,6,2,,103557046,4485,Active,,,0.00398,IC50,Concentration required to block Ca+2-induced contraction of K+ depolarized rat aorta,Confirmatory,2342074.0,
1204,197523,6,2,,103557046,4485,Active,,,0.00398,IC50,Evaluated for the negative logarithm of the molar concentration required to block [Ca2+] induced contraction of K+ depolarized rat aorta by 50%.,Confirmatory,1992115.0,
1205,197526,6,2,,103557046,4485,Active,,,0.00398,IC50,Concentration required to inhibit calcium-induced constriction of potassium-depolarized rat aorta by 50%,Confirmatory,2918502.0,
1206,197527,6,2,,103557046,4485,Active,,,0.03162,IC50,Concentration required to block [Ca2+] induced contraction of K+ depolarized rat aorta by 50%,Confirmatory,2153819.0,
1207,197533,6,2,,103557046,4485,Active,,,0.00398,IC50,Negative logarithm of molar concentration required to block calcium-induced contraction of potassium depolarized rat aorta by 50%,Confirmatory,2795609.0,
1208,205267,9,2,,103557046,4485,Active,,,37.0,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
1209,205268,4,7,,103557046,4485,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
1210,215770,6,3,,103557046,4485,Unspecified,,,10.0,IC50,In vitro inhibition of thromboxane B2 production in rat whole blood.,Confirmatory,8411014.0,
1211,224185,5,1,,103557046,4485,Unspecified,,,,,Evaluated in vitro for the effect on K+ induced aortic contraction in isolated aortic strips of rabbit,Other,2261014.0,
1212,227124,5,3,,103557046,4485,Unspecified,,,,,In vivo evaluation for the antihypertensive effect in the spontaneously hypertensive rat is % decrease in blood pressure during post drug administration at the dose of 15 umol/kg. per oral; 26/15,Other,1387168.0,
1213,227125,5,3,,103557046,4485,Unspecified,,,,,In vivo evaluation for the antihypertensive effect in the spontaneously hypertensive rat is % decrease in blood pressure during post drug administration at the dose of 45 umol/kg. per oral; 33/22,Other,1387168.0,
1214,227268,5,3,,103557046,4485,Unspecified,,,,,In vivo evaluation for the antihypertensive effect in the spontaneously hypertensive rat is % decrease in blood pressure during post drug administration at the dose of 5 umol/kg. per oral; 12/10,Other,1387168.0,
1215,227627,6,3,,103557046,4485,Active,,,0.0036,IC50,Vasorelaxant effect on KCl-Induced contraction of rat aorta,Confirmatory,8809167.0,
1216,227699,3,3,,103557046,4485,Unspecified,,,,,Virtual screen for compounds with anticonvulsant activity,Other,12873507.0,
1217,228679,7,1,,103557046,4485,Unspecified,,,,,Solvation energy,Other,10377225.0,
1218,233859,3,6,,103557046,4485,Unspecified,,,,,Selectivity between calcium antagonist activity vs negative inotropy in guinea pig,Other,2918502.0,
1219,234388,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxant effect on KCl-Induced contraction of porcine coronary artery vs rat aorta,Other,8809167.0,
1220,234478,3,4,,103557046,4485,Unspecified,,,,,ratio between the EC30 values of aortic contracture and atrial rate,Other,2261014.0,
1221,234479,3,4,,103557046,4485,Unspecified,,,,,ratio between the EC30 values of atrial contractility and atrial rate,Other,2261014.0,
1222,234663,3,4,,103557046,4485,Unspecified,,,,,Selectivity index was measured as the IC50 needed to depress the heart beat divided by IC50 needed to block [Ca2+] contractions in rabbit aortic strips,Other,1377748.0,
1223,235556,3,4,,103557046,4485,Unspecified,,,,,Ratio of pIC50 of rat aorta to pIC25 of guinea pig,Other,2342074.0,
1224,235709,3,6,,103557046,4485,Unspecified,,,,,Selectivity for vascular (Ca pIC50) over cardiac (negative inotropy IC25) calcium channels,Other,2795609.0,
1225,235901,3,4,,103557046,4485,Unspecified,,,,,Selectivity index calculated as the ratio of Calcium pIC50 to that of negative inotropy IC25,Other,1992115.0,
1226,240820,9,2,,103557046,4485,Unspecified,,,280.0,IC50,Inhibitory concentration against IKr potassium channel,Confirmatory,15324906.0,
1227,243151,7,2,,103557046,4485,Unspecified,,,50.1187,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
1228,262090,6,3,,103557046,4485,Unspecified,,,,,Antiarrhythmic activity in iv dosed rat,Other,16321526.0,
1229,311367,3,6,,103557046,4485,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
1230,311524,4,3,,103557046,4485,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
1231,317278,3,4,,103557046,4485,Unspecified,,,,,Inotropic activity at L type calcium channel in guinea pig left atrium assessed as decrease in tension at 10 uM relative to control,Other,18303827.0,
1232,317287,3,4,,103557046,4485,Unspecified,,,,,Chronotropic activity at L type calcium channel in guinea pig right atrium assessed as decrease in spontaneous beating at 0.1 uM relative to control,Other,18303827.0,
1233,317288,6,3,,103557046,4485,Active,,,0.26,EC50,Inotropic activity at L type calcium channel in guinea pig left atrium assessed as decrease in tension,Confirmatory,18303827.0,
1234,317289,7,1,,103557046,4485,Active,,,,,Chronotropic activity at L type calcium channel in guinea pig right atrium assessed as decrease in spontaneous beating,Other,18303827.0,
1235,317294,3,4,,103557046,4485,Unspecified,,,,,Activity at L type calcium channel in K+ depolarized guinea pig aortic strip assessed as inhibition of calcium induced contraction at 1 uM,Other,18303827.0,
1236,317301,3,3,,103557046,4485,Unspecified,,,,,Activity at L type calcium channel in K+ depolarized guinea pig longitudinal smooth muscle assessed as inhibition of calcium induced contraction at 5 nM,Other,18303827.0,
1237,317302,6,2,,103557046,4485,Active,,,0.0015,IC50,Activity at L type calcium channel in K+ depolarized guinea pig longitudinal smooth muscle assessed as inhibition of calcium induced contraction,Confirmatory,18303827.0,
1238,317303,3,4,,103557046,4485,Unspecified,,,,,Cardiovascular activity in perfused guinea pig heart assessed as change in maximal rate of rise in left ventricular pressure at 10 nM by ECG,Other,18303827.0,
1239,317304,3,4,,103557046,4485,Unspecified,,,,,Cardiovascular activity in perfused guinea pig heart assessed as change in heart rate at 10 nM by ECG,Other,18303827.0,
1240,317305,3,4,,103557046,4485,Unspecified,,,,,Cardiovascular activity in perfused guinea pig heart assessed as change in coronary perfusion pressure at 1 uM by ECG,Other,18303827.0,
1241,317306,3,4,,103557046,4485,Unspecified,,,,,Cardiovascular activity in perfused guinea pig heart assessed as change in atrioventricular conduction time at 1 uM by ECG,Other,18303827.0,
1242,317307,3,4,,103557046,4485,Unspecified,,,,,Cardiovascular activity in perfused guinea pig heart assessed as change in ventricular repolarization time at 10 nM by ECG,Other,18303827.0,
1243,317313,4,1,,103557046,4485,Active,,,0.00148,Ki,Displacement of (+)-[5-methyl-3H]PN200-100 from L type calcium channel in guinea pig heart ventricles,Confirmatory,18303827.0,
1244,317314,4,4,,103557046,4485,Active,,,0.045,IC50,Displacement of (+)-[5-methyl-3H]PN200-100 from L type calcium channel Cav1.2a in rabbit expressed in HEK293 cells,Confirmatory,18303827.0,
1245,317315,4,4,,103557046,4485,Active,,,0.0036,IC50,Displacement of (+)-[5-methyl-3H]PN200-100 from L type calcium channel Cav1.2b in rabbit expressed in HEK293 cells,Confirmatory,18303827.0,
1246,326586,3,3,,103557046,4485,Unspecified,,,,,Inhibition of CaCl2-induced contraction in potassium-depolarized guinea pig ileal smooth muscle at 10 nM,Other,17936628.0,
1247,332362,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in adrenalectomized anesthetized SHR rat assessed as reduction of mean blood pressure at 15 mg/kg, iv",Other,7513748.0,
1248,332363,3,5,,103557046,4485,Unspecified,,,,,"Vasorelaxation activity in SHR rat assessed as reduction of methoxamine-induced mean arterial blood pressure at 5 mg/kg, iv after 20 mins",Other,7513748.0,
1249,332364,3,5,,103557046,4485,Unspecified,,,,,"Vasorelaxation activity in SHR rat assessed as reduction of methoxamine-induced mean arterial blood pressure at 10 mg/kg, iv after 20 mins",Other,7513748.0,
1250,332365,3,5,,103557046,4485,Unspecified,,,,,"Vasorelaxation activity in SHR rat assessed as reduction of methoxamine-induced mean arterial blood pressure at 15 mg/kg, iv after 20 mins",Other,7513748.0,
1251,332366,3,5,,103557046,4485,Unspecified,,,,,"Vasorelaxation activity in SHR rat assessed as reduction of Bay-K 8644-induced mean arterial blood pressure at 5 mg/kg, iv after 20 mins",Other,7513748.0,
1252,332367,3,5,,103557046,4485,Unspecified,,,,,"Vasorelaxation activity in SHR rat assessed as reduction of Bay-K 8644-induced mean arterial blood pressure at 10 mg/kg, iv after 20 mins",Other,7513748.0,
1253,332368,3,5,,103557046,4485,Unspecified,,,,,"Vasorelaxation activity in SHR rat assessed as reduction of Bay-K 8644-induced mean arterial blood pressure at 15 mg/kg, iv after 20 mins",Other,7513748.0,
1254,332369,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in SHR rat assessed as changes in tail arterial mean blood pressure at 1 mg/kg, iv",Other,7513748.0,
1255,333040,7,1,,103557046,4485,Unspecified,,,,,"Inhibition of noradrenaline release in sham operated anesthetized SHR rat plasma at 1 mg/kg, iv after 20 mins",Other,7513748.0,
1256,333041,7,1,,103557046,4485,Unspecified,,,,,"Inhibition of noradrenaline release in sham operated anesthetized SHR rat plasma at 5 mg/kg, iv after 20 mins",Other,7513748.0,
1257,333042,7,1,,103557046,4485,Unspecified,,,,,"Inhibition of noradrenaline release in sham operated anesthetized SHR rat plasma at 10 mg/kg, iv after 20 mins",Other,7513748.0,
1258,333043,7,1,,103557046,4485,Unspecified,,,,,"Inhibition of noradrenaline release in sham operated anesthetized SHR rat plasma at 15 mg/kg, iv after 20 mins",Other,7513748.0,
1259,333044,7,1,,103557046,4485,Unspecified,,,,,"Inhibition of noradrenaline release in adrenalectomized anesthetized SHR rat plasma at 1 mg/kg, iv after 20 mins",Other,7513748.0,
1260,333045,7,1,,103557046,4485,Unspecified,,,,,"Inhibition of noradrenaline release in adrenalectomized anesthetized SHR rat plasma at 5 mg/kg, iv after 20 mins",Other,7513748.0,
1261,333046,7,1,,103557046,4485,Unspecified,,,,,"Inhibition of noradrenaline release in adrenalectomized anesthetized SHR rat plasma at 10 mg/kg, iv after 20 mins",Other,7513748.0,
1262,333047,7,1,,103557046,4485,Unspecified,,,,,"Inhibition of noradrenaline release in adrenalectomized anesthetized SHR rat plasma at 15 mg/kg, iv after 20 mins",Other,7513748.0,
1263,333048,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in sham operated anesthetized SHR rat assessed as reduction of mean blood pressure at 1 mg/kg, iv",Other,7513748.0,
1264,333049,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in sham operated anesthetized SHR rat assessed as reduction of mean blood pressure at 5 mg/kg, iv",Other,7513748.0,
1265,333050,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in sham operated anesthetized SHR rat assessed as reduction of mean blood pressure at 10 mg/kg, iv",Other,7513748.0,
1266,333051,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in sham operated anesthetized SHR rat assessed as reduction of mean blood pressure at 15 mg/kg, iv",Other,7513748.0,
1267,333052,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in adrenalectomized anesthetized SHR rat assessed as reduction of mean blood pressure at 1 mg/kg, iv",Other,7513748.0,
1268,333053,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in adrenalectomized anesthetized SHR rat assessed as reduction of mean blood pressure at 5 mg/kg, iv",Other,7513748.0,
1269,337899,4,4,,103557046,4485,Active,,,0.0016,Ki,Displacement of [3H]nitrendipine from L-type calcium channel,Confirmatory,8496700.0,
1270,337900,4,4,,103557046,4485,Active,,,0.0016,Ki,Displacement of [3H]nitrendipine from T-type calcium channel,Confirmatory,8496700.0,
1271,338183,3,4,,103557046,4485,Unspecified,,,,,Displacement of [3H]nitrendipine from L-type calcium channel assessed as specific binding relative to total binding,Other,8496700.0,
1272,338184,3,4,,103557046,4485,Unspecified,,,,,Displacement of [3H]nitrendipine from T-type calcium channel assessed as specific binding relative to total binding,Other,8496700.0,
1273,338201,3,4,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel at 1 nM,Other,8496700.0,
1274,338202,3,4,,103557046,4485,Unspecified,,,,,Inhibition of T-type calcium channel at 1 nM,Other,8496700.0,
1275,338203,3,7,,103557046,4485,Unspecified,,,,,Inhibition of adenosine A1 receptor at 10 uM,Other,8496700.0,
1276,338204,3,4,,103557046,4485,Unspecified,,,,,Inhibition of adenosine A2 receptor at 10 uM,Other,8496700.0,
1277,338205,3,4,,103557046,4485,Unspecified,,,,,Inhibition of 5HT1 receptor at 10 uM,Other,8496700.0,
1278,338206,3,4,,103557046,4485,Unspecified,,,,,Inhibition of low conductance potassium channel at 10 uM,Other,8496700.0,
1279,338207,3,4,,103557046,4485,Unspecified,,,,,Inhibition of nicotinic acetylcholine receptor at 10 uM,Other,8496700.0,
1280,339173,8,1,,103557046,4485,Active,,,1.2,IC50,Antagonist activity at voltage-dependent L-type calcium channel in mouse neurobalstoma-rat glioma NG 108-15 hybrid cells assessed as inhibition of KCl-induced increase in intracellular calcium level pretreated for 3 mins before KCl challenge,Confirmatory,8377012.0,
1281,354897,3,5,,103557046,4485,Unspecified,,,,,Vasorelaxant activity against high potassium-induced contraction in Wistar rat thoracic aorta at 1 ug/ml,Other,8778245.0,
1282,355712,3,5,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in adrenalectomized anesthetized SHR rat assessed as reduction of mean blood pressure at 10 mg/kg, iv",Other,7513748.0,
1283,366631,6,2,,103557046,4485,Active,,,0.001,EC50,Displacement of [3H]nitrendipine from voltage-dependent calcium channel in rat brain cortex by scintillation counting,Confirmatory,18640843.0,
1284,373867,6,3,,103557046,4485,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
1285,376850,3,4,,103557046,4485,Unspecified,,,,,Vasorelaxation activity in rat aorta assessed as inhibition of K+-induced contraction at 1 ug/ml preincubated for 15 mins relative to control,Other,10395498.0,
1286,377019,3,5,,103557046,4485,Unspecified,,,,,Antispasmodic activity in guinea pig ileum assessed as inhibition of acetylcholine-induced contraction at 1 uM,Other,16792408.0,
1287,392820,8,1,,103557046,4485,Active,,,0.00107,IC50,Antagonist activity at calcium channel in guinea pig ileum assessed as inhibition of KCl-induced contraction of ileal longitudinal smooth muscle pretreated 15 mins before KCl challenge,Confirmatory,19162489.0,
1288,398728,3,5,,103557046,4485,Unspecified,,,,,Inhibition of norepinephrine-induced contraction in Wistar rat aorta assessed as contraction at 1 uM preincubated 15 mins before addition of norepinephrine relative to control,Other,,
1289,398729,3,5,,103557046,4485,Unspecified,,,,,Inhibition of KCl-induced contraction in Wistar rat aorta assessed as contraction at 1 uM preincubated 15 mins before addition of KCl relative to control,Other,,
1290,398840,3,5,,103557046,4485,Unspecified,,,,,Vasorelaxant activity against 80 mM potassium-induced contractions in rat thoracic aorta assessed as muscle contractions at 1 uM pretreated for 15 mins before potassium administration relative to control,Other,9214740.0,
1291,408340,8,5,,103557046,4485,Unspecified,7531135.0,3757.0,50.1187,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
1292,409954,4,9,,103557046,4485,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
1293,411889,6,2,,103557046,4485,Active,,,0.06,IC50,Inhibition of L-type calcium channel expressed in HEK293 cells,Confirmatory,19004630.0,
1294,411890,9,5,,103557046,4485,Active,146345443.0,3741.0,6.1,IC50,Inhibition of human Kv1.5 channel expressed in mouse L929 cells by EP voltage clamp technique,Confirmatory,19004630.0,
1295,420011,6,2,,103557046,4485,Active,,,10.0,IC50,Inhibition of calcium channel in pig carotid artery assessed as relaxation of KCl-induced tissue contraction,Confirmatory,19008020.0,
1296,420013,4,3,,103557046,4485,Unspecified,,,,,Antagonist activity at voltage dependent L-type calcium channel in New Zealand white rabbit sigmoid colon circular smooth muscle strip assessed as relaxation response relative to papaverine,Other,19013690.0,
1297,420017,3,3,,103557046,4485,Unspecified,,,,,Antagonist activity at voltage dependent L-type calcium channel in New Zealand white rabbit sigmoid colon circular smooth muscle strip assessed as relaxation response,Other,19013690.0,
1298,420019,4,3,,103557046,4485,Inactive,,,,,Antagonist activity at voltage dependent L-type calcium channel in New Zealand white rabbit sigmoid colon circular smooth muscle strip assessed as induction of relaxation response in absence of Ca2+-activated potassium channel blocker tetraethylammonium,Other,19013690.0,
1299,425652,7,2,,103557046,4485,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1300,425653,7,2,,103557046,4485,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1301,428564,7,5,,103557046,4485,Active,,,46.9894,IC50,Inhibition of CYP3A4,Confirmatory,19128860.0,
1302,434138,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 420 mins by non-invasive tail-cuff method",Other,19321237.0,
1303,434139,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 15 mins by non-invasive tail-cuff method",Other,19321237.0,
1304,434140,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 30 mins by non-invasive tail-cuff method",Other,19321237.0,
1305,434141,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 60 mins by non-invasive tail-cuff method",Other,19321237.0,
1306,434142,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 120 mins by non-invasive tail-cuff method",Other,19321237.0,
1307,434143,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 180 mins by non-invasive tail-cuff method",Other,19321237.0,
1308,434144,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 240 mins by non-invasive tail-cuff method",Other,19321237.0,
1309,434145,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 300 mins by non-invasive tail-cuff method",Other,19321237.0,
1310,434146,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 360 mins by non-invasive tail-cuff method",Other,19321237.0,
1311,434147,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced systolic blood pressure at 10 mg/kg, po after 480 mins by non-invasive tail-cuff method",Other,19321237.0,
1312,434148,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced diastolic blood pressure at 10 mg/kg, po after 15 mins by invasive carotid artery cannulation method",Other,19321237.0,
1313,434149,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced diastolic blood pressure at 10 mg/kg, po after 30 mins by invasive carotid artery cannulation method",Other,19321237.0,
1314,434150,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced diastolic blood pressure at 10 mg/kg, po after 60 mins by invasive carotid artery cannulation method",Other,19321237.0,
1315,434298,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced diastolic blood pressure at 10 mg/kg, po after 120 mins by invasive carotid artery cannulation method",Other,19321237.0,
1316,434299,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced diastolic blood pressure at 10 mg/kg, po after 180 mins by invasive carotid artery cannulation method",Other,19321237.0,
1317,434300,3,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of DOCA salt-induced diastolic blood pressure at 10 mg/kg, po after 240 mins by invasive carotid artery cannulation method",Other,19321237.0,
1318,434939,1,2,,49732003,4485,Active,34398348.0,8856.0,,,Counterscreen for activators of the Aryl Hydrocarbon Receptor (AHR): luminescence-based cell-based high throughput screening assay to identify activators of the Pregnane X Receptor (PXR),Screening,,
1319,434955,1,2,,49732003,4485,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1320,434962,1,2,,49732003,4485,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1321,434973,1,3,,49732003,4485,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1322,434989,1,1,,49732003,4485,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1323,435003,1,3,,49732003,4485,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1324,435022,2,2,,49732003,4485,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1325,435030,1,2,,49732003,4485,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1326,435030,1,2,,49732003,4485,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1327,439054,3,4,,103557046,4485,Unspecified,,,,,Inhibition of calcium-induced contraction in guinea pig ileum at 0.01 uM,Other,19793620.0,
1328,439056,6,2,,103557046,4485,Active,,,0.0147,IC50,Inhibition of calcium-induced contraction in guinea pig ileum at 0.001 to 0.1 uM,Confirmatory,19793620.0,
1329,439058,8,1,,103557046,4485,Active,,,0.0147,IC50,Inhibition of calcium-induced contraction in guinea pig ileum,Confirmatory,19793620.0,
1330,444050,7,1,,103557046,4485,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
1331,444051,6,2,,103557046,4485,Unspecified,,,,,Total clearance in human,Other,20070106.0,
1332,444052,6,2,,103557046,4485,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
1333,444053,6,2,,103557046,4485,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
1334,444054,6,1,,103557046,4485,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
1335,444055,3,3,,103557046,4485,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
1336,444056,3,3,,103557046,4485,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
1337,444057,3,3,,103557046,4485,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
1338,444058,6,2,,103557046,4485,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
1339,445748,3,4,,103557046,4485,Unspecified,,,,,Muscle relaxant activity in potassium-depolarized guinea pig ileum assessed as inhibition of calcium-induced contraction at 10 nM,Other,19740655.0,
1340,449728,1,2,,49732003,4485,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1341,449739,1,2,,855613,4485,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1342,449762,1,2,,49732003,4485,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1343,449763,1,3,,49732003,4485,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1344,449768,1,1,,855613,4485,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1345,463073,1,2,,855613,4485,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1346,463075,1,1,,855613,4485,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1347,463079,1,2,,49732003,4485,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1348,463082,1,1,,49732003,4485,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1349,463096,1,1,,50104712,4485,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1350,463097,1,1,,50104712,4485,Active,7705682.0,51053.0,12.5893,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1351,463104,1,2,,49732003,4485,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1352,463106,1,2,,90341123,4485,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1353,463111,1,1,,49732003,4485,Active,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1354,463115,1,1,,855613,4485,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1355,463141,1,2,,49732003,4485,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1356,463165,1,1,,49732003,4485,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1357,463187,1,1,,855613,4485,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1358,463189,1,1,,855613,4485,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1359,463189,1,1,,53777925,4485,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1360,463190,1,2,,49732003,4485,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1361,463193,1,1,,855613,4485,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1362,463195,1,2,,49732003,4485,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1363,463210,1,2,,49732003,4485,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1364,463212,1,1,,49732003,4485,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1365,463254,1,1,,855613,4485,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1366,467612,3,6,,103557046,4485,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
1367,467613,5,3,,103557046,4485,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
1368,478846,3,10,,103557046,4485,Unspecified,6165987.0,29716.0,,,Antagonist activity at rat Cav1.3 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current at 100 nM by FLIPR calcium 4 assay,Other,20382537.0,
1369,478851,3,11,,103557046,4485,Unspecified,116411.0,100144322.0,,,Antagonist activity at rabbit Cav1.2 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current at 100 nM by FLIPR calcium 4 assay,Other,20382537.0,
1370,478856,3,3,,103557046,4485,Unspecified,,,,,Selectivity ratio of antagonist activity at rat Cav1.3 to antagonist activity at rabbit Cav1.2 at 100 nM,Other,20382537.0,
1371,482149,6,6,,103557046,4485,Active,56749781.0,277328.0,0.4,EC50,Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx,Confirmatory,20356305.0,
1372,482865,3,7,,103557046,4485,Unspecified,,,,,Inhibition of K(+)-induced intracellular Ca2+ uptake in human SH-SY5Y cells after 1 hr by Flou/AM fluorescence assay relative to control,Other,20575555.0,
1373,485270,1,1,,49732003,4485,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1374,485272,1,1,,49732003,4485,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1375,485273,2,1,,49732003,4485,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1376,485275,1,3,,49732003,4485,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1377,485281,1,1,,855613,4485,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1378,485281,1,1,,11111549,4485,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1379,485290,1,1,,855613,4485,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1380,485290,1,1,,11111549,4485,Inactive,20150581.0,,22.3872,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1381,485290,1,1,,11113899,4485,Inactive,20150581.0,,44.6684,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1382,485290,1,1,,17388858,4485,Inactive,20150581.0,,56.2341,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1383,485290,1,1,,26747150,4485,Inactive,20150581.0,,17.7828,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1384,485290,1,1,,26752059,4485,Inactive,20150581.0,,50.1187,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1385,485290,1,1,,26752060,4485,Inactive,20150581.0,,44.6684,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1386,485290,1,1,,50104712,4485,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1387,485294,1,1,,855613,4485,Inconclusive,119389684.0,,0.3548,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1388,485295,1,2,,90341123,4485,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1389,485297,1,1,,855613,4485,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1390,485297,1,1,,90341123,4485,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1391,485298,1,1,,855613,4485,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1392,485298,1,1,,90341123,4485,Inconclusive,,,14.581,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1393,485313,1,2,,855613,4485,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1394,485313,1,2,,90341123,4485,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1395,485314,1,1,,855613,4485,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1396,485314,1,1,,50104712,4485,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1397,485317,1,2,,49732003,4485,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1398,485341,1,1,,855613,4485,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1399,485342,1,2,,90341123,4485,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1400,485344,1,1,,855613,4485,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1401,485345,1,2,,90341123,4485,Inconclusive,,,14.581,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1402,485346,1,1,,49732003,4485,Active,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1403,485346,1,1,,49732003,4485,Active,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1404,485347,1,2,,855613,4485,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1405,485349,1,1,,855613,4485,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1406,485350,1,2,,92124243,4485,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1407,485350,1,2,,92125211,4485,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1408,485350,1,2,,99300721,4485,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1409,485353,2,1,,855613,4485,Active,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1410,485358,1,1,,855613,4485,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1411,485360,1,1,,855613,4485,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1412,485364,1,1,,855613,4485,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1413,485366,1,2,,90341123,4485,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1414,485367,1,2,,855613,4485,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1415,485368,1,2,,90341123,4485,Inconclusive,72386991.0,3656265.0,0.8492,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1416,488745,1,4,,85231157,4485,Inconclusive,,,16.5113,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1417,488752,1,4,,85231157,4485,Inconclusive,,,18.526,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1418,488772,1,1,,90341123,4485,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1419,488773,1,2,,90341123,4485,Inconclusive,8659577.0,58819.0,29.9349,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1420,488806,1,2,,49732003,4485,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1421,488816,1,1,,90341123,4485,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1422,488837,1,1,,855613,4485,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1423,488837,1,1,,90341123,4485,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1424,488839,1,1,,56423128,4485,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1425,488839,1,1,,56423128,4485,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1426,488847,1,3,,49732003,4485,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1427,488862,1,1,,49732003,4485,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1428,488862,1,1,,56423128,4485,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1429,488890,1,2,,49732003,4485,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1430,488895,1,2,,49732003,4485,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1431,488895,1,2,,56423128,4485,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1432,488896,1,1,,49732003,4485,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1433,488896,1,1,,56423128,4485,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1434,488899,1,1,,56423128,4485,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1435,488922,1,2,,49732003,4485,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1436,488949,1,2,,85231157,4485,Active,41055989.0,54737.0,39.8107,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1437,488949,1,2,,90341123,4485,Inconclusive,41055989.0,54737.0,37.6858,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1438,488953,1,1,,90341123,4485,Active,187960037.0,10951.0,35.4813,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1439,488965,1,2,,49732003,4485,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1440,488965,1,2,,56423128,4485,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1441,488966,1,1,,56423128,4485,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1442,488975,1,2,,49732003,4485,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1443,488977,1,2,,49732003,4485,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1444,488978,1,1,,90341123,4485,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1445,488979,1,1,,50104712,4485,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1446,488980,1,1,,85231157,4485,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1447,488981,1,1,,90341123,4485,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1448,488982,1,1,,90341123,4485,Active,4503383.0,1812.0,2.5928,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1449,488983,1,1,,90341123,4485,Inconclusive,4503383.0,1812.0,31.6228,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1450,489028,1,2,,49732003,4485,Active,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1451,489028,1,2,,49732003,4485,Active,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1452,489030,2,1,,49732003,4485,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1453,489031,2,1,,49732003,4485,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1454,492947,1,1,,855613,4485,Inconclusive,4501969.0,154.0,28.1838,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1455,492953,1,1,,56423128,4485,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1456,492956,1,1,,56423128,4485,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1457,492967,1,2,,92125211,4485,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1458,492967,1,2,,99301401,4485,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1459,492972,1,1,,56423128,4485,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1460,493005,1,1,,56423128,4485,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1461,493006,1,1,,49732003,4485,Inactive,32479527.0,3784.0,,,Counter screen assay of the parental CHO cells for identification of compounds that potentiate KCNQ1 potassium channels,Screening,,
1462,493007,1,1,,49732003,4485,Inactive,32479527.0,3784.0,,,Validation assay for identification of compounds that potentiate KCNQ1 potassium channels,Screening,,
1463,493008,1,1,,56423128,4485,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1464,493008,1,1,,56423128,4485,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1465,493008,1,1,,56423128,4485,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1466,493008,1,1,,56423128,4485,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1467,493009,1,1,,49732003,4485,Inactive,18959272.0,170848.0,,,Specificity screen assay against KCNQ2 for identification of compounds that potentiate KCNQ1 potassium channels,Screening,,
1468,493011,1,1,,49732003,4485,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1469,493012,1,1,,49732003,4485,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1470,493014,1,1,,855613,4485,Inconclusive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1471,493027,1,2,,56423128,4485,Active,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1472,493027,1,2,,56423128,4485,Active,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1473,493033,1,2,,92124243,4485,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1474,493033,1,2,,92125211,4485,Active,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1475,493033,1,2,,99300721,4485,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1476,493035,1,2,,56423128,4485,Active,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1477,493035,1,2,,56423128,4485,Active,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1478,493036,1,2,,49732003,4485,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1479,493056,1,1,,855613,4485,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1480,493084,1,1,,855613,4485,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1481,493087,1,1,,56423128,4485,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1482,493091,1,1,,56423128,4485,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1483,493098,1,1,,56423128,4485,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1484,493106,1,1,,90341123,4485,Inactive,116283940.0,79915.0,8.1961,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1485,493107,1,1,,90341123,4485,Active,116283940.0,79915.0,18.3489,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1486,493127,1,1,,50104712,4485,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1487,493131,1,1,,56423128,4485,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1488,493140,1,1,,103913902,4485,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1489,493153,1,1,,90341123,4485,Active,,4780.0,12.9953,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1490,493153,1,1,,90341123,4485,Active,224028257.0,4780.0,12.9953,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1491,493160,1,1,,56423128,4485,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1492,493162,1,2,,99301401,4485,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1493,493162,1,2,,99302239,4485,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1494,493164,1,2,,90341123,4485,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1495,493164,1,2,,90341123,4485,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1496,493164,1,2,,90341123,4485,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1497,493184,1,1,,49732003,4485,Inactive,32479527.0,3784.0,,,Secondary automated electrophysiology assay of compounds that potentiate KCNQ1 potassium channels,Screening,,
1498,493187,1,2,,56423128,4485,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1499,493189,1,1,,50104712,4485,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1500,493244,1,1,,56423128,4485,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1501,493244,1,1,,56423128,4485,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1502,493244,1,1,,56423128,4485,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1503,493244,1,1,,56423128,4485,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1504,496817,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
1505,496818,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
1506,496819,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
1507,496820,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
1508,496821,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
1509,496823,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
1510,496824,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
1511,496825,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
1512,496826,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
1513,496827,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
1514,496828,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
1515,496829,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
1516,496830,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
1517,496831,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
1518,496832,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
1519,497005,4,2,,103557046,4485,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
1520,499784,2,3,,103557046,4485,Inactive,,,,,Activation of phospholipase A2/C in human OC2 cells assessed as increase in intracellular calcium level at 1 uM,Other,20669930.0,
1521,504317,2,1,,56423128,4485,Active,31542303.0,51099.0,9.619,IC50,"Luminescence-based biochemical high throughput dose response assay for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1) (2K validation set)",Confirmatory,,
1522,504317,2,1,,56423128,4485,Active,223718203.0,5346.0,9.619,IC50,"Luminescence-based biochemical high throughput dose response assay for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1) (2K validation set)",Confirmatory,,
1523,504319,2,1,,56423128,4485,Active,31542303.0,51099.0,7.132999999999999,IC50,"Luminescence-based biochemical high throughput dose response assay for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5) (2K validation set)",Confirmatory,,
1524,504319,2,1,,56423128,4485,Active,116292172.0,440503.0,7.132999999999999,IC50,"Luminescence-based biochemical high throughput dose response assay for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5) (2K validation set)",Confirmatory,,
1525,504326,1,2,,56423128,4485,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1526,504326,1,2,,56423128,4485,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1527,504327,1,1,,855613,4485,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1528,504327,1,1,,11111549,4485,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1529,504327,1,1,,90341123,4485,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1530,504329,1,1,,56423128,4485,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1531,504332,1,1,,855613,4485,Active,168985070.0,,14.1254,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1532,504332,1,1,,11111549,4485,Active,168985070.0,,11.2202,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1533,504332,1,1,,50104712,4485,Active,168985070.0,,4.4668,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1534,504332,1,1,,90341123,4485,Active,168985070.0,,2.9935,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1535,504333,1,1,,855613,4485,Active,6683500.0,29994.0,39.8107,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1536,504339,1,1,,56423128,4485,Inconclusive,162330054.0,,56.2341,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1537,504357,1,1,,56423128,4485,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1538,504357,1,1,,56423128,4485,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1539,504364,1,1,,85231157,4485,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1540,504406,1,1,,49732003,4485,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1541,504408,2,1,,49732003,4485,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1542,504411,1,1,,56423128,4485,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1543,504414,1,1,,56423128,4485,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1544,504414,1,1,,56423128,4485,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1545,504423,1,1,,56423128,4485,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1546,504441,1,1,,56423128,4485,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1547,504444,1,1,,56423128,4485,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1548,504454,1,3,,56423128,4485,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1549,504462,1,1,,56423128,4485,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1550,504466,1,1,,855613,4485,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1551,504467,1,1,,855613,4485,Active,116283940.0,79915.0,10.3225,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1552,504490,1,2,,56423128,4485,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1553,504523,1,1,,56423128,4485,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1554,504523,1,1,,56423128,4485,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1555,504536,1,1,,90341123,4485,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1556,504541,1,1,,49732003,4485,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1557,504547,1,1,,90341123,4485,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1558,504548,1,2,,90341123,4485,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1559,504558,1,1,,56423128,4485,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1560,504577,2,2,,56423128,4485,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1561,504582,2,1,,56423128,4485,Active,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1562,504594,1,1,,49732003,4485,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1563,504600,1,2,,49732003,4485,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1564,504607,1,1,,49732003,4485,Inactive,,,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,Screening,,
1565,504621,1,1,,56423128,4485,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1566,504634,1,1,,56423128,4485,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1567,504648,1,1,,56423128,4485,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1568,504651,1,1,,855613,4485,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1569,504652,1,1,,855613,4485,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1570,504660,1,1,,855613,4485,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1571,504668,1,1,,49732003,4485,Active,728984.0,672.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
1572,504668,1,1,,49732003,4485,Active,116241265.0,580.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
1573,504690,1,3,,56423128,4485,Active,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1574,504692,2,2,,56423128,4485,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1575,504700,1,1,,56423128,4485,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1576,504700,1,1,,56423128,4485,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1577,504706,1,1,,855613,4485,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1578,504707,1,1,,56423128,4485,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1579,504707,1,1,,56423128,4485,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1580,504720,1,1,,56423128,4485,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1581,504734,1,1,,56423128,4485,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1582,504749,1,3,,26752060,4485,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1583,504749,1,3,,104171202,4485,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1584,504749,1,3,1.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1585,504749,1,3,2.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1586,504749,1,3,3.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1587,504749,1,3,4.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1588,504749,1,3,5.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1589,504749,1,3,6.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1590,504749,1,3,7.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1591,504749,1,3,8.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1592,504749,1,3,9.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1593,504749,1,3,10.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1594,504749,1,3,11.0,26752060,4485,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1595,504749,1,3,12.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1596,504749,1,3,13.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1597,504749,1,3,14.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1598,504749,1,3,15.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1599,504749,1,3,16.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1600,504749,1,3,17.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1601,504749,1,3,18.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1602,504749,1,3,19.0,26752060,4485,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1603,504749,1,3,20.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1604,504749,1,3,21.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1605,504749,1,3,22.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1606,504749,1,3,23.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1607,504749,1,3,24.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1608,504749,1,3,25.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1609,504749,1,3,26.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1610,504749,1,3,27.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1611,504749,1,3,28.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1612,504749,1,3,29.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1613,504749,1,3,30.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1614,504749,1,3,31.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1615,504749,1,3,32.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1616,504749,1,3,33.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1617,504749,1,3,34.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1618,504749,1,3,35.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1619,504749,1,3,36.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1620,504749,1,3,37.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1621,504749,1,3,38.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1622,504749,1,3,39.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1623,504749,1,3,40.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1624,504749,1,3,41.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1625,504749,1,3,42.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1626,504749,1,3,43.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1627,504749,1,3,44.0,26752060,4485,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1628,504749,1,3,45.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1629,504749,1,3,46.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1630,504749,1,3,47.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1631,504749,1,3,48.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1632,504749,1,3,49.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1633,504749,1,3,50.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1634,504749,1,3,51.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1635,504749,1,3,52.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1636,504749,1,3,53.0,104171202,4485,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1637,504749,1,3,54.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1638,504749,1,3,55.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1639,504749,1,3,56.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1640,504749,1,3,57.0,26752060,4485,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1641,504749,1,3,58.0,26752060,4485,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1642,504749,1,3,59.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1643,504749,1,3,60.0,104171202,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1644,504749,1,3,61.0,26752060,4485,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1645,504766,2,1,,56423128,4485,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1646,504770,1,2,,92124243,4485,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1647,504775,1,1,,49732003,4485,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1648,504775,1,1,,56423128,4485,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1649,504803,1,1,,56423128,4485,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1650,504810,1,2,,855613,4485,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1651,504810,1,2,,90341123,4485,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1652,504812,1,2,,855613,4485,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1653,504812,1,2,,90341123,4485,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1654,504821,1,1,,85231157,4485,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
1655,504832,1,1,,855613,4485,Inconclusive,,,13.1154,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1656,504832,1,1,,104171202,4485,Inconclusive,,,19.0115,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1657,504834,1,1,,855613,4485,Inconclusive,,,11.6891,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1658,504834,1,1,,104171202,4485,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1659,504836,1,2,,90341123,4485,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
1660,504842,1,1,,855613,4485,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1661,504845,1,1,,56423128,4485,Inconclusive,86301163.0,5999.0,79.4328,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1662,504845,1,1,,90341123,4485,Active,86301163.0,5999.0,2.1192,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1663,504845,1,1,,104171202,4485,Inconclusive,86301163.0,5999.0,0.0597,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1664,504847,1,1,,11111549,4485,Active,63054845.0,7421.0,5.6234,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1665,504847,1,1,,56423128,4485,Inconclusive,63054845.0,7421.0,15.8489,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1666,504847,1,1,,90341123,4485,Active,63054845.0,7421.0,7.0795,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1667,504847,1,1,,104171202,4485,Active,63054845.0,7421.0,3.5481,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1668,504865,1,1,,11111549,4485,Inconclusive,118600387.0,7398.0,35.4813,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1669,504865,1,1,,90341123,4485,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1670,504865,1,1,,104171202,4485,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1671,504884,1,2,,56423128,4485,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1672,504891,1,1,,56423128,4485,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1673,504894,1,1,,56423128,4485,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1674,504937,1,2,,56423128,4485,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1675,515314,1,3,,103557046,4485,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20705371.0,
1676,521220,3,3,,103557046,4485,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1677,524790,7,2,,103557046,4485,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1678,524791,7,2,,103557046,4485,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1679,524794,7,1,,103557046,4485,Active,,,7.943280000000001,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1680,524795,7,2,,103557046,4485,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1681,524796,7,1,,103557046,4485,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1682,536437,2,4,,103557046,4485,Active,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po up to 360 mins by tail-cuff method",Other,20813434.0,
1683,536438,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 900 mins by tail-cuff method",Other,20813434.0,
1684,536439,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 720 mins by tail-cuff method",Other,20813434.0,
1685,536440,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 600 mins by tail-cuff method",Other,20813434.0,
1686,536441,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 360 mins by tail-cuff method",Other,20813434.0,
1687,536442,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 300 mins by tail-cuff method",Other,20813434.0,
1688,536443,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 240 mins by tail-cuff method",Other,20813434.0,
1689,536444,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 180 mins by tail-cuff method",Other,20813434.0,
1690,536445,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 120 mins by tail-cuff method",Other,20813434.0,
1691,536446,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 60 mins by tail-cuff method",Other,20813434.0,
1692,536447,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 30 mins by tail-cuff method",Other,20813434.0,
1693,536448,2,4,,103557046,4485,Unspecified,,,,,"Antihypertensive activity against DOCA-salt induced hypertension in albino rat assessed as reduction in systolic blood pressure at 10 mg/kg, po after 15 mins by tail-cuff method",Other,20813434.0,
1694,537130,4,2,,103557046,4485,Unspecified,,,146.41,IC50,Antileishmanial activity against promastigotes of Leishmania chagasi MHOM/BR/1972/LD after 18 hrs by MTT assay,Confirmatory,20934347.0,
1695,537131,4,2,,103557046,4485,Unspecified,,,176.24,IC50,Antileishmanial activity against amastigotes of Leishmania chagasi MHOM/BR/1972/LD after 24 hrs by MTT assay,Confirmatory,20934347.0,
1696,537132,4,2,,103557046,4485,Unspecified,,,117.89,IC50,Antileishmanial activity against promastigotes of Leishmania amazonensis WHO/BR/00/LT0016 after 18 hrs by MTT assay,Confirmatory,20934347.0,
1697,537133,4,2,,103557046,4485,Unspecified,,,181.09,IC50,Antileishmanial activity against promastigotes of Leishmania major MHOM/1L/80/Fredlin after 18 hrs by MTT assay,Confirmatory,20934347.0,
1698,537134,4,2,,103557046,4485,Unspecified,,,95.74,IC50,Antileishmanial activity against promastigotes of Leishmania braziliensis MHO/BR/75/M2903 after 18 hrs by MTT assay,Confirmatory,20934347.0,
1699,537135,4,2,,103557046,4485,Unspecified,,,101.75,IC50,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay,Confirmatory,20934347.0,
1700,537136,4,2,,103557046,4485,Unspecified,,,588.73,IC50,Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay,Confirmatory,20934347.0,
1701,537137,1,5,,103557046,4485,Unspecified,,,,,"Selectivity index, ratio of IC50 for rhesus monkey LLC-MK2 cells to IC50 for amastigotes of Leishmania chagasi MHOM/BR/1972/LD",Other,20934347.0,
1702,537138,1,5,,103557046,4485,Unspecified,,,,,"Selectivity index, ratio of IC50 for rhesus monkey LLC-MK2 cells to IC50 for trypomastigotes of Trypanosoma cruzi",Other,20934347.0,
1703,537139,2,5,,103557046,4485,Unspecified,,,,,Cytotoxicity in BALB/c mouse erythrocytes assessed as hemolysis at 50 uM after 3 hrs,Other,20934347.0,
1704,537733,2,3,,103557046,4485,Inactive,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
1705,537734,5,2,,103557046,4485,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
1706,537735,2,3,,103557046,4485,Inactive,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
1707,537736,5,2,,103557046,4485,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
1708,540209,4,3,,103557046,4485,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1709,540210,4,3,,103557046,4485,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1710,540211,2,5,,103557046,4485,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1711,540212,4,3,,103557046,4485,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1712,540213,4,3,,103557046,4485,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1713,540222,4,3,,103557046,4485,Unspecified,,,,,Clearance in rat after iv administration,Other,16621936.0,
1714,540223,3,2,,103557046,4485,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,16621936.0,
1715,540224,4,3,,103557046,4485,Unspecified,,,,,Clearance in dog after iv administration,Other,16621936.0,
1716,540225,4,3,,103557046,4485,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,16621936.0,
1717,540226,4,3,,103557046,4485,Unspecified,,,,,Clearance in monkey after iv administration,Other,16621936.0,
1718,540227,4,3,,103557046,4485,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,16621936.0,
1719,540228,4,3,,103557046,4485,Unspecified,,,,,Clearance in human after iv administration,Other,16621936.0,
1720,540229,4,3,,103557046,4485,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,16621936.0,
1721,540253,1,1,,56423128,4485,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1722,540253,1,1,,56423128,4485,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1723,540253,1,1,,56423128,4485,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1724,540256,1,2,,855613,4485,Inconclusive,,,23.1093,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1725,540256,1,2,,50104712,4485,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1726,540256,1,2,,90341123,4485,Active,,,20.5878,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1727,540263,1,1,,56423128,4485,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1728,540263,1,1,,56423128,4485,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1729,540267,1,1,,56423128,4485,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1730,540275,1,1,,855613,4485,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1731,540276,1,2,,855613,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1732,540276,1,2,,11111548,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1733,540276,1,2,,11111549,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1734,540276,1,2,,11113899,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1735,540276,1,2,,17388858,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1736,540276,1,2,,26747150,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1737,540276,1,2,,26747151,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1738,540276,1,2,,26752059,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1739,540276,1,2,,26752060,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1740,540276,1,2,,50100293,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1741,540276,1,2,,50104712,4485,Inconclusive,420597.0,,10.0,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1742,540276,1,2,,50104713,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1743,540276,1,2,,50104714,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1744,540276,1,2,,56423128,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1745,540276,1,2,,85231157,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1746,540276,1,2,,90341123,4485,Inconclusive,420597.0,,29.081,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1747,540276,1,2,,104171202,4485,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1748,540277,1,1,,855613,4485,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1749,540295,1,1,,56423128,4485,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1750,540299,1,2,,92124243,4485,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1751,540299,1,2,,92125211,4485,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1752,540299,1,2,,99302239,4485,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1753,540303,1,1,,56423128,4485,Inconclusive,6679377.0,18792.0,1.2589,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1754,540303,1,1,,56423128,4485,Inconclusive,7242179.0,18793.0,1.2589,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1755,540303,1,1,,56423128,4485,Inconclusive,257471003.0,18815.0,1.2589,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1756,540308,1,1,,56423128,4485,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1757,540317,1,1,,56423128,4485,Inconclusive,187960037.0,10951.0,2.8184,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1758,540336,1,1,,49732003,4485,Active,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1759,540336,1,1,,49732003,4485,Active,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1760,540336,1,1,,56423128,4485,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1761,540336,1,1,,56423128,4485,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1762,540364,1,2,,56423128,4485,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1763,550020,5,2,,103557046,4485,Inconclusive,,,,IC50,Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins,Confirmatory,21129983.0,
1764,550021,5,2,,103557046,4485,Active,,,0.02,IC50,Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins,Confirmatory,21129983.0,
1765,550022,2,4,,103557046,4485,Inconclusive,,,,,Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins relative to control,Other,21129983.0,
1766,550023,2,4,,103557046,4485,Unspecified,,,,,Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins relative to control,Other,21129983.0,
1767,550024,8,5,,103557046,4485,Inconclusive,49037474.0,,,IC50,Inhibition of human recombinant calmodulin assessed as inhibition of calmodulin-sensitive cAMP phosphodiesterase activation after 15 mins by spectrophotometric analysis,Confirmatory,21129983.0,
1768,550025,2,11,,103557046,4485,Inconclusive,49037474.0,,,,Ratio of chlorpromazine IC50 to compound IC50 for human recombinant calmodulin,Other,21129983.0,
1769,576612,7,5,,103557046,4485,Unspecified,7531135.0,3757.0,50.1187,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
1770,577579,6,5,,103557046,4485,Active,116241312.0,1576.0,11.0,IC50,Inhibition of CYP3A4 in human liver microsome,Confirmatory,21256005.0,
1771,588209,2,3,,103557046,4485,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1772,588210,2,4,,103557046,4485,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1773,588211,2,3,,103557046,4485,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1774,588212,2,3,,103557046,4485,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1775,588213,2,3,,103557046,4485,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1776,588214,2,3,,103557046,4485,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1777,588215,2,3,,103557046,4485,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1778,588216,2,3,,103557046,4485,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1779,588217,2,3,,103557046,4485,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1780,588218,2,3,,103557046,4485,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1781,588219,2,3,,103557046,4485,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1782,588334,1,1,,56423128,4485,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1783,588335,1,1,,56423128,4485,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1784,588342,1,1,,855613,4485,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1785,588349,1,1,,90341123,4485,Active,,,28.1838,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
1786,588352,1,2,,56423128,4485,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1787,588354,1,1,,56423128,4485,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1788,588368,1,2,,49732003,4485,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
1789,588378,1,1,,90341123,4485,Active,171543895.0,6311.0,11.2202,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
1790,588379,1,2,,124880909,4485,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
1791,588391,1,1,,56423128,4485,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1792,588405,1,1,,56423128,4485,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1793,588436,1,1,,49732003,4485,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1794,588436,1,1,,56423128,4485,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1795,588453,1,1,,56423128,4485,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1796,588453,1,1,,85231157,4485,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1797,588453,1,1,,90341123,4485,Inconclusive,8659577.0,58819.0,29.9349,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1798,588453,1,1,,124880908,4485,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1799,588453,1,1,,124880909,4485,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1800,588456,1,1,,56423128,4485,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1801,588456,1,1,,90341123,4485,Inconclusive,8659577.0,58819.0,37.6858,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1802,588456,1,1,,124880908,4485,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1803,588456,1,1,,124880909,4485,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1804,588458,1,1,,56423128,4485,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1805,588459,1,2,,49732003,4485,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
1806,588459,1,2,,49732003,4485,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
1807,588459,1,2,,49732003,4485,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
1808,588460,1,2,,49732003,4485,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
1809,588460,1,2,,49732003,4485,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
1810,588460,1,2,,49732003,4485,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
1811,588461,1,2,,49732003,4485,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
1812,588461,1,2,,49732003,4485,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
1813,588461,1,2,,49732003,4485,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
1814,588473,1,1,,56423128,4485,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1815,588473,1,1,,56423128,4485,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1816,588475,1,2,,56423128,4485,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1817,588475,1,2,,56423128,4485,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1818,588478,1,2,,124800382,4485,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1819,588489,1,1,,56423128,4485,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1820,588492,1,1,,56423128,4485,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1821,588493,1,2,,56423128,4485,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1822,588497,1,2,,56423128,4485,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1823,588497,1,2,,56423128,4485,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1824,588497,1,2,,56423128,4485,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1825,588499,1,3,,56423128,4485,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1826,588499,1,3,,56423128,4485,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1827,588499,1,3,,56423128,4485,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1828,588501,1,2,,56423128,4485,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1829,588501,1,2,,56423128,4485,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1830,588501,1,2,,56423128,4485,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1831,588506,1,2,,49732003,4485,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
1832,588511,1,2,,49732003,4485,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1833,588513,1,1,,17388858,4485,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1834,588514,1,1,,17388858,4485,Inconclusive,348019627.0,2099.0,50.1187,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1835,588515,1,1,,17388858,4485,Inconclusive,124375976.0,367.0,31.6228,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1836,588516,1,1,,17388858,4485,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1837,588519,1,2,,92124243,4485,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1838,588519,1,2,,92125211,4485,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1839,588519,1,2,,99300721,4485,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1840,588519,1,2,,99302239,4485,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1841,588526,1,1,,17388858,4485,Inconclusive,325495553.0,9971.0,22.3872,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1842,588527,1,1,,17388858,4485,Inconclusive,325495553.0,9971.0,25.1189,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1843,588532,1,1,,17388858,4485,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1844,588533,1,1,,17388858,4485,Active,311348376.0,2908.0,31.6228,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1845,588534,1,1,,17388858,4485,Inconclusive,216409690.0,5467.0,11.2202,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1846,588535,1,1,,17388858,4485,Inconclusive,216409690.0,5467.0,25.1189,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1847,588536,1,1,,17388858,4485,Inconclusive,216409692.0,5468.0,15.8489,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1848,588537,1,1,,17388858,4485,Inconclusive,216409692.0,5468.0,50.1187,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1849,588541,1,1,,17388858,4485,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1850,588543,1,1,,17388858,4485,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1851,588544,1,1,,17388858,4485,Inconclusive,325495497.0,6256.0,44.6684,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1852,588545,1,1,,17388858,4485,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1853,588546,1,1,,17388858,4485,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1854,588547,1,1,,17388858,4485,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1855,588549,1,1,,56423128,4485,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1856,588550,1,1,,49732003,4485,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
1857,588579,1,1,,11111549,4485,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1858,588579,1,1,,56423128,4485,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1859,588579,1,1,,90341123,4485,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1860,588579,1,1,,104171202,4485,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1861,588579,1,1,,124880908,4485,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1862,588579,1,1,,124880909,4485,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1863,588579,1,1,,124880910,4485,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1864,588579,1,1,,124880913,4485,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1865,588590,1,1,,50104712,4485,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1866,588590,1,1,,56423128,4485,Inconclusive,154350220.0,11201.0,39.8107,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1867,588590,1,1,,124880908,4485,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1868,588590,1,1,,124880909,4485,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1869,588591,1,1,,50104712,4485,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1870,588591,1,1,,56423128,4485,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1871,588621,1,1,,56423128,4485,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1872,588627,1,1,,49732003,4485,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1873,588664,1,2,,56423128,4485,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1874,588664,1,2,,56423128,4485,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1875,588674,1,2,,56423128,4485,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1876,588675,1,1,,49732003,4485,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1877,588676,1,1,,49732003,4485,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1878,588685,1,1,,49732003,4485,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
1879,588689,1,1,,56423128,4485,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1880,588692,2,1,,49732003,4485,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1881,588692,2,1,,56423128,4485,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1882,588726,1,2,,56423128,4485,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1883,588727,1,1,,56423128,4485,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1884,588795,1,1,,56423128,4485,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1885,588795,1,1,,90341123,4485,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1886,588795,1,1,,124880908,4485,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1887,588795,1,1,,124880909,4485,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1888,588812,1,1,,17388858,4485,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1889,588812,1,1,1.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1890,588812,1,1,2.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1891,588812,1,1,3.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1892,588812,1,1,4.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1893,588812,1,1,5.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1894,588812,1,1,6.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1895,588812,1,1,7.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1896,588812,1,1,8.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1897,588812,1,1,9.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1898,588812,1,1,10.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1899,588812,1,1,11.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1900,588812,1,1,12.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1901,588812,1,1,13.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1902,588812,1,1,14.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1903,588812,1,1,15.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1904,588812,1,1,16.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1905,588812,1,1,17.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1906,588812,1,1,18.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1907,588812,1,1,19.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1908,588812,1,1,20.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1909,588812,1,1,21.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1910,588812,1,1,22.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1911,588812,1,1,23.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1912,588812,1,1,24.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1913,588812,1,1,25.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1914,588812,1,1,26.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1915,588812,1,1,27.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1916,588812,1,1,28.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1917,588812,1,1,29.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1918,588812,1,1,30.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1919,588812,1,1,31.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1920,588812,1,1,32.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1921,588812,1,1,33.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1922,588812,1,1,34.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1923,588812,1,1,35.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1924,588812,1,1,36.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1925,588812,1,1,37.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1926,588812,1,1,38.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1927,588812,1,1,39.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1928,588812,1,1,40.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1929,588812,1,1,41.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1930,588812,1,1,42.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1931,588812,1,1,43.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1932,588812,1,1,44.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1933,588812,1,1,45.0,17388858,4485,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1934,588812,1,1,46.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1935,588812,1,1,47.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1936,588812,1,1,48.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1937,588812,1,1,49.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1938,588812,1,1,50.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1939,588812,1,1,51.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1940,588812,1,1,52.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1941,588812,1,1,53.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1942,588812,1,1,54.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1943,588812,1,1,55.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1944,588812,1,1,56.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1945,588812,1,1,57.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1946,588812,1,1,58.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1947,588812,1,1,59.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1948,588812,1,1,60.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1949,588812,1,1,61.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1950,588812,1,1,62.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1951,588812,1,1,63.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1952,588812,1,1,64.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1953,588812,1,1,65.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1954,588812,1,1,66.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1955,588812,1,1,67.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1956,588812,1,1,68.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1957,588812,1,1,69.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1958,588812,1,1,70.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1959,588812,1,1,71.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1960,588812,1,1,72.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1961,588812,1,1,73.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1962,588812,1,1,74.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1963,588812,1,1,75.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1964,588812,1,1,76.0,17388858,4485,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1965,588812,1,1,77.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1966,588812,1,1,78.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1967,588812,1,1,79.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1968,588812,1,1,80.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1969,588812,1,1,81.0,17388858,4485,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1970,588813,1,1,,17388858,4485,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1971,588813,1,1,1.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1972,588813,1,1,2.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1973,588813,1,1,3.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1974,588813,1,1,4.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1975,588813,1,1,5.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1976,588813,1,1,6.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1977,588813,1,1,7.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1978,588813,1,1,8.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1979,588813,1,1,9.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1980,588813,1,1,10.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1981,588813,1,1,11.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1982,588813,1,1,12.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1983,588813,1,1,13.0,17388858,4485,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1984,588813,1,1,14.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1985,588813,1,1,15.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1986,588813,1,1,16.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1987,588813,1,1,17.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1988,588813,1,1,18.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1989,588813,1,1,19.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1990,588813,1,1,20.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1991,588813,1,1,21.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1992,588813,1,1,22.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1993,588813,1,1,23.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1994,588813,1,1,24.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1995,588813,1,1,25.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1996,588813,1,1,26.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1997,588813,1,1,27.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1998,588813,1,1,28.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1999,588813,1,1,29.0,17388858,4485,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2000,588813,1,1,30.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2001,588813,1,1,31.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2002,588813,1,1,32.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2003,588813,1,1,33.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2004,588813,1,1,34.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2005,588813,1,1,35.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2006,588813,1,1,36.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2007,588813,1,1,37.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2008,588813,1,1,38.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2009,588813,1,1,39.0,17388858,4485,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2010,588813,1,1,40.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2011,588813,1,1,41.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2012,588813,1,1,42.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2013,588813,1,1,43.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2014,588813,1,1,44.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2015,588813,1,1,45.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2016,588813,1,1,46.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2017,588813,1,1,47.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2018,588813,1,1,48.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2019,588813,1,1,49.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2020,588813,1,1,50.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2021,588813,1,1,51.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2022,588813,1,1,52.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2023,588813,1,1,53.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2024,588813,1,1,54.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2025,588813,1,1,55.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2026,588813,1,1,56.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2027,588813,1,1,57.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2028,588813,1,1,58.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2029,588813,1,1,59.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2030,588813,1,1,60.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2031,588813,1,1,61.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2032,588813,1,1,62.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2033,588813,1,1,63.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2034,588813,1,1,64.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2035,588813,1,1,65.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2036,588813,1,1,66.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2037,588813,1,1,67.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2038,588813,1,1,68.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2039,588813,1,1,69.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2040,588813,1,1,70.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2041,588813,1,1,71.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2042,588813,1,1,72.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2043,588813,1,1,73.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2044,588813,1,1,74.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2045,588813,1,1,75.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2046,588813,1,1,76.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2047,588813,1,1,77.0,17388858,4485,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2048,588813,1,1,78.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2049,588813,1,1,79.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2050,588813,1,1,80.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2051,588813,1,1,81.0,17388858,4485,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2052,588814,1,3,,56423128,4485,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2053,588819,1,4,,56423128,4485,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2054,588834,2,1,,17388858,4485,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2055,588834,2,1,,26752060,4485,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2056,588834,2,1,,50104712,4485,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2057,588850,1,1,,56423128,4485,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2058,588852,1,3,,56423128,4485,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2059,588855,1,1,,56423128,4485,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2060,588855,1,1,,124880908,4485,Inconclusive,18418623.0,4088.0,35.4813,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2061,588855,1,1,,124880909,4485,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2062,588856,1,1,,56423128,4485,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2063,588856,1,1,,124880908,4485,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2064,588856,1,1,,124880909,4485,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2065,589025,1,10,,103557046,4485,Unspecified,6093860.0,8856.0,,,Pregnane X receptor agonist,Other,,
2066,589039,1,10,,103557046,4485,Unspecified,116241312.0,1576.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
2067,589056,1,10,,103557046,4485,Unspecified,116241312.0,1576.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
2068,592682,1,4,,103557046,4485,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis,Other,21458999.0,
2069,592683,1,4,,103557046,4485,Unspecified,,,,,Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis,Other,21458999.0,
2070,602123,1,1,,56423128,4485,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2071,602141,1,1,,56423128,4485,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2072,602162,1,1,,56423128,4485,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2073,602163,1,1,,56423128,4485,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2074,602179,1,2,,56423128,4485,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2075,602199,1,1,,11111549,4485,Active,63054845.0,7421.0,25.1189,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen,Confirmatory,,
2076,602199,1,1,,90341123,4485,Active,63054845.0,7421.0,3.1623,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen,Confirmatory,,
2077,602199,1,1,,104171202,4485,Active,63054845.0,7421.0,3.9811,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen,Confirmatory,,
2078,602199,1,1,,124880908,4485,Active,63054845.0,7421.0,6.3096,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen,Confirmatory,,
2079,602199,1,1,,124880910,4485,Active,63054845.0,7421.0,6.3096,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen,Confirmatory,,
2080,602199,1,1,,124880913,4485,Active,63054845.0,7421.0,7.0795,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen,Confirmatory,,
2081,602200,1,1,,11111549,4485,Active,63054845.0,7421.0,10.0,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Fluorescein Assay,Confirmatory,,
2082,602200,1,1,,90341123,4485,Active,63054845.0,7421.0,7.0795,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Fluorescein Assay,Confirmatory,,
2083,602200,1,1,,104171202,4485,Active,63054845.0,7421.0,8.9125,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Fluorescein Assay,Confirmatory,,
2084,602200,1,1,,124880908,4485,Active,63054845.0,7421.0,3.5481,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Fluorescein Assay,Confirmatory,,
2085,602200,1,1,,124880910,4485,Active,63054845.0,7421.0,6.3096,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Fluorescein Assay,Confirmatory,,
2086,602200,1,1,,124880913,4485,Active,63054845.0,7421.0,3.1623,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Fluorescein Assay,Confirmatory,,
2087,602201,1,1,,11111549,4485,Active,63054845.0,7421.0,8.9125,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Texas Red Assay,Confirmatory,,
2088,602201,1,1,,90341123,4485,Inconclusive,63054845.0,7421.0,39.8107,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Texas Red Assay,Confirmatory,,
2089,602201,1,1,,104171202,4485,Active,63054845.0,7421.0,3.5481,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Texas Red Assay,Confirmatory,,
2090,602201,1,1,,124880908,4485,Active,63054845.0,7421.0,3.1623,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Texas Red Assay,Confirmatory,,
2091,602201,1,1,,124880910,4485,Inconclusive,63054845.0,7421.0,39.8107,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Texas Red Assay,Confirmatory,,
2092,602201,1,1,,124880913,4485,Active,63054845.0,7421.0,11.2202,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Texas Red Assay,Confirmatory,,
2093,602202,1,1,,11111549,4485,Inactive,63054845.0,7421.0,,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Beta-Lactamase Assay,Confirmatory,,
2094,602202,1,1,,90341123,4485,Inactive,63054845.0,7421.0,,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Beta-Lactamase Assay,Confirmatory,,
2095,602202,1,1,,104171202,4485,Inconclusive,63054845.0,7421.0,29.0929,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Beta-Lactamase Assay,Confirmatory,,
2096,602202,1,1,,124880908,4485,Inactive,63054845.0,7421.0,,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Beta-Lactamase Assay,Confirmatory,,
2097,602202,1,1,,124880910,4485,Inactive,63054845.0,7421.0,,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Beta-Lactamase Assay,Confirmatory,,
2098,602202,1,1,,124880913,4485,Inconclusive,63054845.0,7421.0,29.0929,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Beta-Lactamase Assay,Confirmatory,,
2099,602204,1,1,,11111549,4485,Inactive,,,,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Cytotoxicity Assay,Confirmatory,,
2100,602204,1,1,,90341123,4485,Inconclusive,,,0.0095,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Cytotoxicity Assay,Confirmatory,,
2101,602204,1,1,,104171202,4485,Inactive,,,,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Cytotoxicity Assay,Confirmatory,,
2102,602204,1,1,,124880908,4485,Inactive,,,,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Cytotoxicity Assay,Confirmatory,,
2103,602204,1,1,,124880910,4485,Inconclusive,,,23.7781,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Cytotoxicity Assay,Confirmatory,,
2104,602204,1,1,,124880913,4485,Inactive,,,,Potency,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Cytotoxicity Assay,Confirmatory,,
2105,602229,1,1,,56423128,4485,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2106,602233,1,1,,56423128,4485,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2107,602244,1,2,,56423128,4485,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2108,602247,1,2,,56423128,4485,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2109,602248,1,2,,56423128,4485,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2110,602250,1,2,,56423128,4485,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2111,602252,1,1,,56423128,4485,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2112,602252,1,1,,56423128,4485,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2113,602261,1,1,,56423128,4485,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2114,602274,1,2,,56423128,4485,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2115,602276,1,1,,855613,4485,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
2116,602277,1,1,,855613,4485,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
2117,602281,1,1,,56423128,4485,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2118,602281,1,1,,56423128,4485,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2119,602310,1,2,,56423128,4485,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2120,602310,1,2,,124880908,4485,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2121,602310,1,2,,124880909,4485,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2122,602313,1,1,,56423128,4485,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2123,602314,1,2,,92124243,4485,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2124,602314,1,2,,92125211,4485,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2125,602314,1,2,,99300721,4485,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2126,602329,1,1,,49732003,4485,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2127,602329,1,1,,56423128,4485,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2128,602332,1,1,,11111549,4485,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2129,602332,1,1,,56423128,4485,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2130,602332,1,1,,90341123,4485,Inactive,168984549.0,,58.4789,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2131,602332,1,1,,104171202,4485,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2132,602332,1,1,,124880908,4485,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2133,602332,1,1,,124880909,4485,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2134,602332,1,1,,124880910,4485,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2135,602332,1,1,,124880913,4485,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2136,602340,1,2,,56423128,4485,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2137,602342,2,1,,56423128,4485,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2138,602346,1,1,,49732003,4485,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2139,602346,1,1,,56423128,4485,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2140,602363,1,1,,49732003,4485,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2141,602363,1,1,,56423128,4485,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2142,602393,1,1,,49732003,4485,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2143,602393,1,1,,56423128,4485,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2144,602396,1,2,,56423128,4485,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2145,602399,1,2,,56423128,4485,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2146,602405,1,1,,49732003,4485,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2147,602405,1,1,,56423128,4485,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2148,602410,1,1,,56423128,4485,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2149,602429,1,1,,56423128,4485,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2150,602438,1,1,,56423128,4485,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2151,602440,1,1,,56423128,4485,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2152,602449,1,2,,56423128,4485,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2153,602481,1,1,,49732003,4485,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2154,602481,1,1,,56423128,4485,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2155,611853,1,5,,103557046,4485,Unspecified,,,,,Activity at CFTR F508 deletion mutant expressed in forskolin-stimulated FRT cells assessed as maximal increase in iodine influx measured as YFP quenching rate after 24 hrs by fluorescence assay,Other,21568323.0,
2156,611854,4,3,,103557046,4485,Active,,,2.9,Kd,Binding affinity to CFTR F508 deletion mutant expressed in forskolin-stimulated FRT cells assessed as increase in iodine influx measured as YFP quenching rate after 24 hrs by fluorescence assay,Confirmatory,21568323.0,
2157,611859,1,6,,103557046,4485,Unspecified,,,,,Negative chronotropic activity against potassium-induced contraction in guinea pig right atrium assessed as decrease atrial rate at 10'-7 M relative to control,Other,21568323.0,
2158,611864,3,4,,103557046,4485,Active,,,0.039,EC50,Negative chronotropic activity against potassium-induced contraction in guinea pig right atrium assessed as decrease atrial rate,Confirmatory,21568323.0,
2159,611867,1,6,,103557046,4485,Unspecified,,,,,Negative ionotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate at 10'-5 M relative to control,Other,21568323.0,
2160,611945,3,4,,103557046,4485,Active,,,0.26,EC50,Negative ionotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate,Confirmatory,21568323.0,
2161,611947,1,5,,103557046,4485,Unspecified,,,,,Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction at 10'-6 M,Other,21568323.0,
2162,611949,3,3,,103557046,4485,Active,,,0.009000000000000001,IC50,Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction,Confirmatory,21568323.0,
2163,611957,1,5,,103557046,4485,Unspecified,,,,,Negative ionotropic activity in potassium depolarized guinea pig longitudinal smooth muscle assessed as inhibition of calcium-induced contraction at 5 X 10'-9 M,Other,21568323.0,
2164,612042,3,3,,103557046,4485,Active,,,0.0015,IC50,Negative ionotropic activity in potassium depolarized guinea pig longitudinal smooth muscle assessed as inhibition of calcium-induced contraction,Confirmatory,21568323.0,
2165,612043,1,6,,103557046,4485,Unspecified,,,,,Bronchodilatory activity in guinea pig trachea assessed as inhibition of carbachol-induced contraction at 10'-5 M,Other,21568323.0,
2166,612046,3,4,,103557046,4485,Active,,,0.096,IC50,Bronchodilatory activity in guinea pig trachea assessed as inhibition of carbachol-induced contraction,Confirmatory,21568323.0,
2167,614827,1,3,,103557046,4485,Active,,,,,Binding affinity to dipalmitoyl phosphatidyl choline lipid bilayer assessed as decrease in pre-transition temperature at compound to lipid molar ratio of 1:1 by DSC technique,Other,21632156.0,
2168,614828,1,3,,103557046,4485,Active,,,,,Binding affinity to dipalmitoyl phosphatidyl choline lipid bilayer assessed as decrease in pre-transition temperature at compound to lipid molar ratio of 1:5 by DSC technique,Other,21632156.0,
2169,614829,1,3,,103557046,4485,Active,,,,,Binding affinity to dipalmitoyl phosphatidyl choline lipid bilayer assessed as decrease in pre-transition temperature at compound to lipid molar ratio of 1:100 by DSC technique,Other,21632156.0,
2170,616223,1,3,,103557046,4485,Unspecified,,,,,Binding affinity to multilamellar vesicles assessed as apparent binding constant after 2 hrs by double reciprocal plot,Other,21632156.0,
2171,616225,1,3,,103557046,4485,Active,,,,,Antifertility activity against goat epididymis sperm cells assessed as inhibition of sperm motility at 1.25 mM after 2 hrs by Sander-Cramer test,Other,21632156.0,
2172,616228,1,4,,103557046,4485,Active,,,,,Antifertility effect in goat epididymis spermatozoa assessed as decrease in lactate production at 1.25 mm after 2 hrs by NMR analysis,Other,21632156.0,
2173,617311,7,5,,103557046,4485,Active,14916998.0,2936.0,23.4,IC50,Inhibition of human erythrocyte Glutathione reductase,Confirmatory,21795044.0,
2174,617312,7,5,,103557046,4485,Active,14916998.0,2936.0,17.4,Ki,Competitive inhibition of human erythrocyte Glutathione reductase using GSSG substrate by Lineweaver-Burk plot analysis,Confirmatory,21795044.0,
2175,623870,1,1,,49732003,4485,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2176,623870,1,1,,49732003,4485,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2177,623870,1,1,,56423128,4485,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2178,623870,1,1,,56423128,4485,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2179,623877,1,1,,56423128,4485,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2180,623901,1,1,,56423128,4485,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2181,624030,1,2,,104171202,4485,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2182,624031,1,2,,104171202,4485,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2183,624032,1,2,,104171202,4485,Active,8393992.0,24660.0,18.1056,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2184,624037,1,3,,56423128,4485,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2185,624038,1,3,,56423128,4485,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2186,624040,1,3,,56423128,4485,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2187,624044,1,2,,104171202,4485,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2188,624125,1,4,,56423128,4485,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2189,624126,1,3,,56423128,4485,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2190,624127,1,2,,56423128,4485,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2191,624146,1,1,,90341123,4485,Inconclusive,71051501.0,2744.0,12.5893,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2192,624147,1,1,,90341123,4485,Inconclusive,62359610.0,,13.4591,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2193,624148,1,2,,90341123,4485,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2194,624149,1,1,,90341123,4485,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2195,624168,1,1,,56423128,4485,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2196,624169,1,1,,56423128,4485,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2197,624170,1,1,,56423128,4485,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2198,624170,1,1,,104171202,4485,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2199,624171,1,1,,56423128,4485,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2200,624172,1,1,,56423128,4485,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2201,624172,1,1,,104171202,4485,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2202,624173,1,3,,56423128,4485,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2203,624173,1,3,,104171202,4485,Inconclusive,62359610.0,,19.9526,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2204,624178,1,1,,56423128,4485,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2205,624178,1,1,,124880908,4485,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2206,624178,1,1,,124880909,4485,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2207,624202,1,1,,56423128,4485,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2208,624202,1,1,,124880908,4485,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2209,624202,1,1,,124880909,4485,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2210,624204,1,2,,56423128,4485,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2211,624246,1,1,,56423128,4485,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2212,624256,1,2,,56423128,4485,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2213,624263,1,1,,56423128,4485,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2214,624263,1,1,,56423128,4485,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2215,624263,1,1,,124880908,4485,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2216,624263,1,1,,124880908,4485,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2217,624263,1,1,,124880909,4485,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2218,624263,1,1,,124880909,4485,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2219,624267,1,2,,56423128,4485,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2220,624267,1,2,,56423128,4485,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2221,624268,1,3,,56423128,4485,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2222,624288,1,1,,56423128,4485,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2223,624296,1,1,,855613,4485,Inconclusive,7705682.0,51053.0,29.0929,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2224,624296,1,1,,56423128,4485,Inconclusive,7705682.0,51053.0,29.0929,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2225,624296,1,1,,104171202,4485,Inconclusive,7705682.0,51053.0,33.4983,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2226,624297,1,1,,855613,4485,Inconclusive,7705682.0,51053.0,29.0929,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2227,624297,1,1,,56423128,4485,Inconclusive,7705682.0,51053.0,20.5962,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2228,624297,1,1,,104171202,4485,Inconclusive,7705682.0,51053.0,33.4983,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2229,624304,1,2,,56423128,4485,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2230,624330,1,2,,56423128,4485,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2231,624349,1,2,,92124243,4485,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2232,624349,1,2,,92125211,4485,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2233,624349,1,2,,92307350,4485,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2234,624349,1,2,,92308513,4485,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2235,624349,1,2,,92308827,4485,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2236,624349,1,2,,121362882,4485,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2237,624352,1,1,,56423128,4485,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2238,624354,1,1,,56423128,4485,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2239,624377,1,1,,855613,4485,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2240,624414,1,1,,56423128,4485,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2241,624414,1,1,,124880908,4485,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2242,624414,1,1,,124880909,4485,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2243,624415,1,2,,56423128,4485,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2244,624416,1,1,,855613,4485,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2245,624417,1,1,,56423128,4485,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2246,624418,1,1,,56423128,4485,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2247,624455,1,1,,90341123,4485,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2248,624463,1,1,,56423128,4485,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2249,624464,1,1,,56423128,4485,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2250,624465,1,1,,56423128,4485,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2251,624466,1,3,,855613,4485,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2252,624467,1,1,,855613,4485,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2253,624483,1,1,,56423128,4485,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2254,624622,3,1,,103557046,4485,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
2255,624623,3,1,,103557046,4485,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
2256,624626,1,9,,103557046,4485,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
2257,624628,1,9,,103557046,4485,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
2258,624629,1,9,,103557046,4485,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
2259,625144,5,5,,103557046,4485,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2260,625145,4,7,,103557046,4485,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2261,625146,5,5,,103557046,4485,Active,126397.0,100009114.0,15.100999999999999,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2262,625147,4,7,,103557046,4485,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2263,625148,4,7,,103557046,4485,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2264,625149,4,7,,103557046,4485,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2265,625150,5,5,,103557046,4485,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2266,625151,4,7,,103557046,4485,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2267,625152,4,7,,103557046,4485,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2268,625153,4,7,,103557046,4485,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2269,625154,4,7,,103557046,4485,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2270,625155,4,7,,103557046,4485,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2271,625156,1,9,,103557046,4485,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2272,625157,6,2,,103557046,4485,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2273,625158,3,4,,103557046,4485,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2274,625159,5,5,,103557046,4485,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2275,625160,1,9,,103557046,4485,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2276,625161,4,7,,103557046,4485,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2277,625162,4,7,,103557046,4485,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2278,625163,4,7,,103557046,4485,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2279,625164,1,6,,103557046,4485,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2280,625165,3,4,,103557046,4485,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2281,625166,3,4,,103557046,4485,Active,,,44.158,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2282,625167,5,5,,103557046,4485,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2283,625168,4,7,,103557046,4485,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2284,625169,1,6,,103557046,4485,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2285,625170,3,4,,103557046,4485,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2286,625171,4,7,,103557046,4485,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2287,625172,4,7,,103557046,4485,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2288,625173,5,5,,103557046,4485,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2289,625174,5,5,,103557046,4485,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2290,625175,5,5,,103557046,4485,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2291,625176,1,9,,103557046,4485,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2292,625177,5,5,,103557046,4485,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2293,625178,5,5,,103557046,4485,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2294,625179,1,9,,103557046,4485,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2295,625180,5,5,,103557046,4485,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2296,625181,5,5,,103557046,4485,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2297,625182,5,5,,103557046,4485,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2298,625183,5,5,,103557046,4485,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2299,625184,5,5,,103557046,4485,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2300,625185,5,5,,103557046,4485,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2301,625186,5,5,,103557046,4485,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2302,625187,5,5,,103557046,4485,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2303,625188,1,9,,103557046,4485,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2304,625189,1,7,,103557046,4485,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2305,625190,4,5,,103557046,4485,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2306,625191,4,7,,103557046,4485,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2307,625192,4,7,,103557046,4485,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2308,625193,5,5,,103557046,4485,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2309,625194,4,7,,103557046,4485,Active,231473.0,134.0,7.7010000000000005,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2310,625195,4,7,,103557046,4485,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2311,625196,5,6,,103557046,4485,Active,803374855.0,140.0,7.2139999999999995,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2312,625197,3,4,,103557046,4485,Active,,,23.831999999999997,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2313,625198,4,7,,103557046,4485,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2314,625199,4,7,,103557046,4485,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2315,625200,4,7,,103557046,4485,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2316,625201,4,7,,103557046,4485,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2317,625202,4,7,,103557046,4485,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2318,625203,4,7,,103557046,4485,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2319,625204,4,7,,103557046,4485,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2320,625205,4,7,,103557046,4485,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2321,625206,4,7,,103557046,4485,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2322,625207,4,7,,103557046,4485,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2323,625208,5,5,,103557046,4485,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2324,625209,4,7,,103557046,4485,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2325,625210,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2326,625211,1,6,,103557046,4485,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2327,625212,3,4,,103557046,4485,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2328,625213,4,7,,103557046,4485,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2329,625214,1,9,,103557046,4485,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2330,625215,3,4,,103557046,4485,Active,,,0.00867,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2331,625216,3,4,,103557046,4485,Active,,,0.048,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2332,625217,4,7,,103557046,4485,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2333,625218,4,7,,103557046,4485,Active,112816.0,3358.0,18.273,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2334,625219,3,4,,103557046,4485,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2335,625220,4,7,,103557046,4485,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2336,625221,4,7,,103557046,4485,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2337,625222,4,7,,103557046,4485,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2338,625223,4,7,,103557046,4485,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2339,625224,3,4,,103557046,4485,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2340,625225,3,4,,103557046,4485,Active,,,3.779,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2341,625226,4,7,,103557046,4485,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2342,625227,4,7,,103557046,4485,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2343,625228,4,7,,103557046,4485,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2344,625229,5,5,,103557046,4485,Active,254763392.0,6916.0,18.594,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2345,625230,1,6,,103557046,4485,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2346,625231,4,7,,103557046,4485,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2347,625232,1,9,,103557046,4485,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2348,625233,4,7,,103557046,4485,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2349,625234,3,4,,103557046,4485,Active,,,0.878,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2350,625235,4,7,,103557046,4485,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2351,625236,5,5,,103557046,4485,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2352,625237,4,7,,103557046,4485,Active,1168965.0,729230.0,2.191,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2353,625238,4,7,,103557046,4485,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2354,625239,4,7,,103557046,4485,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2355,625240,1,9,,103557046,4485,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2356,625241,4,7,,103557046,4485,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2357,625242,4,7,,103557046,4485,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2358,625243,5,5,,103557046,4485,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2359,625244,5,5,,103557046,4485,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2360,625245,5,5,,103557046,4485,Active,117144.0,1544.0,0.3,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2361,625246,1,9,,103557046,4485,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2362,625247,5,5,,103557046,4485,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2363,625248,5,5,,103557046,4485,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2364,625249,5,5,,103557046,4485,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2365,625250,5,5,,103557046,4485,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2366,625251,5,5,,103557046,4485,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2367,625252,4,7,,103557046,4485,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2368,625253,4,7,,103557046,4485,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2369,625254,4,7,,103557046,4485,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2370,625255,4,7,,103557046,4485,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2371,625256,4,7,,103557046,4485,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2372,625257,4,7,,103557046,4485,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2373,625258,4,7,,103557046,4485,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2374,625259,4,7,,103557046,4485,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2375,625260,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2376,625261,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2377,625262,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2378,625263,4,7,,103557046,4485,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2379,625264,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2380,625265,1,6,,103557046,4485,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2381,625266,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2382,625267,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2383,625268,4,2,,103557046,4485,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2384,625268,4,2,,103557046,4485,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2385,625268,4,2,,103557046,4485,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2386,625268,4,2,,103557046,4485,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2387,625269,4,7,,103557046,4485,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2388,625270,4,7,,103557046,4485,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2389,625271,5,5,,103557046,4485,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2390,625272,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2391,625273,4,6,,103557046,4485,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2392,625274,1,6,,103557046,4485,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2393,625275,3,4,,103557046,4485,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2394,625277,1,3,,103557046,4485,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
2395,625279,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2396,625280,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2397,625281,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2398,625282,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2399,625283,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2400,625284,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2401,625285,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2402,625286,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2403,625287,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2404,625288,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2405,625289,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2406,625290,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2407,625291,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2408,625292,1,3,,103557046,4485,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2409,639462,1,6,,103557046,4485,Unspecified,,,,,Inhibition of potassium chloride-induced cytosolic calcium level in human SH-SY5Y cells at 10 uM treated after 10 mins before potassium chloride challenge by Fluo-4/AM fluorescence assay,Other,21420206.0,
2410,640615,3,3,,103557046,4485,Unspecified,,,,,Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis,Other,22197392.0,
2411,651550,1,1,,56423128,4485,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2412,651560,1,1,,56423128,4485,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2413,651572,1,2,,855613,4485,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2414,651582,1,1,,56423128,4485,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2415,651602,1,1,,855613,4485,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2416,651602,1,1,,855613,4485,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2417,651602,1,1,,855613,4485,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2418,651610,2,1,,855613,4485,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2419,651631,4,1,,144203763,4485,Inconclusive,269849759.0,7157.0,33.4915,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2420,651631,4,1,,144207502,4485,Inconclusive,269849759.0,7157.0,68.6594,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2421,651632,4,1,,144203763,4485,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2422,651632,4,1,,144207502,4485,Inactive,296439460.0,79915.0,21.712,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2423,651633,4,1,,144203763,4485,Inactive,,,6.6824,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2424,651633,4,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2425,651634,4,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2426,651634,4,1,,144207502,4485,Active,,,54.5381,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2427,651635,1,3,,11111549,4485,Inconclusive,171543895.0,6311.0,10.0,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2428,651635,1,3,,56423128,4485,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2429,651635,1,3,,90341123,4485,Active,171543895.0,6311.0,28.1838,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2430,651636,1,1,,56423128,4485,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2431,651640,1,1,,855613,4485,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2432,651644,1,1,,56423128,4485,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2433,651647,1,1,,56423128,4485,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2434,651654,1,1,,49732003,4485,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2435,651654,1,1,,56423128,4485,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2436,651658,1,1,,855613,4485,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2437,651661,2,1,,855613,4485,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2438,651687,1,1,,56423128,4485,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2439,651699,1,1,,56423128,4485,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2440,651699,1,1,,56423128,4485,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2441,651702,1,2,,56423128,4485,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2442,651704,2,1,,855613,4485,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2443,651710,1,1,,855613,4485,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2444,651711,2,1,,855613,4485,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2445,651718,1,2,,855613,4485,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2446,651723,1,1,,56423128,4485,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2447,651724,1,1,,56423128,4485,Inconclusive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2448,651725,1,1,,56423128,4485,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2449,651741,1,1,,17388858,4485,Inconclusive,20149576.0,4780.0,42.1632,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2450,651743,1,1,,17388858,4485,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2451,651749,1,1,,17388858,4485,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2452,651751,1,1,,17388858,4485,Inconclusive,5702233.0,84385.0,70.7946,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2453,651754,1,1,,17388858,4485,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2454,651755,1,1,,17388858,4485,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2455,651757,1,1,,17388858,4485,Inconclusive,25952111.0,7124.0,10.5909,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2456,651758,1,1,,17388858,4485,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2457,651768,1,2,,56423128,4485,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2458,651777,1,1,,17388858,4485,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2459,651778,1,1,,17388858,4485,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2460,651800,1,1,,855613,4485,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2461,651802,1,1,,17388858,4485,Active,49066040.0,6097.0,66.8242,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2462,651819,1,1,,56423128,4485,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2463,651820,1,1,,855613,4485,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2464,651820,1,1,,56423128,4485,Inconclusive,,,3.1623,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2465,651821,2,4,,855613,4485,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2466,651828,1,2,,92308513,4485,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2467,651828,1,2,,92308827,4485,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2468,651828,1,2,,121361523,4485,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2469,651838,1,1,,17388858,4485,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2470,651838,1,1,1.0,17388858,4485,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2471,651838,1,1,2.0,17388858,4485,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2472,651838,1,1,3.0,17388858,4485,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2473,651838,1,1,4.0,17388858,4485,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2474,651838,1,1,5.0,17388858,4485,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2475,651838,1,1,6.0,17388858,4485,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2476,651838,1,1,7.0,17388858,4485,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2477,651838,1,1,8.0,17388858,4485,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2478,651957,1,1,,855613,4485,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2479,651958,1,1,,855613,4485,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2480,651965,1,1,,56423128,4485,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2481,651965,1,1,,124880908,4485,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2482,651965,1,1,,124880909,4485,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2483,651999,1,1,,56423128,4485,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2484,652010,1,1,,855613,4485,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2485,652017,1,1,,855613,4485,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2486,652025,1,1,,56423128,4485,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2487,652039,1,1,,855613,4485,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2488,652048,1,2,,56423128,4485,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2489,652048,1,2,,144203763,4485,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2490,652051,1,1,,56423128,4485,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2491,652051,1,1,,144203763,4485,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2492,652054,1,1,,56423128,4485,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2493,652067,1,4,,855613,4485,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2494,652104,1,1,,56423128,4485,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2495,652105,1,1,,56423128,4485,Active,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2496,652106,1,1,,56423128,4485,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2497,652106,1,1,,90341123,4485,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2498,652106,1,1,,124880908,4485,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2499,652106,1,1,,124880909,4485,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2500,652115,1,1,,855613,4485,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2501,652126,1,3,,855613,4485,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2502,652154,1,1,,855613,4485,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2503,652162,2,1,,855613,4485,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2504,652163,1,1,,855613,4485,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2505,652163,1,1,,49732003,4485,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2506,652197,1,1,,855613,4485,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2507,652257,1,1,,855613,4485,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2508,667572,2,2,,103557046,4485,Active,,,0.01,IC50,Inhibition of calcium channel in pig carotid artery assessed as relaxation of KCl-induced vascular smooth muscle contraction,Confirmatory,22703843.0,
2509,670195,4,2,,103557046,4485,Active,,,0.012,EC50,Inhibition of L-type calcium channel in Sprague-Dawley rat aorta assessed as relaxation of Kcl-induced tissue contraction by aortic ring relaxation assay,Confirmatory,22626552.0,
2510,675412,1,5,,103557046,4485,Unspecified,,,,,Solubility of the compound in phosphate buffer at pH 7.4 at 10 mg/mL after 30 mins by HPLC-UV-MS analysis,Other,22889557.0,
2511,678134,1,4,,103557046,4485,Unspecified,,,,,Metabolic stability in human microsomes assessed as glutathione adduct formation,Other,22868228.0,
2512,678712,1,8,,103557046,4485,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
2513,678713,1,8,,103557046,4485,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
2514,678714,1,8,,103557046,4485,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2515,678715,1,8,,103557046,4485,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2516,678716,1,8,,103557046,4485,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
2517,678717,1,8,,103557046,4485,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
2518,678719,1,5,,103557046,4485,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
2519,678722,1,5,,103557046,4485,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
2520,678835,1,8,,103557046,4485,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells,Other,10213372.0,
2521,679183,1,8,,103557046,4485,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Northern blot in vitro, primary rat hepatocyte",Other,12206135.0,
2522,679600,1,8,,103557046,4485,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM, Nifedipine: 100 uM) in Caco-2 cells",Other,10213372.0,
2523,679779,1,8,,103557046,4485,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5uM, Nifedipine:125uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
2524,680053,1,8,,103557046,4485,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 uM, Nifedipine: 50 uM) in MDR1-expressing LLC-PK1 cells",Other,11231118.0,
2525,681132,1,8,,103557046,4485,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells,Other,11602674.0,
2526,681153,3,6,,103557046,4485,Unspecified,238054374.0,5243.0,113.0,IC50,TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells,Confirmatory,11743742.0,
2527,681167,1,8,,103557046,4485,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: Northern blot from LS174T cell,Other,11297522.0,
2528,681335,3,6,,103557046,4485,Unspecified,238054374.0,5243.0,472.0,IC50,TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM) in MDR1-expressing LLC-PK1 cells,Confirmatory,12128170.0,
2529,681586,1,8,,103557046,4485,Unspecified,218526606.0,76408.0,,,"TP_TRANSPORTER: quantitative PCR in vivo, liver of mouse",Other,14570758.0,
2530,686940,1,1,,855613,4485,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2531,686964,1,1,,855613,4485,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2532,686970,1,2,,56423128,4485,Inconclusive,49168486.0,3417.0,5.1735,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2533,686971,1,2,,56423128,4485,Active,,,3.6626,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2534,686977,2,1,,49698329,4485,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2535,686978,1,1,,56423128,4485,Active,79154014.0,55775.0,5.1735,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2536,686978,1,1,,124880908,4485,Active,79154014.0,55775.0,10.0,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2537,686978,1,1,,124880909,4485,Active,79154014.0,55775.0,11.8856,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2538,686978,1,1,,124880910,4485,Active,79154014.0,55775.0,12.9953,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2539,686978,1,1,,124880913,4485,Active,79154014.0,55775.0,9.2,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2540,686978,1,1,,144203763,4485,Active,79154014.0,55775.0,23.715,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2541,686979,1,1,,56423128,4485,Active,79154014.0,55775.0,2.5929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2542,686979,1,1,,124880908,4485,Active,79154014.0,55775.0,7.0795,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2543,686979,1,1,,124880909,4485,Active,79154014.0,55775.0,9.4411,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2544,686979,1,1,,124880910,4485,Active,79154014.0,55775.0,12.9953,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2545,686979,1,1,,124880913,4485,Active,79154014.0,55775.0,11.5821,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2546,686979,1,1,,144203763,4485,Inconclusive,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2547,686992,2,1,,855613,4485,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2548,686996,1,1,,855613,4485,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2549,687014,1,1,,855613,4485,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2550,687016,1,1,,855613,4485,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2551,687035,1,1,,163564773,4485,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2552,687037,1,3,,163564773,4485,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
2553,694787,1,2,,103557046,4485,Unspecified,,,,,Inhibition of KCl-induced Ca2+ overload in Sprague-Dawley rat primary cortical neurons assessed as reduction in F340/F380 fluorescence ratio at 1 uM by Fura-2/AM-based fluorescence assay (Rvb = 1.31 +/- 0.24),Other,23000296.0,
2554,699539,1,7,,103557046,4485,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2555,699540,1,7,,103557046,4485,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2556,699541,1,7,,103557046,4485,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2557,709633,1,2,,103557046,4485,Unspecified,,,,,Inhibition of calcium transients in mouse HL-1 cells after 10 mins using Fluo-4 by fluorescene assay,Other,23130626.0,
2558,717839,1,4,,103557046,4485,Unspecified,,,,,Cytotoxicity against HEK293T cells assessed as decrease in cell viability at 12.5 uM after 24 hrs by trypan blue exclusion assay,Other,23122865.0,
2559,717840,1,7,,103557046,4485,Unspecified,221222505.0,56720.0,,,Inhibition of mouse Tdo2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 100 uM after 45 mins by spectrophotometric analysis relative to control,Other,23122865.0,
2560,717843,1,2,,103557046,4485,Unspecified,,,,,Selectivity ratio of IC50 for mouse Ido1 to IC50 for mouse Ido2,Other,23122865.0,
2561,717844,1,7,,103557046,4485,Unspecified,939108065.0,209176.0,,,Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control,Other,23122865.0,
2562,717845,4,5,,103557046,4485,Active,939108065.0,209176.0,1.5,IC50,Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis,Confirmatory,23122865.0,
2563,717846,4,5,,103557046,4485,Active,123949.0,15930.0,46.0,IC50,Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis,Confirmatory,23122865.0,
2564,718301,1,2,,103557046,4485,Unspecified,,,,,Vasorelaxant activity in Wistar rat aorta without endothelium assessed as inhibition of norepinephrine-induced contraction relative to control,Other,23234371.0,
2565,718302,2,2,,103557046,4485,Active,,,4.31,EC50,Vasorelaxant activity in Wistar rat aorta without endothelium assessed as inhibition of norepinephrine-induced contraction,Confirmatory,23234371.0,
2566,718303,1,2,,103557046,4485,Inconclusive,,,,,Vasorelaxant activity in Wistar rat aorta with endothelium assessed as inhibition of norepinephrine-induced contraction relative to control,Other,23234371.0,
2567,718304,2,2,,103557046,4485,Inconclusive,,,,EC50,Vasorelaxant activity in Wistar rat aorta with endothelium assessed as inhibition of norepinephrine-induced contraction,Confirmatory,23234371.0,
2568,720504,1,1,,56423128,4485,Inconclusive,21359873.0,5347.0,4.7444,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2569,720508,1,1,,855613,4485,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2570,720509,1,1,,855613,4485,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2571,720511,1,1,,855613,4485,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2572,720516,2,1,,144203763,4485,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2573,720516,2,1,,144207502,4485,Inconclusive,296439460.0,79915.0,26.3047,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2574,720532,1,1,,11111549,4485,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2575,720532,1,1,,124880909,4485,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2576,720532,1,1,,124880910,4485,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2577,720532,1,1,,124880913,4485,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2578,720532,1,1,,144203763,4485,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2579,720533,1,1,,11111549,4485,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2580,720533,1,1,,124880909,4485,Inconclusive,,,22.3872,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2581,720533,1,1,,124880910,4485,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2582,720533,1,1,,124880913,4485,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2583,720533,1,1,,144203763,4485,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2584,720538,1,2,,90341123,4485,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2585,720540,1,1,,124880909,4485,Inconclusive,26667227.0,2139.0,10.6928,Potency,qHTS for Inhibitors of the Phosphatase Activity of Eya2: Confirmatory Assay for Cherry-picked Compounds,Confirmatory,,
2586,720541,1,1,,124880909,4485,Active,6014741.0,1487.0,10.6928,Potency,qHTS for Inhibitors of the Phosphatase Activity of Eya2: Carboxyl-terminal binding protein (CtBP) Counterscreen for Cherry-picked Compounds,Confirmatory,,
2587,720542,1,2,,56423128,4485,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2588,720543,1,1,,855613,4485,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2589,720551,1,2,,56423128,4485,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2590,720552,2,1,,144203763,4485,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2591,720552,2,1,,144207502,4485,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2592,720553,1,2,,56423128,4485,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2593,720554,1,3,,92308513,4485,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2594,720559,1,2,,90341123,4485,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2595,720572,1,2,,90341123,4485,Active,3063388.0,5071.0,23.1093,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2596,720573,1,2,,90341123,4485,Inconclusive,3063388.0,5071.0,18.3564,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2597,720579,2,1,,56423128,4485,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2598,720579,2,1,,124880908,4485,Inconclusive,222762.0,3707576.0,10.0,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2599,720579,2,1,,124880909,4485,Inconclusive,222762.0,3707576.0,15.8489,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2600,720579,2,1,,124880910,4485,Inconclusive,222762.0,3707576.0,11.2202,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2601,720579,2,1,,124880913,4485,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2602,720580,1,1,,56423128,4485,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2603,720580,1,1,,124880908,4485,Inconclusive,222762.0,3707576.0,10.0,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2604,720580,1,1,,124880909,4485,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2605,720580,1,1,,124880910,4485,Inconclusive,222762.0,3707576.0,3.5481,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2606,720580,1,1,,124880913,4485,Inconclusive,222762.0,3707576.0,28.1838,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2607,720582,1,1,,855613,4485,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2608,720596,1,1,,855613,4485,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2609,720634,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2610,720634,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2611,720635,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2612,720635,2,1,,144207502,4485,Active,,,61.1927,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2613,720636,1,1,,17388858,4485,Inconclusive,20149576.0,4780.0,59.5572,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2614,720637,2,1,,144203763,4485,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2615,720637,2,1,,144207502,4485,Inconclusive,,,61.1927,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2616,720641,1,2,,92307350,4485,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2617,720641,1,2,,92308513,4485,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2618,720641,1,2,,92308827,4485,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2619,720647,1,2,,855613,4485,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2620,720648,1,1,,855613,4485,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2621,720652,1,1,,17388858,4485,Inconclusive,,,42.1632,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2622,720653,1,1,,17388858,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2623,720659,1,1,,17388858,4485,Inconclusive,325495557.0,8856.0,56.2341,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2624,720674,2,2,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2625,720674,2,2,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2626,720675,2,2,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2627,720675,2,2,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2628,720678,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2629,720678,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2630,720679,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2631,720679,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2632,720680,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2633,720680,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2634,720681,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2635,720681,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2636,720682,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2637,720682,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2638,720683,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2639,720683,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2640,720684,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2641,720684,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2642,720685,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2643,720685,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2644,720686,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2645,720686,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2646,720687,2,2,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2647,720687,2,2,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2648,720691,4,1,,144203763,4485,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2649,720691,4,1,,144207502,4485,Inconclusive,311348376.0,2908.0,49.0441,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2650,720692,3,1,,144203763,4485,Active,311348376.0,2908.0,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2651,720692,3,1,,144207502,4485,Active,311348376.0,2908.0,27.5795,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2652,720693,3,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2653,720693,3,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2654,720700,1,4,,855613,4485,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2655,720702,1,1,,855613,4485,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2656,720704,1,4,,855613,4485,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2657,720706,1,2,,855613,4485,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2658,720707,1,2,,56423128,4485,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2659,720708,1,2,,56423128,4485,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2660,720709,1,2,,56423128,4485,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2661,720711,1,2,,56423128,4485,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2662,720717,1,3,,92124243,4485,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2663,720717,1,3,,92125211,4485,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2664,720717,1,3,,92307350,4485,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2665,720717,1,3,,92308513,4485,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2666,720717,1,3,,92308827,4485,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2667,720717,1,3,,92309807,4485,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2668,720719,2,1,,144203763,4485,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2669,720719,2,1,,144207502,4485,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2670,720725,2,1,,144203763,4485,Active,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2671,720725,2,1,,144207502,4485,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2672,721501,1,2,,103557046,4485,Unspecified,,,,,Stimulation of alkaline phosphatase activity in mouse calvarial osteoblasts at 1 pM to 1 uM after 48 hrs by spectrophotometric analysis,Other,23214410.0,
2673,721504,1,2,,103557046,4485,Active,,,1.54,EC50,Induction of mineralization in mouse calvarial osteoblasts assessed as increase of mineralized nodules formation after 21 days by alizarin red-S staining based spectrophotometric analysis,Confirmatory,23214410.0,
2674,721506,3,1,,103557046,4485,Active,,,,,Induction of mineralization in mouse calvarial osteoblasts assessed as increase of mineralized nodules formation measuring concentration required for maximum activity after 21 days by alizarin red-S staining based spectrophotometric analysis,Other,23214410.0,
2675,721507,1,2,,103557046,4485,Active,,,,,Induction of proliferation of mouse calvarial osteoblasts at 1 pM to 1 uM after 48 hrs,Other,23214410.0,
2676,721508,3,1,,103557046,4485,Active,,,,,Stimulation of alkaline phosphatase activity in mouse calvarial osteoblasts assessed as concentration required for maximum activity after 48 hrs by spectrophotometric analysis,Other,23214410.0,
2677,721696,1,2,,103557046,4485,Active,,,1.45,EC50,Stimulation of alkaline phosphatase activity in mouse calvarial osteoblasts after 48 hrs by spectrophotometric analysis,Confirmatory,23214410.0,
2678,743012,3,1,,144203763,4485,Active,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2679,743012,3,1,,144207502,4485,Active,,,19.3508,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2680,743014,3,1,,144203763,4485,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2681,743014,3,1,,144207502,4485,Active,,,13.6993,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2682,743015,3,1,,144203763,4485,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2683,743015,3,1,,144207502,4485,Active,,,21.712,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2684,743033,3,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2685,743033,3,1,,144207502,4485,Active,,,49.0441,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2686,743035,2,1,,144203763,4485,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2687,743035,2,1,,144207502,4485,Active,124375976.0,367.0,55.0284,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2688,743036,2,1,,144203763,4485,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2689,743036,2,1,,144207502,4485,Inconclusive,124375976.0,367.0,61.7429,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2690,743040,3,1,,144203763,4485,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2691,743040,3,1,,144207502,4485,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2692,743041,3,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2693,743041,3,1,,144207502,4485,Inconclusive,,,68.6594,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2694,743042,3,1,,144203763,4485,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2695,743042,3,1,,144207502,4485,Active,124375976.0,367.0,54.5381,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2696,743053,2,1,,144203763,4485,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2697,743053,2,1,,144207502,4485,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2698,743054,2,1,,144203763,4485,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2699,743054,2,1,,144207502,4485,Inconclusive,124375976.0,367.0,52.4848,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2700,743063,2,1,,144203763,4485,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2701,743063,2,1,,144207502,4485,Inconclusive,124375976.0,367.0,42.0649,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2702,743064,3,1,,144203763,4485,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2703,743064,3,1,,144207502,4485,Active,,,48.6071,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2704,743065,3,1,,144203763,4485,Inconclusive,399498506.0,24831.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2705,743065,3,1,,144207502,4485,Active,399498506.0,24831.0,30.669,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2706,743066,3,1,,144203763,4485,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2707,743066,3,1,,144207502,4485,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2708,743067,2,1,,144203763,4485,Inconclusive,399498506.0,24831.0,26.6032,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2709,743067,2,1,,144207502,4485,Inconclusive,399498506.0,24831.0,24.3613,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2710,743069,2,1,,144203763,4485,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2711,743069,2,1,,144207502,4485,Inconclusive,348019627.0,2099.0,38.9571,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2712,743074,2,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2713,743074,2,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2714,743075,2,1,,144203763,4485,Inconclusive,348019627.0,2099.0,8.4852,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2715,743075,2,1,,144207502,4485,Inactive,348019627.0,2099.0,1.9522,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2716,743077,2,1,,144203763,4485,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2717,743077,2,1,,144207502,4485,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2718,743078,2,1,,144203763,4485,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2719,743078,2,1,,144207502,4485,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2720,743079,3,1,,144203763,4485,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2721,743079,3,1,,144207502,4485,Inconclusive,348019627.0,2099.0,68.6594,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2722,743080,3,1,,144203763,4485,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2723,743080,3,1,,144207502,4485,Inconclusive,348019627.0,2099.0,34.4112,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2724,743081,3,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2725,743081,3,1,,144207502,4485,Inconclusive,,,61.1927,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2726,743083,3,1,,144203763,4485,Inconclusive,119597822.0,1588.0,26.6032,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2727,743083,3,1,,144207502,4485,Active,119597822.0,1588.0,68.6594,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2728,743084,3,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2729,743084,3,1,,144207502,4485,Active,,,54.5381,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2730,743085,3,1,,144203763,4485,Inconclusive,51095037.0,196.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2731,743085,3,1,,144207502,4485,Inconclusive,51095037.0,196.0,24.3613,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2732,743086,3,1,,144203763,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2733,743086,3,1,,144207502,4485,Inconclusive,,,54.5381,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2734,743091,2,1,,144203763,4485,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2735,743091,2,1,,144207502,4485,Inconclusive,348019627.0,2099.0,68.6594,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2736,743094,3,1,,144203763,4485,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2737,743094,3,1,,144207502,4485,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2738,743122,2,1,,144203763,4485,Active,51095037.0,196.0,9.80846,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2739,743122,2,1,,144207502,4485,Active,51095037.0,196.0,3.0669,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2740,743126,1,1,,855613,4485,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2741,743139,2,1,,144203763,4485,Active,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2742,743139,2,1,,144207502,4485,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2743,743140,2,1,,144203763,4485,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2744,743140,2,1,,144207502,4485,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2745,743191,3,1,,144207502,4485,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2746,743191,3,1,,170465006,4485,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2747,743194,3,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2748,743194,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2749,743199,2,1,,144207502,4485,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2750,743199,2,1,,170465006,4485,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2751,743202,4,1,,144207502,4485,Inconclusive,20149576.0,4780.0,77.0371,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2752,743202,4,1,,170465006,4485,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2753,743203,3,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2754,743203,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2755,743205,1,1,,90341123,4485,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2756,743205,1,1,,90341123,4485,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2757,743206,1,1,,90341123,4485,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2758,743206,1,1,,90341123,4485,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2759,743207,1,1,,90341123,4485,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2760,743207,1,1,,90341123,4485,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2761,743209,3,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2762,743209,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2763,743210,4,1,,144207502,4485,Inconclusive,4504517.0,3315.0,49.0441,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2764,743210,4,1,,170465006,4485,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2765,743211,3,1,,144207502,4485,Active,,,49.0441,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2766,743211,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2767,743212,3,1,,144207502,4485,Inconclusive,216409690.0,5467.0,55.0284,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2768,743212,3,1,,170465006,4485,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2769,743213,3,1,,144207502,4485,Inconclusive,,,13.8225,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2770,743213,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2771,743215,3,1,,144207502,4485,Inconclusive,216409690.0,5467.0,61.7429,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2772,743215,3,1,,170465006,4485,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2773,743217,3,1,,144207502,4485,Inconclusive,325495553.0,9971.0,12.3193,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2774,743217,3,1,,170465006,4485,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2775,743218,3,1,,144207502,4485,Inconclusive,,,30.9447,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2776,743218,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2777,743219,3,1,,144207502,4485,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2778,743219,3,1,,170465006,4485,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2779,743220,3,1,,144207502,4485,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2780,743220,3,1,,170465006,4485,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2781,743221,3,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2782,743221,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2783,743222,3,1,,144207502,4485,Inconclusive,216409708.0,7421.0,55.0284,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2784,743222,3,1,,170465006,4485,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2785,743223,3,1,,144207502,4485,Inconclusive,216409708.0,7421.0,55.0284,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2786,743223,3,1,,170465006,4485,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2787,743224,3,1,,144207502,4485,Active,,,38.9571,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2788,743224,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2789,743225,3,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2790,743225,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2791,743226,2,1,,144207502,4485,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2792,743226,2,1,,170465006,4485,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2793,743227,2,1,,144207502,4485,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2794,743227,2,1,,170465006,4485,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2795,743228,3,1,,144207502,4485,Inconclusive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2796,743228,3,1,,170465006,4485,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2797,743238,1,1,,855613,4485,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2798,743239,2,1,,144207502,4485,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2799,743239,2,1,,170465006,4485,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2800,743240,2,1,,144207502,4485,Active,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2801,743240,2,1,,170465006,4485,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2802,743241,2,1,,144207502,4485,Inconclusive,216409708.0,7421.0,49.0441,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2803,743241,2,1,,170465006,4485,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2804,743242,2,1,,144207502,4485,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2805,743242,2,1,,170465006,4485,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2806,743244,1,1,,90341123,4485,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2807,743244,1,1,,144203763,4485,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2808,743247,1,2,,855613,4485,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2809,743255,1,1,,56423128,4485,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2810,743266,1,2,,56423128,4485,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2811,743268,1,1,,172080131,4485,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2812,743269,1,1,,855613,4485,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2813,743269,1,1,,855613,4485,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2814,743270,1,1,,172080131,4485,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2815,743271,1,1,,172080131,4485,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2816,743272,1,1,,172080131,4485,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2817,743279,1,2,,56423128,4485,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2818,743281,1,1,,46386790,4485,Inactive,1778357.0,22341.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
2819,743281,1,1,,46386790,4485,Inactive,219520294.0,8828.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
2820,743287,1,1,,855613,4485,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
2821,743288,1,1,,17388858,4485,Inconclusive,,,35.4813,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2822,743292,1,1,,17388858,4485,Inconclusive,,,50.1187,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2823,743397,1,1,,855613,4485,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2824,743398,1,1,,855613,4485,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2825,747090,1,2,,103557046,4485,Active,,,,IC50,Displacement of [3H]-PN200-110 from L-type calcium channel dihydropyridine binding site in Wistar rat cortex homogenate after 60 mins by liquid scintillation spectometric analysis,Confirmatory,23586669.0,
2826,747091,1,2,,103557046,4485,Unspecified,,,,,Displacement of [3H]-PN200-110 from L-type calcium channel dihydropyridine binding site in Wistar rat cortex homogenate at 100 uM after 60 mins by liquid scintillation spectometric analysis relative to control,Other,23586669.0,
2827,747092,1,1,,103557046,4485,Active,,,0.086,IC50,Displacement of [3H]-PN200-110 from voltage-gated calcium channel subunit alpha Cav1.2a (unknown origin) expressed in HEK293 cells after 90 mins by liquid scintillation counting analysis,Confirmatory,23586669.0,
2828,747093,1,1,,103557046,4485,Active,,,0.0057,IC50,Displacement of [3H]-PN200-110 from L-type calcium channel in Hartley guinea pig ventricular membrane at 100 uM after 90 mins,Confirmatory,23586669.0,
2829,747094,1,1,,103557046,4485,Unspecified,,,,,Displacement of [3H]-PN200-110 from L-type calcium channel in Hartley guinea pig ventricular membrane at 100 uM after 90 mins relative to control,Other,23586669.0,
2830,747095,1,2,,103557046,4485,Active,,,,IC50,Displacement of [3H]-PN200-110 from L-type calcium channel in Hartley guinea pig atrial membrane after 90 mins,Confirmatory,23586669.0,
2831,747096,1,2,,103557046,4485,Unspecified,,,,,Displacement of [3H]-PN200-110 from L-type calcium channel in Hartley guinea pig atrial membrane at 100 uM after 90 mins relative to control,Other,23586669.0,
2832,747097,1,1,,103557046,4485,Active,,,0.009000000000000001,IC50,Relaxant activity in potassium depolarized guinea pig aortic strips assessed as inhibition of calcium-induced contraction,Confirmatory,23586669.0,
2833,747098,1,1,,103557046,4485,Unspecified,,,,,Relaxant activity in potassium depolarized guinea pig aortic strips assessed as inhibition of calcium-induced contraction at 10'-6 M relative to control,Other,23586669.0,
2834,747099,1,1,,103557046,4485,Unspecified,,,,,Relaxant activity in potassium depolarized guinea pig ileum longitudinal smooth muscle assessed as inhibition of calcium-induced contraction at 5x10'-9 M relative to control,Other,23586669.0,
2835,747100,1,1,,103557046,4485,Active,,,0.0015,IC50,Relaxant activity in potassium depolarized guinea pig ileum longitudinal smooth muscle assessed as inhibition of calcium-induced contraction,Confirmatory,23586669.0,
2836,747111,1,2,,103557046,4485,Active,,,0.039,EC50,Negative chronotropic activity in guinea pig right atrium assessed as decrease in atrial rate,Confirmatory,23586669.0,
2837,747112,1,2,,103557046,4485,Unspecified,,,,,Negative chronotropic activity in guinea pig right atrium assessed as decrease in atrial rate at 10'-7 M relative to control,Other,23586669.0,
2838,747118,1,2,,103557046,4485,Unspecified,,,,,Negative inotropic activity in guinea pig left atrium assessed as decrease in developed tension at 10'-5 M relative to control,Other,23586669.0,
2839,747122,1,2,,103557046,4485,Active,,,0.26,EC50,Negative inotropic activity in guinea pig left atrium assessed as decrease in developed tension,Confirmatory,23586669.0,
2840,747123,1,1,,103557046,4485,Unspecified,,,,,Displacement of [3H]-PN200-110 from voltage-gated calcium channel subunit alpha Cav1.2a (unknown origin) expressed in HEK293 cells at 100 uM after 90 mins by liquid scintillation counting analysis relative to control,Other,23586669.0,
2841,764465,1,1,,103557046,4485,Unspecified,,,,,Anticonvulsant activity in Wistar albino rat assessed as protection against maximum electric shock-induced hind limb tonic extension at 30 mg/kg administered 1 hr followed by maximum electric shock induction relative to control,Other,23831812.0,
2842,764468,1,1,,103557046,4485,Unspecified,,,,,Anticonvulsant activity in Wistar albino rat assessed as protection against subcutaneous pentylenetetrazole-induced mortality at 30 mg/kg administered 1 hr prior to pentylenetetrazole challenge measured for 300 secs relative to control,Other,23831812.0,
2843,764471,1,1,,103557046,4485,Unspecified,,,,,Anticonvulsant activity in Wistar albino rat assessed as time of onset of subcutaneous pentylenetetrazole-induced clonic convulsion at 30 mg/kg administered 1 hr prior to pentylenetetrazole challenge measured for 300 secs (Rvb = 83 +/- 4 secs),Other,23831812.0,
2844,780994,3,1,,103557046,4485,Active,,,,,Antagonist activity at calcium channel albino guinea pig ileal longitudinal smooth muscle assessed as inhibition of KCl-induced contraction,Other,24113238.0,
2845,815669,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/5,Other,,
2846,815670,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/5,Other,,
2847,815671,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/5,Other,,
2848,815672,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/5,Other,,
2849,815673,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/5,Other,,
2850,815674,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/5,Other,,
2851,815675,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/5,Other,,
2852,815676,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/5,Other,,
2853,815677,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/5,Other,,
2854,815678,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/5,Other,,
2855,815679,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/5,Other,,
2856,815680,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/5,Other,,
2857,815681,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/5,Other,,
2858,815682,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/5,Other,,
2859,816349,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/5,Other,,
2860,816350,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/5,Other,,
2861,816351,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/5,Other,,
2862,816352,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/6,Other,,
2863,816353,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/6,Other,,
2864,816354,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/6,Other,,
2865,816355,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/6,Other,,
2866,816356,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/6,Other,,
2867,816357,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/6,Other,,
2868,816358,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/6,Other,,
2869,816359,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/6,Other,,
2870,816360,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/6,Other,,
2871,816361,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/6,Other,,
2872,816362,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/6,Other,,
2873,816397,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/14,Other,,
2874,816398,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/14,Other,,
2875,816399,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/14,Other,,
2876,816400,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/14,Other,,
2877,816401,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/14,Other,,
2878,816402,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/14,Other,,
2879,816403,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/14,Other,,
2880,816404,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/14,Other,,
2881,816405,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/14,Other,,
2882,816406,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/14,Other,,
2883,816407,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/14,Other,,
2884,816408,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/14,Other,,
2885,816409,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/14,Other,,
2886,816410,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/14,Other,,
2887,816411,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/14,Other,,
2888,816412,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/14,Other,,
2889,816413,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/14,Other,,
2890,816414,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/15,Other,,
2891,816415,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/15,Other,,
2892,816416,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/15,Other,,
2893,816417,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/15,Other,,
2894,816418,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/15,Other,,
2895,816419,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/15,Other,,
2896,816420,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/15,Other,,
2897,816421,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/15,Other,,
2898,816422,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/15,Other,,
2899,816423,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/15,Other,,
2900,816424,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/15,Other,,
2901,816425,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/15,Other,,
2902,816426,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/15,Other,,
2903,816427,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/15,Other,,
2904,816428,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/15,Other,,
2905,816429,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/15,Other,,
2906,816430,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/15,Other,,
2907,816431,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/16,Other,,
2908,816432,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/16,Other,,
2909,816433,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/16,Other,,
2910,816434,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/16,Other,,
2911,816435,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/16,Other,,
2912,816436,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/16,Other,,
2913,816437,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/16,Other,,
2914,816480,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/5,Other,,
2915,816481,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/5,Other,,
2916,816482,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/5,Other,,
2917,817103,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/16,Other,,
2918,817104,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/16,Other,,
2919,817105,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/16,Other,,
2920,817106,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/16,Other,,
2921,817107,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/16,Other,,
2922,817108,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/16,Other,,
2923,817147,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/6,Other,,
2924,817148,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/6,Other,,
2925,817149,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/6,Other,,
2926,817150,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/6,Other,,
2927,817151,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/6,Other,,
2928,817152,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/6,Other,,
2929,817153,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/6,Other,,
2930,817154,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/6,Other,,
2931,817155,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/6,Other,,
2932,817156,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/6,Other,,
2933,817157,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/6,Other,,
2934,817158,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/6,Other,,
2935,817159,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/6,Other,,
2936,817160,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/6,Other,,
2937,817161,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/6,Other,,
2938,817162,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/6,Other,,
2939,817163,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/6,Other,,
2940,817164,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/7,Other,,
2941,817165,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/7,Other,,
2942,817166,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/7,Other,,
2943,817167,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/7,Other,,
2944,817168,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/7,Other,,
2945,817169,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/7,Other,,
2946,817170,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/7,Other,,
2947,817171,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/7,Other,,
2948,817172,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/7,Other,,
2949,817173,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/7,Other,,
2950,817174,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/7,Other,,
2951,817175,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/7,Other,,
2952,817176,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/7,Other,,
2953,817177,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/7,Other,,
2954,817178,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/7,Other,,
2955,817179,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/7,Other,,
2956,817180,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/7,Other,,
2957,817181,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/8,Other,,
2958,817182,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/8,Other,,
2959,817183,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/8,Other,,
2960,817184,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/8,Other,,
2961,817185,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/8,Other,,
2962,817186,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/8,Other,,
2963,817187,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/8,Other,,
2964,817188,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/8,Other,,
2965,817189,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/8,Other,,
2966,817190,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/8,Other,,
2967,818509,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/6,Other,,
2968,818510,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/6,Other,,
2969,818511,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/6,Other,,
2970,818512,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/6,Other,,
2971,818513,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/6,Other,,
2972,818514,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/6,Other,,
2973,818515,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/7,Other,,
2974,818516,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/7,Other,,
2975,818517,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/7,Other,,
2976,818518,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/7,Other,,
2977,818519,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/7,Other,,
2978,818520,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/7,Other,,
2979,818521,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/7,Other,,
2980,818522,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/7,Other,,
2981,818523,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/7,Other,,
2982,818524,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/7,Other,,
2983,818525,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/7,Other,,
2984,818526,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/7,Other,,
2985,818527,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/7,Other,,
2986,818528,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/7,Other,,
2987,818529,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/7,Other,,
2988,818530,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/7,Other,,
2989,818531,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/7,Other,,
2990,818532,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/8,Other,,
2991,819196,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/8,Other,,
2992,819197,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/8,Other,,
2993,819198,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/8,Other,,
2994,819199,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/8,Other,,
2995,819200,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/8,Other,,
2996,819201,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/8,Other,,
2997,819202,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/8,Other,,
2998,819203,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/8,Other,,
2999,819204,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/8,Other,,
3000,819205,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/8,Other,,
3001,819206,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/8,Other,,
3002,819207,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/8,Other,,
3003,819208,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/8,Other,,
3004,819209,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/8,Other,,
3005,819210,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/8,Other,,
3006,819211,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/8,Other,,
3007,819212,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/9,Other,,
3008,819213,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/9,Other,,
3009,819214,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/9,Other,,
3010,819215,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/9,Other,,
3011,819216,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/9,Other,,
3012,819217,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/9,Other,,
3013,819218,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/9,Other,,
3014,819219,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/9,Other,,
3015,819254,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/15,Other,,
3016,819255,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/15,Other,,
3017,819256,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/15,Other,,
3018,819257,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/15,Other,,
3019,819258,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/15,Other,,
3020,819259,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/15,Other,,
3021,819260,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/15,Other,,
3022,819261,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/15,Other,,
3023,819262,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/15,Other,,
3024,819263,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/15,Other,,
3025,819264,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/15,Other,,
3026,819265,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/15,Other,,
3027,819266,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/15,Other,,
3028,819267,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/15,Other,,
3029,819268,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/15,Other,,
3030,819269,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/15,Other,,
3031,819270,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/16,Other,,
3032,819271,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/16,Other,,
3033,819272,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/16,Other,,
3034,819273,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/16,Other,,
3035,819274,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/16,Other,,
3036,819275,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/16,Other,,
3037,819276,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/16,Other,,
3038,819277,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/16,Other,,
3039,819278,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/16,Other,,
3040,819279,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/16,Other,,
3041,819280,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/16,Other,,
3042,819281,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/16,Other,,
3043,819282,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/16,Other,,
3044,819283,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/16,Other,,
3045,819284,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/16,Other,,
3046,819285,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/16,Other,,
3047,819951,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/16,Other,,
3048,819952,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/5,Other,,
3049,819953,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/5,Other,,
3050,819954,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/5,Other,,
3051,819955,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/5,Other,,
3052,819956,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/5,Other,,
3053,819957,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/5,Other,,
3054,819958,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/5,Other,,
3055,819959,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/5,Other,,
3056,819960,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/5,Other,,
3057,819961,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/5,Other,,
3058,819962,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/5,Other,,
3059,819963,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/5,Other,,
3060,819964,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/5,Other,,
3061,819965,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/5,Other,,
3062,820190,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/16,Other,,
3063,820191,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/16,Other,,
3064,820192,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/16,Other,,
3065,820193,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/16,Other,,
3066,821367,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/9,Other,,
3067,821368,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/9,Other,,
3068,821369,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/9,Other,,
3069,821370,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/9,Other,,
3070,821371,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/9,Other,,
3071,821372,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/9,Other,,
3072,821373,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/9,Other,,
3073,821374,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/9,Other,,
3074,821375,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/9,Other,,
3075,821376,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/10,Other,,
3076,821377,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/10,Other,,
3077,821378,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/10,Other,,
3078,821379,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/10,Other,,
3079,821380,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/10,Other,,
3080,822045,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/10,Other,,
3081,822046,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/10,Other,,
3082,822047,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/10,Other,,
3083,822048,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/10,Other,,
3084,822049,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/10,Other,,
3085,822050,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/10,Other,,
3086,822051,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/10,Other,,
3087,822052,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/10,Other,,
3088,822053,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/10,Other,,
3089,822054,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/10,Other,,
3090,822055,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/10,Other,,
3091,822056,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/10,Other,,
3092,822057,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/11,Other,,
3093,822058,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/11,Other,,
3094,822059,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/11,Other,,
3095,822060,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/11,Other,,
3096,822061,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/11,Other,,
3097,822062,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/11,Other,,
3098,822063,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/11,Other,,
3099,822064,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/11,Other,,
3100,822065,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/11,Other,,
3101,822066,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/11,Other,,
3102,822067,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/11,Other,,
3103,822068,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/11,Other,,
3104,822069,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/11,Other,,
3105,822070,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/11,Other,,
3106,822071,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/11,Other,,
3107,822072,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/11,Other,,
3108,822073,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/11,Other,,
3109,822074,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/12,Other,,
3110,822075,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/12,Other,,
3111,822076,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/12,Other,,
3112,822077,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/12,Other,,
3113,822111,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/11,Other,,
3114,822112,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/11,Other,,
3115,822113,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/11,Other,,
3116,822114,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/11,Other,,
3117,822115,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/11,Other,,
3118,822116,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/11,Other,,
3119,822117,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/11,Other,,
3120,822118,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/11,Other,,
3121,822119,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/11,Other,,
3122,822120,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/11,Other,,
3123,822121,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/11,Other,,
3124,822122,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/11,Other,,
3125,822123,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/12,Other,,
3126,822124,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/12,Other,,
3127,822125,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/12,Other,,
3128,822126,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/12,Other,,
3129,822127,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/12,Other,,
3130,822128,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/12,Other,,
3131,822129,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/12,Other,,
3132,822130,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/12,Other,,
3133,822131,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/12,Other,,
3134,822132,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/12,Other,,
3135,822133,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/12,Other,,
3136,822796,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/12,Other,,
3137,822797,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/12,Other,,
3138,822798,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/12,Other,,
3139,822799,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/12,Other,,
3140,822800,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/12,Other,,
3141,822801,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/12,Other,,
3142,822802,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/13,Other,,
3143,822803,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/13,Other,,
3144,822804,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/13,Other,,
3145,822805,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/13,Other,,
3146,822806,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/13,Other,,
3147,822807,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/13,Other,,
3148,822808,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/13,Other,,
3149,822809,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/13,Other,,
3150,822810,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/13,Other,,
3151,822811,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/13,Other,,
3152,822812,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/13,Other,,
3153,822813,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/13,Other,,
3154,822814,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/13,Other,,
3155,822815,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/13,Other,,
3156,822816,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/13,Other,,
3157,822817,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/13,Other,,
3158,822818,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/13,Other,,
3159,824221,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/8,Other,,
3160,824222,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/8,Other,,
3161,824223,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/8,Other,,
3162,824224,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/8,Other,,
3163,824225,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/8,Other,,
3164,824226,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/8,Other,,
3165,824896,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/8,Other,,
3166,824897,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/9,Other,,
3167,824898,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/9,Other,,
3168,824899,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/9,Other,,
3169,824900,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/9,Other,,
3170,824901,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/9,Other,,
3171,824902,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/9,Other,,
3172,824903,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/9,Other,,
3173,824904,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/9,Other,,
3174,824905,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/9,Other,,
3175,824906,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/9,Other,,
3176,824907,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/9,Other,,
3177,824908,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/9,Other,,
3178,824909,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/9,Other,,
3179,824910,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/9,Other,,
3180,824911,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/9,Other,,
3181,824912,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/9,Other,,
3182,824913,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/9,Other,,
3183,824914,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/10,Other,,
3184,824915,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/10,Other,,
3185,824916,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/10,Other,,
3186,824917,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/10,Other,,
3187,824918,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/10,Other,,
3188,824919,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 411/10,Other,,
3189,824920,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 411/10,Other,,
3190,824921,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 411/10,Other,,
3191,824922,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 411/10,Other,,
3192,824923,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 411/10,Other,,
3193,824924,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 411/10,Other,,
3194,824925,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 411/10,Other,,
3195,824926,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 411/10,Other,,
3196,824927,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 411/10,Other,,
3197,824928,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 411/10,Other,,
3198,824929,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 411/10,Other,,
3199,824930,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 411/10,Other,,
3200,824931,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 411/11,Other,,
3201,824932,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 411/11,Other,,
3202,824933,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 411/11,Other,,
3203,824934,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 411/11,Other,,
3204,824935,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 411/11,Other,,
3205,824970,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/12,Other,,
3206,824971,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/12,Other,,
3207,824972,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/12,Other,,
3208,824973,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/12,Other,,
3209,824974,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/12,Other,,
3210,824975,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/12,Other,,
3211,824976,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/12,Other,,
3212,824977,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/12,Other,,
3213,824978,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/12,Other,,
3214,824979,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/12,Other,,
3215,824980,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/12,Other,,
3216,824981,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/12,Other,,
3217,824982,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/12,Other,,
3218,824983,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/13,Other,,
3219,824984,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/13,Other,,
3220,825647,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/13,Other,,
3221,825648,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/13,Other,,
3222,825649,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/13,Other,,
3223,825650,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/13,Other,,
3224,825651,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/13,Other,,
3225,825652,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/13,Other,,
3226,825653,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/13,Other,,
3227,825654,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/13,Other,,
3228,825655,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/13,Other,,
3229,825656,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/13,Other,,
3230,825657,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/13,Other,,
3231,825658,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/13,Other,,
3232,825659,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/13,Other,,
3233,825660,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/13,Other,,
3234,825661,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/13,Other,,
3235,825662,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/14,Other,,
3236,825663,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 410/14,Other,,
3237,825664,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 410/14,Other,,
3238,825665,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 410/14,Other,,
3239,825666,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 410/14,Other,,
3240,825667,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 410/14,Other,,
3241,825668,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 410/14,Other,,
3242,825669,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 410/14,Other,,
3243,825670,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 410/14,Other,,
3244,825671,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 410/14,Other,,
3245,825672,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 410/14,Other,,
3246,825673,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 410/14,Other,,
3247,825674,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 410/14,Other,,
3248,825675,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 410/14,Other,,
3249,825676,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 410/14,Other,,
3250,825677,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 410/14,Other,,
3251,825678,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 410/14,Other,,
3252,825679,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 410/15,Other,,
3253,849023,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/7,Other,,
3254,849159,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/7,Other,,
3255,849160,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/7,Other,,
3256,849161,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/7,Other,,
3257,849700,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/7,Other,,
3258,849701,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/7,Other,,
3259,849702,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/7,Other,,
3260,849703,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/7,Other,,
3261,849704,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/7,Other,,
3262,849705,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/7,Other,,
3263,849706,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/7,Other,,
3264,849707,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/8,Other,,
3265,849708,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/8,Other,,
3266,849709,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/8,Other,,
3267,849710,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/8,Other,,
3268,849711,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/8,Other,,
3269,849712,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/8,Other,,
3270,849713,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/8,Other,,
3271,849714,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/8,Other,,
3272,849715,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/8,Other,,
3273,849716,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/8,Other,,
3274,849717,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/8,Other,,
3275,849718,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/8,Other,,
3276,849719,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/8,Other,,
3277,849720,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/8,Other,,
3278,849721,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/8,Other,,
3279,849722,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/8,Other,,
3280,849723,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/8,Other,,
3281,849724,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/8,Other,,
3282,849725,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/8,Other,,
3283,849726,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/8,Other,,
3284,849727,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/8,Other,,
3285,849728,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/9,Other,,
3286,849729,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/9,Other,,
3287,849730,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/9,Other,,
3288,849731,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/9,Other,,
3289,849732,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/9,Other,,
3290,849733,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/9,Other,,
3291,849734,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/9,Other,,
3292,849735,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/9,Other,,
3293,849736,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/9,Other,,
3294,849737,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/9,Other,,
3295,849738,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/9,Other,,
3296,849739,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/9,Other,,
3297,849740,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/9,Other,,
3298,849741,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/9,Other,,
3299,849742,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/9,Other,,
3300,849743,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/9,Other,,
3301,849744,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/9,Other,,
3302,849745,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/9,Other,,
3303,849783,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/16,Other,,
3304,849784,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/16,Other,,
3305,849785,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/16,Other,,
3306,849786,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/16,Other,,
3307,849787,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/16,Other,,
3308,849788,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/5,Other,,
3309,849789,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/5,Other,,
3310,849790,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/5,Other,,
3311,849791,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/5,Other,,
3312,850419,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/9,Other,,
3313,850464,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/5,Other,,
3314,850465,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/5,Other,,
3315,850466,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/5,Other,,
3316,850467,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/5,Other,,
3317,850468,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/5,Other,,
3318,850469,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/5,Other,,
3319,850470,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/5,Other,,
3320,850471,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/5,Other,,
3321,850472,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/5,Other,,
3322,850473,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/5,Other,,
3323,850474,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/5,Other,,
3324,850475,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/5,Other,,
3325,850476,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/5,Other,,
3326,850477,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/5,Other,,
3327,850478,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/5,Other,,
3328,850479,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/5,Other,,
3329,850480,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/5,Other,,
3330,850481,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/6,Other,,
3331,850482,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/6,Other,,
3332,850483,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/6,Other,,
3333,850484,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/6,Other,,
3334,850485,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/6,Other,,
3335,850486,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/6,Other,,
3336,850487,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/6,Other,,
3337,850488,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/6,Other,,
3338,850489,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/6,Other,,
3339,850490,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/6,Other,,
3340,850491,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/6,Other,,
3341,850492,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/6,Other,,
3342,850493,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/6,Other,,
3343,850494,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/6,Other,,
3344,850495,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/6,Other,,
3345,850496,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/6,Other,,
3346,850497,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/6,Other,,
3347,850498,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/6,Other,,
3348,850499,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/6,Other,,
3349,850500,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/6,Other,,
3350,850501,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/6,Other,,
3351,850536,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/13,Other,,
3352,850537,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/13,Other,,
3353,850538,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/13,Other,,
3354,850539,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/13,Other,,
3355,850540,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/13,Other,,
3356,850541,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/13,Other,,
3357,850542,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/14,Other,,
3358,850543,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/14,Other,,
3359,850544,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/14,Other,,
3360,850545,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/14,Other,,
3361,850546,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/14,Other,,
3362,850547,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/14,Other,,
3363,850548,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/14,Other,,
3364,850549,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/14,Other,,
3365,850550,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/14,Other,,
3366,850551,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/14,Other,,
3367,850552,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/14,Other,,
3368,851225,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/14,Other,,
3369,851226,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/14,Other,,
3370,851227,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/14,Other,,
3371,851228,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/14,Other,,
3372,851229,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/14,Other,,
3373,851230,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/14,Other,,
3374,851231,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/14,Other,,
3375,851232,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/14,Other,,
3376,851233,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/14,Other,,
3377,851234,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/14,Other,,
3378,851235,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/15,Other,,
3379,851236,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/15,Other,,
3380,851237,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/15,Other,,
3381,851238,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/15,Other,,
3382,851239,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/15,Other,,
3383,851240,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/15,Other,,
3384,851241,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/15,Other,,
3385,851242,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/15,Other,,
3386,851243,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/15,Other,,
3387,851244,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/15,Other,,
3388,851245,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/15,Other,,
3389,851246,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/15,Other,,
3390,851247,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/15,Other,,
3391,851248,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/15,Other,,
3392,851249,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/15,Other,,
3393,851250,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/15,Other,,
3394,851251,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/15,Other,,
3395,851252,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/15,Other,,
3396,851253,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/15,Other,,
3397,851254,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/15,Other,,
3398,852586,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/9,Other,,
3399,852587,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/9,Other,,
3400,852588,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/10,Other,,
3401,852589,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/10,Other,,
3402,852590,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/10,Other,,
3403,852591,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/10,Other,,
3404,852592,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/10,Other,,
3405,852593,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/10,Other,,
3406,852594,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/10,Other,,
3407,852595,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/10,Other,,
3408,852596,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/10,Other,,
3409,852597,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/10,Other,,
3410,852598,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/10,Other,,
3411,852599,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/10,Other,,
3412,852600,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/10,Other,,
3413,852601,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/10,Other,,
3414,852602,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/10,Other,,
3415,852603,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/10,Other,,
3416,852604,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/10,Other,,
3417,852605,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/10,Other,,
3418,852606,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/10,Other,,
3419,852607,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/10,Other,,
3420,852608,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/10,Other,,
3421,852609,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/11,Other,,
3422,852610,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/11,Other,,
3423,852611,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/11,Other,,
3424,852612,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/11,Other,,
3425,852613,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/11,Other,,
3426,852614,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/11,Other,,
3427,852615,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/11,Other,,
3428,852616,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/11,Other,,
3429,852617,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/11,Other,,
3430,852618,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/11,Other,,
3431,852619,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/11,Other,,
3432,852620,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/11,Other,,
3433,852621,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/11,Other,,
3434,852622,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/11,Other,,
3435,852623,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/11,Other,,
3436,852669,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/7,Other,,
3437,853298,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/11,Other,,
3438,853299,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/11,Other,,
3439,853300,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/11,Other,,
3440,853301,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/11,Other,,
3441,853302,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/11,Other,,
3442,853303,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/11,Other,,
3443,853304,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/12,Other,,
3444,853305,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/12,Other,,
3445,853306,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/12,Other,,
3446,853307,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/12,Other,,
3447,853343,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/7,Other,,
3448,853344,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/7,Other,,
3449,853345,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/7,Other,,
3450,853346,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/7,Other,,
3451,853347,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/7,Other,,
3452,853348,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/7,Other,,
3453,853349,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/7,Other,,
3454,853350,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/7,Other,,
3455,853351,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/7,Other,,
3456,853352,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/7,Other,,
3457,853353,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/7,Other,,
3458,853354,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/7,Other,,
3459,853355,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/7,Other,,
3460,853356,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/7,Other,,
3461,853357,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/7,Other,,
3462,853358,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/7,Other,,
3463,853359,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/7,Other,,
3464,853360,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/7,Other,,
3465,853361,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/7,Other,,
3466,853362,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/7,Other,,
3467,853363,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/8,Other,,
3468,853364,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/8,Other,,
3469,853365,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/8,Other,,
3470,853366,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/8,Other,,
3471,853367,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/8,Other,,
3472,853368,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/8,Other,,
3473,853369,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/8,Other,,
3474,853370,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/8,Other,,
3475,853371,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/8,Other,,
3476,853372,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/8,Other,,
3477,853373,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/8,Other,,
3478,853374,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/8,Other,,
3479,853375,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/8,Other,,
3480,853376,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/8,Other,,
3481,853377,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/8,Other,,
3482,853378,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/8,Other,,
3483,853379,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/8,Other,,
3484,853380,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/8,Other,,
3485,853381,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/8,Other,,
3486,853382,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/8,Other,,
3487,853383,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/8,Other,,
3488,853384,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/9,Other,,
3489,853385,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/9,Other,,
3490,853386,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/9,Other,,
3491,853387,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/9,Other,,
3492,853426,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/15,Other,,
3493,853427,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/16,Other,,
3494,853428,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/16,Other,,
3495,853429,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/16,Other,,
3496,853430,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/16,Other,,
3497,853431,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/16,Other,,
3498,853432,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/16,Other,,
3499,854061,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/9,Other,,
3500,854107,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/16,Other,,
3501,854108,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/16,Other,,
3502,854109,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/16,Other,,
3503,854110,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/16,Other,,
3504,854111,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/16,Other,,
3505,854112,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/16,Other,,
3506,854113,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/16,Other,,
3507,854114,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/16,Other,,
3508,854115,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/16,Other,,
3509,854116,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/16,Other,,
3510,854117,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/16,Other,,
3511,854118,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/16,Other,,
3512,854119,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/16,Other,,
3513,854120,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/16,Other,,
3514,854121,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/16,Other,,
3515,855476,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/12,Other,,
3516,855477,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/12,Other,,
3517,855478,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/12,Other,,
3518,855479,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/12,Other,,
3519,855480,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/12,Other,,
3520,855481,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/12,Other,,
3521,855482,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/12,Other,,
3522,855483,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/12,Other,,
3523,855484,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/12,Other,,
3524,855485,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/12,Other,,
3525,855486,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/12,Other,,
3526,855487,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/12,Other,,
3527,855488,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/12,Other,,
3528,855489,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/12,Other,,
3529,855490,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/12,Other,,
3530,855491,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/12,Other,,
3531,855492,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/12,Other,,
3532,855493,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/13,Other,,
3533,855494,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/13,Other,,
3534,855495,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/13,Other,,
3535,855496,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/13,Other,,
3536,855497,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/13,Other,,
3537,855498,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/13,Other,,
3538,855499,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/13,Other,,
3539,855500,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/13,Other,,
3540,855501,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/13,Other,,
3541,855502,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/13,Other,,
3542,855503,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/13,Other,,
3543,856175,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/13,Other,,
3544,856176,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/13,Other,,
3545,856177,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/13,Other,,
3546,856178,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/13,Other,,
3547,856179,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/13,Other,,
3548,856180,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/13,Other,,
3549,856181,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/13,Other,,
3550,856182,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/13,Other,,
3551,856183,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/13,Other,,
3552,856184,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/13,Other,,
3553,856185,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/14,Other,,
3554,856186,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/14,Other,,
3555,856187,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/14,Other,,
3556,856188,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/14,Other,,
3557,856189,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/14,Other,,
3558,856190,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/14,Other,,
3559,856191,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/14,Other,,
3560,856192,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/14,Other,,
3561,856193,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/14,Other,,
3562,856194,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/14,Other,,
3563,856228,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/9,Other,,
3564,856229,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/9,Other,,
3565,856230,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/9,Other,,
3566,856231,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/9,Other,,
3567,856232,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/9,Other,,
3568,856233,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/9,Other,,
3569,856234,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/9,Other,,
3570,856235,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/9,Other,,
3571,856236,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/9,Other,,
3572,856237,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/9,Other,,
3573,856238,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/9,Other,,
3574,856239,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/9,Other,,
3575,856240,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/9,Other,,
3576,856241,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/9,Other,,
3577,856242,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/9,Other,,
3578,856243,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/9,Other,,
3579,856244,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/10,Other,,
3580,856245,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/10,Other,,
3581,856246,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/10,Other,,
3582,856247,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/10,Other,,
3583,856248,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/10,Other,,
3584,856249,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/10,Other,,
3585,856250,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/10,Other,,
3586,856251,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/10,Other,,
3587,856252,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/10,Other,,
3588,856253,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/10,Other,,
3589,856254,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/10,Other,,
3590,856255,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/10,Other,,
3591,856256,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/10,Other,,
3592,856257,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/10,Other,,
3593,856258,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/10,Other,,
3594,856259,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/10,Other,,
3595,856260,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/10,Other,,
3596,856261,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/10,Other,,
3597,856262,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/10,Other,,
3598,856263,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/10,Other,,
3599,856264,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/10,Other,,
3600,856937,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/11,Other,,
3601,856938,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/11,Other,,
3602,856939,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/11,Other,,
3603,856940,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/11,Other,,
3604,856941,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/11,Other,,
3605,856942,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/11,Other,,
3606,856943,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/11,Other,,
3607,856944,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/11,Other,,
3608,856945,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/11,Other,,
3609,856946,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/11,Other,,
3610,857061,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/5,Other,,
3611,857062,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/5,Other,,
3612,857063,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/5,Other,,
3613,857064,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/5,Other,,
3614,857065,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/5,Other,,
3615,857066,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/5,Other,,
3616,857067,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/5,Other,,
3617,858361,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/14,Other,,
3618,858362,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/14,Other,,
3619,858363,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/14,Other,,
3620,858364,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/14,Other,,
3621,858365,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/14,Other,,
3622,858366,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/14,Other,,
3623,858367,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/14,Other,,
3624,858368,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/14,Other,,
3625,858369,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/14,Other,,
3626,858370,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/14,Other,,
3627,858371,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/14,Other,,
3628,858372,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/15,Other,,
3629,858373,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/15,Other,,
3630,858374,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/15,Other,,
3631,858375,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/15,Other,,
3632,858376,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/15,Other,,
3633,858377,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/15,Other,,
3634,858378,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/15,Other,,
3635,859053,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/15,Other,,
3636,859054,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/15,Other,,
3637,859055,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/15,Other,,
3638,859056,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/15,Other,,
3639,859057,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/15,Other,,
3640,859058,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/15,Other,,
3641,859059,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/15,Other,,
3642,859060,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/15,Other,,
3643,859061,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/15,Other,,
3644,859062,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/15,Other,,
3645,859063,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/15,Other,,
3646,859064,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/15,Other,,
3647,859065,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/15,Other,,
3648,859066,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/15,Other,,
3649,859067,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/16,Other,,
3650,859068,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/16,Other,,
3651,859069,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/16,Other,,
3652,859070,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/16,Other,,
3653,859071,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/16,Other,,
3654,859072,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/16,Other,,
3655,859073,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/16,Other,,
3656,859074,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/16,Other,,
3657,859075,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/16,Other,,
3658,859076,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/16,Other,,
3659,859077,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/16,Other,,
3660,859078,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/16,Other,,
3661,859079,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/16,Other,,
3662,859080,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/16,Other,,
3663,859081,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/16,Other,,
3664,859082,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/16,Other,,
3665,859117,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/11,Other,,
3666,859118,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/11,Other,,
3667,859119,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/11,Other,,
3668,859120,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/11,Other,,
3669,859121,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/11,Other,,
3670,859122,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/11,Other,,
3671,859123,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/11,Other,,
3672,859124,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/11,Other,,
3673,859125,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/11,Other,,
3674,859126,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/11,Other,,
3675,859127,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/11,Other,,
3676,859128,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/12,Other,,
3677,859129,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/12,Other,,
3678,859130,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/12,Other,,
3679,859131,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/12,Other,,
3680,859132,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/12,Other,,
3681,859133,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/12,Other,,
3682,859134,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/12,Other,,
3683,859135,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/12,Other,,
3684,859136,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/12,Other,,
3685,859137,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/12,Other,,
3686,859138,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/12,Other,,
3687,859139,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/12,Other,,
3688,859140,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/12,Other,,
3689,859141,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/12,Other,,
3690,859142,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/12,Other,,
3691,859143,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 411/12,Other,,
3692,859818,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 411/12,Other,,
3693,859819,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 411/12,Other,,
3694,859820,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 411/12,Other,,
3695,859821,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 411/12,Other,,
3696,859822,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 411/12,Other,,
3697,859823,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 411/13,Other,,
3698,859824,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 411/13,Other,,
3699,859825,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 411/13,Other,,
3700,859826,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 411/13,Other,,
3701,859827,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 411/13,Other,,
3702,859828,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 411/13,Other,,
3703,859829,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 411/13,Other,,
3704,859830,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 411/13,Other,,
3705,859831,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 411/13,Other,,
3706,859832,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 411/13,Other,,
3707,859833,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 411/13,Other,,
3708,859834,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 411/13,Other,,
3709,859835,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 411/13,Other,,
3710,859836,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 411/13,Other,,
3711,859837,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 411/13,Other,,
3712,859909,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/5,Other,,
3713,859910,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/5,Other,,
3714,859911,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/5,Other,,
3715,859912,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/5,Other,,
3716,859913,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/5,Other,,
3717,859914,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/5,Other,,
3718,859915,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/5,Other,,
3719,859916,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/5,Other,,
3720,859917,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/5,Other,,
3721,859918,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/5,Other,,
3722,859919,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/5,Other,,
3723,859920,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/5,Other,,
3724,859921,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/5,Other,,
3725,859922,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/5,Other,,
3726,859923,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/6,Other,,
3727,859924,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/6,Other,,
3728,859925,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/6,Other,,
3729,859926,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/6,Other,,
3730,859927,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/6,Other,,
3731,859928,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/6,Other,,
3732,859929,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/6,Other,,
3733,859930,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/6,Other,,
3734,859931,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/6,Other,,
3735,859932,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/6,Other,,
3736,859933,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 410/6,Other,,
3737,859934,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 410/6,Other,,
3738,859935,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 410/6,Other,,
3739,859936,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 410/6,Other,,
3740,859937,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 410/6,Other,,
3741,859938,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 410/6,Other,,
3742,859939,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 410/6,Other,,
3743,859940,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 410/6,Other,,
3744,859941,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 410/6,Other,,
3745,859942,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 410/6,Other,,
3746,859943,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 410/6,Other,,
3747,859944,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 410/7,Other,,
3748,859945,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 410/7,Other,,
3749,859946,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 410/7,Other,,
3750,859947,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 410/7,Other,,
3751,859948,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 410/7,Other,,
3752,859949,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 410/7,Other,,
3753,859950,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 410/7,Other,,
3754,859951,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 410/7,Other,,
3755,859952,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 410/7,Other,,
3756,859953,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 410/7,Other,,
3757,930783,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020805,Other,,
3758,930784,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020805,Other,,
3759,930785,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020805,Other,,
3760,932803,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020805,Other,,
3761,932804,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020805,Other,,
3762,932805,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020805,Other,,
3763,932806,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020805",Other,,
3764,932807,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020805,Other,,
3765,932808,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020805,Other,,
3766,932809,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020805,Other,,
3767,932810,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020805,Other,,
3768,932811,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020805,Other,,
3769,932812,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020805,Other,,
3770,933440,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020805,Other,,
3771,933441,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020805,Other,,
3772,933442,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020805,Other,,
3773,933443,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020805,Other,,
3774,933444,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020805,Other,,
3775,933445,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020805,Other,,
3776,937886,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020805,Other,,
3777,937887,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020805,Other,,
3778,937888,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020805,Other,,
3779,945919,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020805,Other,,
3780,945920,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020805,Other,,
3781,945921,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020805,Other,,
3782,945922,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020805,Other,,
3783,945923,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020805,Other,,
3784,945924,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020805,Other,,
3785,945925,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020805,Other,,
3786,945926,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020805,Other,,
3787,945927,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020805,Other,,
3788,945928,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020805,Other,,
3789,945929,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020805,Other,,
3790,945930,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020805",Other,,
3791,945931,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020805,Other,,
3792,945932,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020805,Other,,
3793,945933,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020805,Other,,
3794,945934,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020805,Other,,
3795,952828,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020805,Other,,
3796,952829,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020805,Other,,
3797,952830,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020805,Other,,
3798,952831,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020805,Other,,
3799,952832,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020805,Other,,
3800,952833,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020805,Other,,
3801,952834,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020805,Other,,
3802,952835,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020805,Other,,
3803,952836,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020805,Other,,
3804,952837,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020805,Other,,
3805,952838,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020805,Other,,
3806,952839,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020805,Other,,
3807,952840,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020805,Other,,
3808,952841,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020805,Other,,
3809,952842,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020805,Other,,
3810,953473,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020805,Other,,
3811,953474,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020805,Other,,
3812,953475,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020805,Other,,
3813,953476,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020805,Other,,
3814,971167,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020805,Other,,
3815,971168,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020805,Other,,
3816,971169,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020805,Other,,
3817,971170,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020805,Other,,
3818,971801,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020805,Other,,
3819,971802,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020805,Other,,
3820,971803,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020805,Other,,
3821,971804,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020805,Other,,
3822,971805,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020805,Other,,
3823,971806,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020805,Other,,
3824,971807,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020805,Other,,
3825,971808,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020805,Other,,
3826,971809,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020805,Other,,
3827,971810,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020805,Other,,
3828,971811,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020805,Other,,
3829,971812,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020805,Other,,
3830,971813,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020805,Other,,
3831,971814,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020805,Other,,
3832,971815,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020805,Other,,
3833,977599,1,1,,103557046,4485,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3834,977602,1,2,,103557046,4485,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3835,980397,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020805",Other,,
3836,980398,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020805",Other,,
3837,980399,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020805",Other,,
3838,980400,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3839,980401,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3840,980402,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020805",Other,,
3841,980403,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020805",Other,,
3842,980404,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020805,Other,,
3843,980405,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020805",Other,,
3844,980406,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020805",Other,,
3845,980407,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020805",Other,,
3846,980408,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020805",Other,,
3847,980409,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020805",Other,,
3848,980410,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020805",Other,,
3849,980411,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3850,982882,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3851,982883,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3852,982884,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020805",Other,,
3853,982885,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020805",Other,,
3854,982886,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020805",Other,,
3855,982887,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020805",Other,,
3856,982888,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020805",Other,,
3857,982889,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020805",Other,,
3858,982890,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020805",Other,,
3859,982891,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020805",Other,,
3860,982892,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3861,982893,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020805,Other,,
3862,982894,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020805",Other,,
3863,982895,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020805,Other,,
3864,982896,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020805",Other,,
3865,982897,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020805",Other,,
3866,982898,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020805",Other,,
3867,982899,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020805",Other,,
3868,982900,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020805",Other,,
3869,982901,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020805",Other,,
3870,982902,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020805",Other,,
3871,982903,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020805",Other,,
3872,982904,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020805",Other,,
3873,982905,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020805",Other,,
3874,982906,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3875,982907,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3876,982908,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3877,982909,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020805",Other,,
3878,982910,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020805",Other,,
3879,983378,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020805",Other,,
3880,983379,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020805",Other,,
3881,983380,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020805",Other,,
3882,983381,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020805",Other,,
3883,983382,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020805",Other,,
3884,983383,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020805",Other,,
3885,984905,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020805",Other,,
3886,984906,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020805",Other,,
3887,984907,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020805",Other,,
3888,984908,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020805",Other,,
3889,984909,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020805",Other,,
3890,984910,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020805",Other,,
3891,984911,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020805,Other,,
3892,984912,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020805,Other,,
3893,984913,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020805",Other,,
3894,984914,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020805",Other,,
3895,984915,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3896,984916,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020805",Other,,
3897,984917,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020805",Other,,
3898,984918,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3899,984919,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3900,984920,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020805",Other,,
3901,984921,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3902,984922,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020805",Other,,
3903,984923,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020805",Other,,
3904,984924,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020805,Other,,
3905,984925,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3906,984926,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020805",Other,,
3907,984927,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020805",Other,,
3908,984928,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020805",Other,,
3909,984929,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020805,Other,,
3910,984930,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020805",Other,,
3911,984931,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020805",Other,,
3912,984932,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3913,984933,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020805",Other,,
3914,985400,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3915,985401,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020805",Other,,
3916,985402,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020805",Other,,
3917,985403,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020805",Other,,
3918,985404,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020805",Other,,
3919,985405,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3920,985406,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020805",Other,,
3921,985407,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020805",Other,,
3922,985408,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020805",Other,,
3923,985409,1,3,,103557046,4485,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020805,Other,,
3924,985410,1,3,,103557046,4485,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020805",Other,,
3925,1036014,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/15,Other,,
3926,1036015,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/15,Other,,
3927,1036016,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/15,Other,,
3928,1036017,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/16,Other,,
3929,1036018,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/16,Other,,
3930,1036019,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/16,Other,,
3931,1036020,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/16,Other,,
3932,1036021,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/16,Other,,
3933,1038821,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/5,Other,,
3934,1038822,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/5,Other,,
3935,1038823,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/5,Other,,
3936,1038824,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/5,Other,,
3937,1038825,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/5,Other,,
3938,1038826,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/6,Other,,
3939,1038827,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/6,Other,,
3940,1038828,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/6,Other,,
3941,1038829,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/6,Other,,
3942,1038830,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/6,Other,,
3943,1038831,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/7,Other,,
3944,1038832,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/7,Other,,
3945,1038833,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/7,Other,,
3946,1038834,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/7,Other,,
3947,1038835,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/7,Other,,
3948,1038836,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/8,Other,,
3949,1038837,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/8,Other,,
3950,1038838,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/8,Other,,
3951,1038839,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/8,Other,,
3952,1040985,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/8,Other,,
3953,1040986,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/9,Other,,
3954,1040987,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/9,Other,,
3955,1040988,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/9,Other,,
3956,1040989,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/9,Other,,
3957,1040990,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/9,Other,,
3958,1040991,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/10,Other,,
3959,1040992,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/10,Other,,
3960,1040993,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/10,Other,,
3961,1040994,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/10,Other,,
3962,1041665,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/10,Other,,
3963,1041666,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/11,Other,,
3964,1041667,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/11,Other,,
3965,1041668,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/11,Other,,
3966,1041669,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/11,Other,,
3967,1041670,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/11,Other,,
3968,1041671,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/12,Other,,
3969,1041672,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/12,Other,,
3970,1041673,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/12,Other,,
3971,1041674,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/12,Other,,
3972,1041675,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/12,Other,,
3973,1041676,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/13,Other,,
3974,1041677,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/13,Other,,
3975,1041678,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/13,Other,,
3976,1041679,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/13,Other,,
3977,1041680,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/13,Other,,
3978,1041681,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/14,Other,,
3979,1041682,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/14,Other,,
3980,1041683,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/14,Other,,
3981,1041684,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/14,Other,,
3982,1041685,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/14,Other,,
3983,1041686,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/15,Other,,
3984,1041687,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/15,Other,,
3985,1041688,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/15,Other,,
3986,1041689,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/15,Other,,
3987,1041690,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/15,Other,,
3988,1041691,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 410/16,Other,,
3989,1041692,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 410/16,Other,,
3990,1041693,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 410/16,Other,,
3991,1041694,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 410/16,Other,,
3992,1041695,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 410/16,Other,,
3993,1041696,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/5,Other,,
3994,1041697,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/5,Other,,
3995,1041698,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/5,Other,,
3996,1041699,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/5,Other,,
3997,1041700,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/5,Other,,
3998,1041701,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/6,Other,,
3999,1043846,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/6,Other,,
4000,1043847,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/6,Other,,
4001,1044512,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/6,Other,,
4002,1044513,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/6,Other,,
4003,1044514,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/7,Other,,
4004,1044515,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/7,Other,,
4005,1044516,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/7,Other,,
4006,1044517,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/7,Other,,
4007,1044518,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/7,Other,,
4008,1044519,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/8,Other,,
4009,1044520,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/8,Other,,
4010,1044521,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/8,Other,,
4011,1044522,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/8,Other,,
4012,1044523,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/8,Other,,
4013,1044524,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/9,Other,,
4014,1044525,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/9,Other,,
4015,1044526,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/9,Other,,
4016,1044527,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/9,Other,,
4017,1044528,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/9,Other,,
4018,1044529,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/10,Other,,
4019,1044530,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/10,Other,,
4020,1044531,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/10,Other,,
4021,1044532,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/10,Other,,
4022,1044533,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/10,Other,,
4023,1044534,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/11,Other,,
4024,1044535,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/11,Other,,
4025,1044536,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/11,Other,,
4026,1044537,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/11,Other,,
4027,1044538,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/11,Other,,
4028,1044539,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/12,Other,,
4029,1044540,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/12,Other,,
4030,1044541,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/12,Other,,
4031,1044542,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/12,Other,,
4032,1044543,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/12,Other,,
4033,1044544,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/13,Other,,
4034,1044545,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/13,Other,,
4035,1044546,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/13,Other,,
4036,1044547,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/13,Other,,
4037,1044548,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/13,Other,,
4038,1044549,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/14,Other,,
4039,1044550,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/14,Other,,
4040,1044551,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 411/14,Other,,
4041,1044552,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 411/14,Other,,
4042,1044553,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 411/14,Other,,
4043,1044554,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 411/15,Other,,
4044,1044555,1,2,,103557046,4485,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 411/15,Other,,
4045,1053197,1,1,,855613,4485,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
4046,1055883,1,2,,103557046,4485,Unspecified,,,,,Vasorelaxant activity in rat endothelium-denuded thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction relative to control,Other,24212125.0,
4047,1055884,1,2,,103557046,4485,Active,,,0.03,EC50,Vasorelaxant activity in rat endothelium-denuded thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction,Confirmatory,24212125.0,
4048,1055885,1,2,,103557046,4485,Inconclusive,,,,EC50,Vasorelaxant activity in rat endothelium-intact thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction,Confirmatory,24212125.0,
4049,1055886,1,2,,103557046,4485,Inconclusive,,,,,Vasorelaxant activity in rat endothelium-intact thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction relative to control,Other,24212125.0,
4050,1061889,1,2,,103557046,4485,Unspecified,,,,IC50,Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting,Confirmatory,24332655.0,
4051,1068420,1,1,,103557046,4485,Unspecified,,,,,"Anticonvulsant activity in Wistar albino rat assessed as protection against subcutaneous pentylenetetrazole-induced mortality at 30 mg/kg, po pretreated for 1 hr followed by pentylenetetrazole challenge relative to control",Other,24384550.0,
4052,1068421,1,1,,103557046,4485,Unspecified,,,,,"Anticonvulsant activity in Wistar albino rat assessed as protection against maximal electroshock-induced electroconvulsive seizures at 30 mg/kg, po pretreated for 1 hr followed by maximal electroshock challenge relative to control",Other,24384550.0,
4053,1068423,1,1,,103557046,4485,Unspecified,,,,,"Anticonvulsant activity in Wistar albino rat assessed as protection against maximal electroshock-induced seizures by measuring duration of limb extension at 30 mg/kg, po pretreated for 1 hr followed by maximal electroshock challenge (Rvb = 16 +/- 1 secs)",Other,24384550.0,
4054,1068426,1,1,,103557046,4485,Unspecified,,,,,"Anticonvulsant activity in Wistar albino rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures by measuring latency period at 30 mg/kg, po pretreated for 1 hr followed by pentylenetetrazole challenge measured over 300 secs (Rvb = 72 +/- 2 secs)",Other,24384550.0,
4055,1070215,1,1,,103557046,4485,Active,,,,,Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis,Other,24468412.0,
4056,1079931,1,1,,103557046,4485,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
4057,1079932,1,1,,103557046,4485,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
4058,1079933,1,1,,103557046,4485,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
4059,1079934,1,1,,103557046,4485,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
4060,1079935,1,1,,103557046,4485,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
4061,1079936,1,1,,103557046,4485,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
4062,1079937,1,1,,103557046,4485,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
4063,1079938,1,1,,103557046,4485,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
4064,1079939,1,1,,103557046,4485,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
4065,1079940,1,1,,103557046,4485,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
4066,1079941,1,1,,103557046,4485,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
4067,1079942,1,1,,103557046,4485,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
4068,1079943,1,1,,103557046,4485,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
4069,1079944,1,1,,103557046,4485,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
4070,1079945,1,1,,103557046,4485,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
4071,1079946,1,1,,103557046,4485,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
4072,1079947,1,1,,103557046,4485,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
4073,1079948,1,1,,103557046,4485,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
4074,1079949,1,1,,103557046,4485,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
4075,1084138,4,2,,103557046,4485,Unspecified,5921694.0,100135490.0,,IC50,Inhibition of Calcium channel in Cavia porcellus albino (guinea pig) ileocecal SMC assessed as inhibition of 80 mM KCl-induced contraction,Confirmatory,,
4076,1084625,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of KCl-induced vasoconstriction at 10'-9 M after 30 min relative to control,Other,,
4077,1084626,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of KCl-induced vasoconstriction at 10'-10 M after 30 min relative to control,Other,,
4078,1084627,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of KCl-induced vasoconstriction at 10'-11 M after 30 min relative to control,Other,,
4079,1084628,3,2,,103557046,4485,Active,,,0.00257,IC50,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of KCl-induced vasoconstriction after 30 min relative to control,Confirmatory,,
4080,1084633,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of KCl-induced vasoconstriction at 10'-7 M after 30 min relative to control,Other,,
4081,1084634,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of KCl-induced vasoconstriction at 10'-8 M after 30 min relative to control,Other,,
4082,1084635,3,2,,103557046,4485,Active,,,0.02754,IC50,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of phenylephrine-induced vasoconstriction after 30 min relative to control,Confirmatory,,
4083,1084636,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of phenylephrine-induced vasoconstriction at 10'-5 M after 30 min relative to control,Other,,
4084,1084637,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of phenylephrine-induced vasoconstriction at 10'-6 M after 30 min relative to control,Other,,
4085,1084638,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of phenylephrine-induced vasoconstriction at 10'-7 M after 30 min relative to control,Other,,
4086,1084639,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of phenylephrine-induced vasoconstriction at 10'-8 M after 30 min relative to control,Other,,
4087,1084640,1,3,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in Rattus norvegicus Wistar (rat) thoracic aorta assessed as relaxation of phenylephrine-induced vasoconstriction at 10'-9 M after 30 min relative to control,Other,,
4088,1084641,1,2,,103557046,4485,Unspecified,,,,,Inhibition of L-type calcium channel in rat NG108-15 cells assessed as inhibition of veratridine-induced intracellular calcium level incubated at 10 uM for 30 min followed by veratridine induction for 2 min by fluorimetric analysis,Other,,
4089,1084642,3,1,,103557046,4485,Active,,,0.0577,IC50,Inhibition of L-type calcium channel in neonatal rat cortical neurons assessed as inhibition of veratridine-induced intracellular calcium level incubated for 30 min followed by veratridine induction for 2 min by fluorimetric analysis,Confirmatory,,
4090,1085234,1,2,,103557046,4485,Unspecified,,,,,"Cardioprotective activity in adrenaline-induced MI Rattus norvegicus Sprague-Dawley (rat) model assessed as decrease in QT interval prolongation at 5 mg/kg, po for 15 days challenged with adrenaline on day 14 and day 15 measured after 24 hr post second adrenaline injection by ECG analysis (Rvb = 0.08205 +/- 0.0023 sec)",Other,,
4091,1085235,1,3,,103557046,4485,Unspecified,,,,,"Cardioprotective activity in adrenaline-induced MI Rattus norvegicus Sprague-Dawley (rat) model assessed as decrease in heart rate at 5 mg/kg, po for 15 days challenged with adrenaline on day 14 and day 15 measured after 24 hr post second adrenaline injection (Rvb = 422.76 +/- 6.158 bpm)",Other,,
4092,1085236,1,2,,103557046,4485,Unspecified,,,,,"Cardioprotective activity in adrenaline-induced MI Rattus norvegicus Sprague-Dawley (rat) model assessed as effect on P-duration at 5 mg/kg, po for 15 days challenged with adrenaline on day 14 and day 15 measured after 24 hr post second adrenaline injection by ECG analysis (Rvb = 0.01136 +/- 0.0044 sec)",Other,,
4093,1085237,1,2,,103557046,4485,Unspecified,,,,,"Cardioprotective activity in adrenaline-induced MI Rattus norvegicus Sprague-Dawley (rat) model assessed as decrease in ST interval at 5 mg/kg, po for 15 days challenged with adrenaline on day 14 and day 15 measured after 24 hr post second adrenaline injection by ECG analysis (Rvb = 0.0829 +/- 0.0024 sec)",Other,,
4094,1085238,1,2,,103557046,4485,Unspecified,,,,,"Cardioprotective activity in adrenaline-induced MI Rattus norvegicus Sprague-Dawley (rat) model assessed as increase in R-R interval at 5 mg/kg, po for 15 days challenged with adrenaline on day 14 and day 15 measured after 24 hr post second adrenaline injection by ECG analysis (Rvb = 0.135 +/- 0.0176 sec)",Other,,
4095,1085881,4,2,,103557046,4485,Active,5921694.0,100135490.0,0.0026,IC50,Antagonist activity at Cavia porcellus albino (guinea pig) calcium channel assessed as inhibition of KCl-induced ileal longitudinal smooth muscle contraction,Confirmatory,,
4096,1086940,1,2,,103557046,4485,Active,,,,,"Anticonvulsant activity in Mus musculus NMRI (mouse) assessed as protection against pentylenetetrazole-induced seizures at 20 mg/kg, ip administered 30 min prior to pentylenetetrazole induction relative to vehicle-treated control",Other,,
4097,1093609,1,4,,103557046,4485,Active,21362409.0,100033901.0,,,Reversible mixed-type inhibition of Equus caballus (horse) serum butyrylcholinesterase (BChE) assessed as inhibition of BTCh hydrolysis by Ellman method,Other,,
4098,1093610,1,4,,103557046,4485,Active,14916521.0,,,,Reversible mixed-type inhibition of Electrophorus electricus (electric eel) acetylcholinesterase (AChE) assessed as inhibition of ATCh hydrolysis by Ellman method,Other,,
4099,1093611,4,2,,103557046,4485,Active,21362409.0,100033901.0,1.2,Ki,Inhibition of Equus caballus (horse) serum butyrylcholinesterase (BChE) assessed as inhibition of BTCh hydrolysis by Ellman method,Confirmatory,,
4100,1093612,4,2,,103557046,4485,Active,14916521.0,,4.0,Ki,Inhibition of Electrophorus electricus (electric eel) acetylcholinesterase (AChE) assessed as inhibition of ATCh hydrolysis by Ellman method,Confirmatory,,
4101,1094439,1,2,,103557046,4485,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizures in Mus musculus NMRI (mouse) assessed as time of maximal effect at 20 mg/kg, ip administered 30 min before PTZ challenge",Other,,
4102,1094442,1,2,,103557046,4485,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizures in Mus musculus NMRI (mouse) assessed as time of maximal effect at 10 mg/kg, ip administered 30 min before PTZ challenge (Rvb = 24.86 +/- 0.96 min)",Other,,
4103,1094445,1,2,,103557046,4485,Unspecified,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizures in Mus musculus NMRI (mouse) assessed as time of maximal effect at 5 mg/kg, ip administered 30 min before PTZ challenge",Other,,
4104,1094446,4,2,,103557046,4485,Active,5921694.0,100135490.0,0.05,IC50,Antagonist activity at Calcium channel in Cavia porcellus (guinea pig) ileal smooth muscle assessed as inhibition of 40 mM KCl-induced contraction compound pretreated for 15 min before KCl treatment,Confirmatory,,
4105,1095825,1,2,,103557046,4485,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as Rmax at 30 mg/kg, ip measured after 60 min by ECG analysis (Rvb = 0.07 +/- 0.004 mv)",Other,,
4106,1095829,1,2,,103557046,4485,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as Rmax at 30 mg/kg, ip measured after 45 min by ECG analysis (Rvb = 0.08 +/- 0.008 mv)",Other,,
4107,1095833,1,2,,103557046,4485,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as Rmax at 30 mg/kg, ip measured after 30 min by ECG analysis (Rvb = 0.08 +/- 0.008 mv)",Other,,
4108,1095837,1,3,,103557046,4485,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as heart rate at 30 mg/kg, ip measured after 60 min by ECG analysis (Rvb = 307.62 +/- 0.053 bpm)",Other,,
4109,1095841,1,3,,103557046,4485,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as heart rate at 30 mg/kg, ip measured after 45 min by ECG analysis (Rvb = 307.62 +/- 0.023 bpm)",Other,,
4110,1095845,1,3,,103557046,4485,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as heart rate at 30 mg/kg, ip measured after 30 min by ECG analysis (Rvb = 307.62 +/- 0.439 bpm)",Other,,
4111,1097336,1,3,,103557046,4485,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
4112,1113802,1,4,,103557046,4485,Active,5921694.0,100135490.0,,,Antagonist activity at calcium channel in Cavia porcellus (guinea pig) ileum assessed as inhibition of KCl-induced muscle contraction at 10 mM,Other,,
4113,1117065,1,2,,103557046,4485,Active,,,,,"Antihypertensive activity in hypoxic pulmonary arterial Sprague-Dawley Rattus norvegicus (rat) model assessed as decrease in hypoxia-induced central vein pressure at 10 mg/kg, po administered for 28 days measured on day 29 by hemodynamic analyzer relative to untreated control",Other,,
4114,1117066,1,2,,103557046,4485,Active,,,,,"Antihypertensive activity in hypoxic pulmonary arterial Sprague-Dawley Rattus norvegicus (rat) model assessed as decrease in hypoxia-induced right ventricular systolic pressure at 10 mg/kg, po administered for 28 days measured on day 29 by hemodynamic analyzer relative to untreated control",Other,,
4115,1117298,1,2,,170465006,4485,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
4116,1117304,1,2,,170465006,4485,Inactive,,,35.4813,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
4117,1117305,1,2,,170465006,4485,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
4118,1117310,1,1,,170465006,4485,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
4119,1117312,1,1,,170465006,4485,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
4120,1117314,1,1,,170465006,4485,Inactive,,,35.4813,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
4121,1117319,1,2,,855613,4485,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
4122,1117319,1,2,,855613,4485,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
4123,1117326,1,1,,170465006,4485,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
4124,1117329,1,1,,170465006,4485,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
4125,1117336,1,1,,170465006,4485,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
4126,1117340,1,1,,170465006,4485,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
4127,1117341,1,1,,170465006,4485,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
4128,1117342,1,1,,170465006,4485,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
4129,1117343,1,1,,170465006,4485,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
4130,1117346,1,1,,170465006,4485,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
4131,1122945,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity in human SH-SY5Y cells under oxygen and glucose deprived condition assessed as protection against oxidative stress at 0.3 uM co-incubated for 4 hrs under anaerobic condition measured after 20 hrs by MTT assay relative to control,Other,,
4132,1122948,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity in human SH-SY5Y cells under oxygen and glucose deprived condition assessed as cell survival at 0.3 uM co-incubated for 4 hrs under anaerobic condition measured after 20 hrs by MTT assay relative to control,Other,,
4133,1122950,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity in human SH-SY5Y cells under serum-free condition assessed as protection against potassium-induced toxicity at 0.3 uM after 24 hrs by MTT assay relative to control,Other,,
4134,1122952,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity in human SH-SY5Y cells under serum-free condition assessed as cell survival at 0.3 uM after 24 hrs by MTT assay in presence of potassium relative to control,Other,,
4135,1122954,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity in human SH-SY5Y cells assessed as inhibition of potassium-induced Ca2+ increase at 10 uM preincubated for 15 mins followed by potassium addition measured for 14 seconds by fluorescence assay relative to control,Other,,
4136,1141116,1,3,,103557046,4485,Active,116241275.0,776.0,1.35,IC50,Inhibition of human Cav1.3 channel in human SH-SY5Y cells assessed as 70 mM K+ induced calcium elevation compound treated 15 mins before stimulus by Fluo-4/AM assay,Confirmatory,24754640.0,
4137,1141117,1,3,,103557046,4485,Unspecified,116412.0,24239.0,,IC50,Inhibition of rat Cav1.2 channel in rat mesenteric artery assessed as relaxation of 70 mM K+ induced contraction,Confirmatory,24754640.0,
4138,1141118,1,1,,103557046,4485,Unspecified,,,,,Selectivity ratio of IC50 for human Cav1.3 channel to IC50 for rat Cav1.2 channel,Other,24754640.0,
4139,1141119,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity against K+ induced Ca2+ overload in human SH-SY5Y cells assessed as survival at 5 uM after 24 hrs by MTT assay (Rvb = 52.1 +/- 3.5%),Other,24754640.0,
4140,1141120,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity against K+ induced Ca2+ overload in human SH-SY5Y cells assessed as protection at 5 uM after 24 hrs by MTT assay relative to control,Other,24754640.0,
4141,1141121,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity against rotenone-oligomycin A-induced oxidative stress in human SH-SY5Y cells assessed as survival at 5 uM co-incubated rot/oligo for 24 hrs by MTT assay (Rvb =65.6 +/- 1.3%),Other,24754640.0,
4142,1141122,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity against rotenone-oligomycin A-induced oxidative stress in human SH-SY5Y cells assessed as protection at 5 uM co-incubated rot/oligo for 24 hrs by MTT assay relative to control,Other,24754640.0,
4143,1141123,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity against rotenone-oligomycin A-induced oxidative stress in human SH-SY5Y cells assessed as survival incubated with rot/oligo for 8 hrs followed by treated with compound at 5 uM for 16 hrs by MTT assay (Rvb =70.6 +/- 1.8%),Other,24754640.0,
4144,1141124,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity against rotenone-oligomycin A-induced oxidative stress in human SH-SY5Y cells assessed as protection incubated with rot/oligo for 8 hrs followed by treated with compound at 5 uM for 16 hrs by MTT assay relative to control,Other,24754640.0,
4145,1141125,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity against K+ induced Ca2+ overload in human SH-SY5Y cells assessed as survival at 0.3 uM after 24 hrs by MTT assay (Rvb = 52.1 +/- 3.5%),Other,24754640.0,
4146,1141126,1,1,,103557046,4485,Unspecified,,,,,Neuroprotective activity against K+ induced Ca2+ overload in human SH-SY5Y cells assessed as protection at 0.3 uM after 24 hrs by MTT assay relative to control,Other,24754640.0,
4147,1141131,1,2,,103557046,4485,Inactive,,,,,Neuroprotective activity against oxygen-glucose deprivation induced-oxidative stress in rat hippocampal slices assessed as maximum protection treated at 10 uM during 120 mins of reoxygenation period by MTT assay (Rvb =40%),Other,24754640.0,
4148,1143753,1,1,,103557046,4485,Inconclusive,,,,,Antioxidant activity in human SH-SY5Y cells assessed as rotenone-oligomycin-induced sequestering of mitochondrial free radicals at 0.3 uM after 120 mins using DCFH-DA by fluorescence microplate reader analysis,Other,24858540.0,
4149,1143754,1,1,,103557046,4485,Unspecified,,,,,Inhibition of calcium channel in human SH-SY5Y cells assessed as blockade of K+-evoked cytosolic calcium increase at 3 uM after 15 mins using Fluo-4/AM by fluorescence microplate reader analysis,Other,24858540.0,
4150,1156817,1,2,,103557046,4485,Active,,,,,Inhibition of voltage-dependent calcium channel in Sprague-Dawley rat thoracic aorta assessed as inhibition of CaCl2-induced contraction at 0.001 to 100 mM by isometric force transducer,Other,24980116.0,
4151,1159387,1,2,,103557046,4485,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
4152,1159388,1,2,,103557046,4485,Unspecified,,,,,"ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM",Other,,
4153,1159389,1,2,,103557046,4485,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
4154,1159390,1,2,,103557046,4485,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
4155,1159391,1,2,,103557046,4485,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
4156,1159394,1,2,,103557046,4485,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
4157,1159395,1,2,,103557046,4485,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
4158,1159396,1,2,,103557046,4485,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
4159,1159509,1,1,,144207502,4485,Inconclusive,119626539.0,4790.0,38.9571,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4160,1159509,1,1,,170465006,4485,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4161,1159515,1,1,,144207502,4485,Inconclusive,,,55.0284,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4162,1159515,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4163,1159516,1,1,,144207502,4485,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4164,1159516,1,1,,170465006,4485,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4165,1159517,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4166,1159517,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4167,1159518,1,1,,144207502,4485,Inconclusive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4168,1159518,1,1,,170465006,4485,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4169,1159519,1,1,,144207502,4485,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4170,1159519,1,1,,170465006,4485,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4171,1159520,1,1,,144207502,4485,Inconclusive,,,68.6594,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4172,1159520,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4173,1159521,1,1,,144207502,4485,Inconclusive,15928672.0,19885.0,77.0371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4174,1159521,1,1,,170465006,4485,Inactive,15928672.0,19885.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4175,1159523,1,1,,144207502,4485,Inconclusive,15928672.0,19885.0,30.669,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4176,1159523,1,1,,170465006,4485,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4177,1159524,1,1,,56423128,4485,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4178,1159524,1,1,,124880909,4485,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4179,1159524,1,1,,124880910,4485,Inconclusive,,,39.8107,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4180,1159524,1,1,,124880913,4485,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4181,1159525,1,1,,144207502,4485,Active,,,49.0441,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4182,1159525,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4183,1159526,1,1,,144207502,4485,Inconclusive,119627033.0,3725.0,49.0441,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4184,1159526,1,1,,170465006,4485,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4185,1159527,1,1,,144207502,4485,Inconclusive,325495497.0,6256.0,61.7429,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4186,1159527,1,1,,170465006,4485,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4187,1159528,1,1,,144207502,4485,Inconclusive,119627033.0,3725.0,8.72141,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4188,1159528,1,1,,170465006,4485,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4189,1159529,1,1,,144207502,4485,Active,,,27.5795,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4190,1159529,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4191,1159531,1,1,,144207502,4485,Inconclusive,325495497.0,6256.0,55.0284,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4192,1159531,1,1,,170465006,4485,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4193,1159550,3,1,,252402372,4485,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
4194,1159551,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4195,1159551,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4196,1159552,1,1,,144207502,4485,Inconclusive,325495463.0,5914.0,77.0371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4197,1159552,1,1,,170465006,4485,Inactive,325495463.0,5914.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4198,1159553,2,1,,144207502,4485,Active,325495463.0,5914.0,24.3613,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4199,1159553,2,1,,170465006,4485,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4200,1159555,1,1,,144207502,4485,Inconclusive,325495463.0,5914.0,48.6071,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4201,1159555,1,1,,170465006,4485,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4202,1159580,2,1,,268734636,4485,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
4203,1159580,2,1,,273002898,4485,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
4204,1159606,1,1,,56423128,4485,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
4205,1159607,2,1,,312310126,4485,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
4206,1159607,2,1,,312596121,4485,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
4207,1159614,1,2,,170465006,4485,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
4208,1159620,1,1,,103557046,4485,Active,,,,,Summary of drug indications.,Other,,
4209,1184068,1,2,,103557046,4485,Inactive,123948.0,3620.0,,IC50,Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC,Confirmatory,25036789.0,
4210,1184074,1,1,,103557046,4485,Unspecified,,,,,Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO,Other,25036789.0,
4211,1184075,1,2,,103557046,4485,Unspecified,123948.0,3620.0,,,Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC,Other,25036789.0,
4212,1192703,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated right ventricular systolic pressure at 10 mg/kg, po administered for 28 days measured on day 29 relative to untreated control",Other,25614116.0,
4213,1192707,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced central vein pressure at 10 mg/kg, po administered for 28 days measured on day 29 relative to untreated control",Other,25614116.0,
4214,1192713,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated RV/BW at 10 mg/kg, po administered for 28 days measured on day 29 relative to untreated control",Other,25614116.0,
4215,1192717,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated RV/(LV+S) at 10 mg/kg, po administered for 28 days measured on day 29 relative to untreated control",Other,25614116.0,
4216,1193492,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method",Other,25740159.0,
4217,1193493,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
4218,1193494,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
4219,1193495,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
4220,1193496,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method",Other,25740159.0,
4221,1193497,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method",Other,25740159.0,
4222,1193498,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method",Other,25740159.0,
4223,1193499,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method",Other,25740159.0,
4224,1193500,1,1,,103557046,4485,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound",Other,25740159.0,
4225,1207162,1,1,,103557046,4485,Active,,,37.0,IC50,Inhibition of Na channel (species unknown),Confirmatory,21300721.0,
4226,1207191,1,1,,103557046,4485,Active,,,0.06,IC50,Inhibition of voltage-gated L-type Ca channel (species unknown),Confirmatory,21300721.0,
4227,1207221,1,1,,103557046,4485,Unspecified,,,275.0,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
4228,1207252,1,2,,103557046,4485,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
4229,1207670,1,1,,103557046,4485,Active,,,0.05,IC50,Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Chinese hamster ovary cells heterologically expressing alpha-1C subunit,Confirmatory,22761000.0,
4230,1207671,1,2,,103557046,4485,Active,5921694.0,100135490.0,0.26,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
4231,1207672,1,2,,103557046,4485,Active,308153651.0,775.0,0.022000000000000002,IC50,Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit,Confirmatory,22761000.0,
4232,1207673,1,2,,103557046,4485,Active,308153651.0,775.0,0.055,IC50,Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit,Confirmatory,22761000.0,
4233,1207674,1,2,,103557046,4485,Active,5921694.0,100135490.0,0.3,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
4234,1207675,1,2,,103557046,4485,Active,5921694.0,100135490.0,0.05,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
4235,1207754,1,1,,103557046,4485,Active,,,0.01,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
4236,1209455,1,2,,103557046,4485,Active,262527527.0,8647.0,30.7,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
4237,1209456,1,2,,103557046,4485,Active,12585136.0,83569.0,45.4,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
4238,1209457,1,1,,103557046,4485,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
4239,1210069,1,2,,103557046,4485,Active,21264413.0,1573.0,3.06,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
4240,1210070,1,2,,103557046,4485,Unspecified,84028191.0,1565.0,50.0,IC50,Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method,Confirmatory,23033255.0,
4241,1210071,1,2,,103557046,4485,Active,116241312.0,1576.0,5.62,IC50,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,Confirmatory,23033255.0,
4242,1210072,1,2,,103557046,4485,Active,6686268.0,1559.0,4.08,IC50,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,Confirmatory,23033255.0,
4243,1210073,1,2,,103557046,4485,Active,60416369.0,1557.0,5.42,IC50,Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method,Confirmatory,23033255.0,
4244,1210074,1,2,,103557046,4485,Active,117144.0,1544.0,2.3,IC50,Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method,Confirmatory,23033255.0,
4245,1211791,1,1,,103557046,4485,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
4246,1211792,1,1,,103557046,4485,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
4247,1211793,1,1,,103557046,4485,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21998403.0,
4248,1211794,1,2,,103557046,4485,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
4249,1211795,1,1,,103557046,4485,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
4250,1211796,1,1,,103557046,4485,Unspecified,,,,,Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
4251,1211797,1,1,,103557046,4485,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
4252,1211798,1,1,,103557046,4485,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
4253,1212314,1,1,,103557046,4485,Unspecified,,,500.0,IC50,Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins,Confirmatory,23378628.0,
4254,1212341,1,1,,103557046,4485,Unspecified,,,,,Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay,Other,23378628.0,
4255,1216347,1,2,,103557046,4485,Unspecified,,,,,"AUC (0 to infinity) in healthy human assessed as fold change in presence of casopitant 30 mg, po once daily administered for 3 days",Other,21149541.0,
4256,1216348,1,2,,103557046,4485,Unspecified,,,,,"AUC (0 to infinity) in healthy human assessed as fold change in presence of casopitant 30 mg, po once daily administered for 14 days",Other,21149541.0,
4257,1216349,1,2,,103557046,4485,Unspecified,,,,,"AUC (0 to infinity) in healthy human assessed as fold change in presence of casopitant 120 mg, po once daily administered for 3 days",Other,21149541.0,
4258,1216350,1,2,,103557046,4485,Unspecified,,,,,"AUC (0 to infinity) in healthy human assessed as fold change in presence of casopitant 120 mg, po once daily administered for 14 days",Other,21149541.0,
4259,1224818,1,1,,312344943,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
4260,1224819,1,1,,312344943,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
4261,1224820,1,1,,312344943,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
4262,1224821,1,1,,312344943,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
4263,1224822,1,1,,312344943,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
4264,1224823,1,1,,312344943,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
4265,1224834,3,1,,144207502,4485,Active,,,54.5381,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4266,1224834,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4267,1224835,1,1,,144207502,4485,Active,160794.0,,39.98,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4268,1224835,1,1,,170465006,4485,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4269,1224836,1,1,,144207502,4485,Inconclusive,,,48.6071,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4270,1224836,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4271,1224837,1,1,,144207502,4485,Inconclusive,,,61.1927,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4272,1224837,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4273,1224838,1,1,,144207502,4485,Inactive,66775687.0,9970.0,2.4361,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4274,1224838,1,1,,170465006,4485,Inactive,66775687.0,9970.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4275,1224839,1,1,,144207502,4485,Inconclusive,66775687.0,9970.0,34.4112,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4276,1224839,1,1,,170465006,4485,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4277,1224840,3,1,,144207502,4485,Inconclusive,,,61.1927,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4278,1224840,3,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4279,1224841,3,1,,144207502,4485,Inconclusive,325495545.0,2101.0,61.1927,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4280,1224841,3,1,,170465006,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4281,1224842,3,1,,144207502,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4282,1224842,3,1,,170465006,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4283,1224843,1,1,,144207502,4485,Active,119601739.0,7253.0,54.5381,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4284,1224843,1,1,,170465006,4485,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4285,1224844,1,1,,144207502,4485,Active,,,49.0441,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4286,1224844,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4287,1224845,1,1,,144207502,4485,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
4288,1224845,1,1,,170465006,4485,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
4289,1224846,1,1,,144207502,4485,Inconclusive,11995455.0,3091.0,55.0284,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
4290,1224846,1,1,,170465006,4485,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
4291,1224847,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
4292,1224847,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
4293,1224848,3,1,,144207502,4485,Inconclusive,325495545.0,2101.0,34.4112,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4294,1224848,3,1,,170465006,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4295,1224849,3,1,,144207502,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4296,1224849,3,1,,170465006,4485,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4297,1224857,2,1,,170465006,4485,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
4298,1224857,2,1,,312344943,4485,Inconclusive,,,35.4813,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
4299,1224859,2,1,,90341123,4485,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
4300,1224859,2,1,,170465006,4485,Inactive,,,14.1254,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
4301,1224863,1,1,,176484119,4485,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
4302,1224863,1,1,,316920443,4485,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
4303,1224864,1,2,,316935359,4485,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
4304,1224865,1,2,,56423128,4485,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
4305,1224867,1,1,,144207502,4485,Inconclusive,,,55.0284,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
4306,1224867,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
4307,1224868,1,1,,144207502,4485,Inconclusive,,,49.0441,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4308,1224868,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4309,1224869,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4310,1224869,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4311,1224870,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4312,1224870,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4313,1224871,1,1,,144207502,4485,Inconclusive,,,55.0284,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4314,1224871,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4315,1224872,1,1,,144207502,4485,Inconclusive,,,43.7106,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4316,1224872,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4317,1224873,1,1,,144207502,4485,Inconclusive,,,24.5803,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4318,1224873,1,1,,170465006,4485,Inconclusive,,,16.9301,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4319,1224874,1,1,,144207502,4485,Inconclusive,,,49.0441,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4320,1224874,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4321,1224875,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4322,1224875,1,1,,170465006,4485,Inconclusive,,,0.2391,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4323,1224876,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4324,1224876,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4325,1224877,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4326,1224877,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4327,1224878,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4328,1224878,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4329,1224879,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4330,1224879,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4331,1224880,1,1,,144207502,4485,Active,,,24.5803,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4332,1224880,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4333,1224881,1,1,,144207502,4485,Inconclusive,,,55.0284,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4334,1224881,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4335,1224882,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4336,1224882,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4337,1224883,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4338,1224883,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4339,1224884,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4340,1224884,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4341,1224885,1,1,,144207502,4485,Inconclusive,,,43.7106,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4342,1224885,1,1,,170465006,4485,Inconclusive,,,16.9301,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4343,1224886,1,1,,144207502,4485,Inconclusive,,,49.0441,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4344,1224886,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4345,1224887,1,1,,144207502,4485,Inconclusive,,,49.0441,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4346,1224887,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4347,1224888,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4348,1224888,1,1,,170465006,4485,Inconclusive,,,0.2391,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4349,1224889,1,1,,144207502,4485,Inconclusive,,,43.7106,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4350,1224889,1,1,,170465006,4485,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4351,1224890,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4352,1224890,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4353,1224892,1,1,,144207502,4485,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4354,1224892,1,1,,170465006,4485,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4355,1224893,1,1,,144207502,4485,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4356,1224893,1,1,,170465006,4485,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4357,1224894,1,1,,144207502,4485,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4358,1224894,1,1,,170465006,4485,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4359,1224895,1,1,,144207502,4485,Active,119601739.0,7253.0,54.5381,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4360,1224895,1,1,,170465006,4485,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4361,1224896,1,1,,144207502,4485,Inconclusive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4362,1224896,1,1,,170465006,4485,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4363,1224905,2,1,,92308827,4485,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4364,1224905,2,1,,92308827,4485,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4365,1224905,2,1,,121361523,4485,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4366,1224905,2,1,,121361523,4485,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4367,1232307,1,1,,103557046,4485,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,25799158.0,
4368,1232310,1,1,,103557046,4485,Unspecified,,,,,Volume of distribution at steady state in human,Other,25799158.0,
4369,1232312,1,1,,103557046,4485,Unspecified,,,,,Clearance in human,Other,25799158.0,
4370,1232313,1,1,,103557046,4485,Unspecified,,,,,Elimination half life in human,Other,25799158.0,
4371,1248192,1,1,,103557046,4485,Active,300669714.0,4638.0,2.02,IC50,Inhibition of MLCK (unknown origin) incubated for 15 mins using [gamma-32P]-ATP by scintillation counting method,Confirmatory,26385444.0,
4372,1248193,1,1,,103557046,4485,Active,,,2.34,IC50,Inhibition of porcine kidney ACE assessed as reduction in hippuryl-histidyl-leucine hydrolysis to hippuric acid release incubated for 30 mins high-throughput colorimetric method,Confirmatory,26385444.0,
4373,1248194,1,1,,103557046,4485,Unspecified,,,,,"Lipophilicity, log P of the compound at pH 7.4 by shake flask method",Other,26385444.0,
4374,1248195,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 1 hr by non-invasive tail cuff method relative to control",Other,26385444.0,
4375,1248196,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 2 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4376,1248197,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 3 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4377,1248198,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 4 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4378,1248199,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 5 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4379,1248200,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 6 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4380,1248201,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 7 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4381,1248202,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 8 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4382,1248203,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 9 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4383,1248204,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat model of DOCA-salt-induced hypertension assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 10 hrs by non-invasive tail cuff method relative to control",Other,26385444.0,
4384,1248205,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 0.15 hrs by invasive carotid artery cannulation method relative to control",Other,26385444.0,
4385,1248206,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 0.3 hrs by invasive carotid artery cannulation method relative to control",Other,26385444.0,
4386,1248207,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 1 hr by invasive carotid artery cannulation method relative to control",Other,26385444.0,
4387,1248208,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 2 hrs by invasive carotid artery cannulation method relative to control",Other,26385444.0,
4388,1248209,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 3 hrs by invasive carotid artery cannulation method relative to control",Other,26385444.0,
4389,1248210,1,1,,103557046,4485,Unspecified,,,,,"Antihypertensive activity in Norwegian albino rat assessed as inhibition of systolic blood pressure at 10 mg/kg, po after 4 hrs by invasive carotid artery cannulation method relative to control",Other,26385444.0,
4390,1248211,1,1,,103557046,4485,Unspecified,,,,,"Gastrointestinal toxicity in Norwegian rat assessed as ulcerative index at 50 mg/kg, po after 17 hrs",Other,26385444.0,
4391,1259241,1,1,,144207502,4485,Inconclusive,,,17.2465,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4392,1259241,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4393,1259242,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4394,1259242,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4395,1259243,1,1,,144207502,4485,Inconclusive,124375976.0,367.0,68.6594,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4396,1259243,1,1,,170465006,4485,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4397,1259244,1,1,,144207502,4485,Inconclusive,348019627.0,2099.0,17.2465,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4398,1259244,1,1,,170465006,4485,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4399,1259247,1,1,,144207502,4485,Active,124375976.0,367.0,54.5381,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4400,1259247,1,1,,170465006,4485,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4401,1259248,1,1,,144207502,4485,Inconclusive,348019627.0,2099.0,29.5143,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4402,1259248,1,1,,170465006,4485,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4403,1259310,1,1,,46386790,4485,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4404,1259310,1,1,,321942192,4485,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4405,1259310,1,1,,332949338,4485,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4406,1259310,1,1,,332949439,4485,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4407,1259310,1,1,,332949751,4485,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4408,1259313,1,1,,56423128,4485,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
4409,1259318,1,1,,855613,4485,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
4410,1259325,1,2,,336954226,4485,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
4411,1259344,1,1,,144203763,4485,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
4412,1259354,1,1,,348404242,4485,Inconclusive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
4413,1259355,1,1,,26752060,4485,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
4414,1259356,1,1,,144203763,4485,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
4415,1259364,1,1,,144207502,4485,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4416,1259364,1,1,,170465006,4485,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4417,1259365,1,1,,144207502,4485,Inconclusive,,,30.669,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4418,1259365,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4419,1259366,1,1,,144207502,4485,Active,,,27.3338,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4420,1259366,1,1,,170465006,4485,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4421,1259367,1,1,,144207502,4485,Active,,,30.669,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4422,1259367,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4423,1259368,1,1,,144207502,4485,Inactive,109731339.0,2737.0,77.0371,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4424,1259368,1,1,,170465006,4485,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4425,1259369,1,1,,144207502,4485,Active,109731339.0,2737.0,6.1193,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4426,1259369,1,1,,170465006,4485,Active,109731339.0,2737.0,6.6824,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4427,1259370,2,2,,124637934,4485,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4428,1259370,2,2,,124637934,4485,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4429,1259370,2,2,,124637934,4485,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4430,1259377,1,1,,144207502,4485,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4431,1259377,1,1,,170465006,4485,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4432,1259378,1,1,,144207502,4485,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4433,1259378,1,1,,170465006,4485,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4434,1259379,1,1,,144207502,4485,Inconclusive,,,61.1927,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4435,1259379,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4436,1259380,1,1,,144207502,4485,Inconclusive,,,27.3338,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4437,1259380,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4438,1259381,1,1,,144207502,4485,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4439,1259381,1,1,,170465006,4485,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4440,1259382,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4441,1259382,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4442,1259383,1,1,,144207502,4485,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4443,1259383,1,1,,170465006,4485,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4444,1259384,1,1,,144207502,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4445,1259384,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4446,1259385,1,1,,144207502,4485,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4447,1259385,1,1,,170465006,4485,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4448,1259386,1,1,,144207502,4485,Inconclusive,,,54.5381,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4449,1259386,1,1,,170465006,4485,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4450,1259387,1,1,,144207502,4485,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4451,1259387,1,1,,170465006,4485,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4452,1259388,1,1,,144207502,4485,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4453,1259388,1,1,,170465006,4485,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4454,1259389,1,1,,124637934,4485,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
4455,1259389,1,1,,124658782,4485,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
4456,1259390,1,1,,144207502,4485,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4457,1259390,1,1,,170465006,4485,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4458,1259391,1,1,,144207502,4485,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4459,1259391,1,1,,170465006,4485,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4460,1259392,1,1,,144207502,4485,Active,109731339.0,2737.0,6.35867,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4461,1259392,1,1,,170465006,4485,Active,109731339.0,2737.0,1.33332,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4462,1259393,1,1,,144207502,4485,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4463,1259393,1,1,,170465006,4485,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4464,1259394,1,1,,144207502,4485,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4465,1259394,1,1,,170465006,4485,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4466,1259395,1,1,,144207502,4485,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4467,1259395,1,1,,170465006,4485,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4468,1259396,1,1,,144207502,4485,Active,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4469,1259396,1,1,,170465006,4485,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4470,1259400,1,1,,170465006,4485,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
4471,1259401,1,1,,144207502,4485,Active,325495545.0,2101.0,16.2817,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4472,1259401,1,1,,170465006,4485,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4473,1259402,1,1,,144207502,4485,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4474,1259402,1,1,,170465006,4485,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4475,1259403,1,1,,144207502,4485,Inconclusive,325495545.0,2101.0,54.5381,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4476,1259403,1,1,,170465006,4485,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4477,1259404,1,1,,144207502,4485,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4478,1259404,1,1,,170465006,4485,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4479,1259407,1,1,,363904024,4485,Inactive,,,,,CCRIS mutagenicity studies,Other,,
4480,1259413,1,2,,46386790,4485,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
4481,1259415,1,1,,855613,4485,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
4482,1259416,1,2,,855613,4485,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4483,1259416,1,2,,375174471,4485,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4484,1259421,1,1,,375174471,4485,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4485,1259423,1,2,,354748540,4485,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4486,1259423,1,2,,354748654,4485,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4487,1259423,1,2,,354909960,4485,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4488,1259423,1,2,,354910046,4485,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4489,1259423,1,2,,354931949,4485,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
